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Ultrasonically probing optical absorption, photoacoustic tomography (PAT) combines rich optical
contrast with high ultrasonic resolution at depths beyond the optical diffusion limit. With
consistent optical absorption contrast at different scales and highly scalable spatial resolution and
penetration depth, PAT holds great promise as an important tool for both fundamental research
and clinical application. Despite tremendous progress, PAT still encounters certain limitations that
prevent it from becoming readily adopted in the clinical settings. This dissertation aims to advance
both the technical development and application of PAT towards its clinical translation.

The first part of this dissertation describes the development of photoacoustic elastography
techniques, which complement PAT with the capability to image the elastic properties of
biological tissue and detect pathological conditions associated with its alterations. First, I
demonstrated vascular-elastic PAT (VE-PAT), capable of quantifying blood vessel compliance
changes due to thrombosis and occlusions. Then, I developed photoacoustic elastography to
noninvasively map the elasticity distribution in biological tissue. Third, I further enhanced its
x

performance by combing conventional photoacoustic elastography with a stress sensor having
known stress–strain behavior to achieve quantitative photoacoustic elastography (QPAE). QPAE
can quantify the Young’s modulus of biological tissues on an absolute scale.

The second part of this dissertation introduces technical improvements of photoacoustic
microscopy (PAM). First, by employing near-infrared (NIR) light for illumination, a greater
imaging depth and finer lateral resolution were achieved by near-infrared optical-resolution PAM
(NIR-OR-PAM). In addition, NIR-OR-PAM was capable of imaging other tissue components,
including lipid and melanin. Second, I upgraded a high-speed functional OR-PAM (HF-OR-PAM)
system and applied it to image neurovascular coupling during epileptic seizure propagation in
mouse brains in vivo with high spatio-temporal resolution. Last, I developed a single-cell metabolic
PAM (SCM-PAM) system, which improves the current single-cell oxygen consumption rate
(OCR) measurement throughput from ~30 cells over 15 minutes to ~3000 cells over 15 minutes.
This throughput enhancement of two orders of magnitude achieves modeling of single-cell OCR
distribution with a statistically meaningful cell count. SCM-PAM enables imaging of intratumoral
metabolic heterogeneity with single-cell resolution.

The third part of this dissertation introduces the application of linear-array-based PAT (LA-PAT)
in label-free high-throughput imaging of melanoma circulating tumor cells (CTCs) in patients in
vivo. Taking advantage of the strong optical absorption of melanin and the unique capability of
PAT to image optical absorption, with 100% relative sensitivity, at depths with high ultrasonic
spatial resolution, LA-PAT is inherently suitable for melanoma CTC imaging. First, with a center
ultrasonic frequency of 21 MHz, the LA-PAT system was able to detect melanoma CTCs clusters
and quantify their sizes based on the contrast-to-noise ratio (CNR). Second, I developed an LAxi

PAT system with a center ultrasonic frequency of 40 MHz and imaged melanoma CTCs in patients
in vivo with a CNR greater than 12. We successfully imaged 16 melanoma patients and detected
melanoma CTCs in 3 of them. Among the CTC-positive patients, 67% had disease progression
despite systemic therapy. In contrast, only 23% of the CTC-negative patients showed disease
progression. This study lays a solid foundation for translating CTC detection to bedside for clinical
care and decision-making.

xii

Chapter 1 Introduction
1.1 Photoacoustic Tomography
By converting interior structures (anatomy) and functions (physiology) to comprehensive visual
illustrations, biomedical imaging has revolutionized fundamental life sciences research and
modern healthcare. Among various biomedical imaging modalities, optical imaging techniques are
uniquely positioned to probe biomolecules with high resolution and rich contrast because light
occupies a specific range of the electromagnetic spectrum. However, due to the strong light
scattering, high-resolution optical imaging is usually restricted to the ~1 mm optical diffusion limit
in biological tissue1.

First discovered by A. G. Bell back in 1880, the photoacoustic effect describes the phenomenon
of converting light absorption by an object to a pressure rise that propagates as acoustic waves2.
Based on this effect, photoacoustic tomography (PAT, also called optoacoustic tomography) forms
high-resolution images of optical absorption in biological tissue beyond the optical diffusion limit
by detecting the acoustic waves3. There are five essential steps in PAT4. (1) The object is irradiated
by a short-pulsed or an intensity-modulated laser beam. (2) Light is absorbed by the object and
partially or fully converted into heat. (3) The heat causes a thermos-elastic expansion that gives a
pressure rise. (4) The pressure rise propagates as an ultrasonic wave, referred to as photoacoustic
wave. (5) The photoacoustic wave is detected by one or more ultrasonic transducers and an image
is formed based on the detected signals.

As a hybrid imaging modality, PAT has four unique advantages by combing optical excitation
with ultrasonic detection. (1) PAT has a 100% relative sensitivity to optical absorption (i.e., a given
1

percentage change in the optical absorption coefficient yields the same percentage change in the
photoacoustic amplitude)5. (2) Exploiting the rich optical contrast, PAT achieves structural,
functional, metabolic, molecular, and genetic imaging of biological systems6–12. (3) Taking
advantage of the ultrasonic transparency of biological tissue, PAT breaks the optical diffusion limit
and enables high-resolution imaging of optical contrasts at depths. (4) PAT provides multiscale
imaging capability with highly scalable penetration depth and spatial resolution based on a
consistent contrast mechanism of optical absorption13.

With these unique advantages, PAT can be implemented in many forms according to the desired
imaging parameters and specific biological applications. Based on the image-formation method,
there are two major types of implementation of PAT, photoacoustic computed tomography
(PACT) and photoacoustic microscopy (PAM). PACT uses an inverse reconstruction imaging
formation method by wide-field illumination and multi-position acoustic detection with an array
of transducers14. PACT can be configured with different transducer array geometries, including
linear, half ring, full ring, and hemisphere15–18. In PACT, the axial (along the acoustic axis) and
lateral (perpendicular to the acoustic axis within the imaging plane) resolutions are derived from
image reconstruction. The elevation (orthogonal to the imaging plane) resolution is determined by
the cylindrical acoustic focusing. PAM utilizes a focused-scanning imaging formation method by
focusing both the optical excitation and acoustic detection and scanning either the imaging focus
or the object imaged19. For each laser pulse, a one dimensional (1D) photoacoustic signal (referred
as to A-line) along the axial direction is acquired. To form a three dimensional (3D) photoacoustic
image, lateral raster scanning is usually performed. Based on the relative size of the optical and
acoustic focus, PAM can be further classified into optical-resolution PAM (OR-PAM) and
acoustic-resolution PAM (AR-PAM). In OR-PAM, the optical focus is tighter than the acoustic
2

focus. The excitation laser beam is usually tightly focused to achieve optical diffraction-limited
lateral resolution20. In AR-PAM, the acoustic focus, smaller than the diffused optical beam,
determines the lateral resolution. For both OR-PAM and AR-PAM, the axial resolution is
determined by the acoustic time of arrival21. In addition to PAM and PACT, PAT can also be
implemented for endoscopy22. Based on the desired imaging parameters regarding penetration
depth, spatial resolution, temporal resolution, and imaging contrast, a particular PAT system can
be selected to solve the specific biological and medical problems.

1.2 Motivation
This dissertation aims to push the frontier of PAT in the following three aspects.

First, this dissertation aims to develop photoacoustic elastography (Chapter 2). Although PAT can
provide multi-dimensional information of biological tissue, one critical dimension missing is the
elastic property. Alterations of elastic properties are often associated with pathological states in
biological tissue23. Physicians have long used manual palpation to detect such alterations. Inspired
by such manual palpation, elastography, an imaging technique that is typically implemented using
existing medical imaging techniques, was developed to map the elasticity distribution in biological
tissue24. So far, elastography has not been successfully implemented using PAT. So, I aim to
develop photoacoustic elastography to complement PAT with the capability to image elastic
properties of biological tissue.

Second, this dissertation aims to further enhance the performance of OR-PAM (Chapter 3). I want
to achieve greater penetration depth and finer lateral resolution in the deeper regions with ORPAM, which can be realized by employing near-infrared (NIR) light for illumination. Then, we
3

target to improve OR-PAM to image fast dynamic biological processes such epilepsy propagation
in mouse brain in vivo with high spatio-temporal resolution. Additionally, we want to further boost
the functionality of OR-PAM by developing the capability of performing label-free highthroughput single-cell oxygen consumption rate measurement and characterizing intratumoral
metabolic heterogeneity with single-cell resolution.

Third, this dissertation aims to develop linear-array-based PAT systems for label-free highthroughput imaging of circulating melanoma tumor cells in vivo (Chapter 4). Metastasis accounts
for more than 90% of cancer deaths25. In metastasis, the rare circulating tumor cells (CTCs) are
the key determinants of metastatic propensity26. Effective detection and characterization of the rare
CTCs will greatly contribute to understanding tumor metastasis and improving cancer therapy.
Current CTC detection techniques all encounter certain limits that impedes their clinical
translation. We aim to overcome these challenges by developing linear-array-based PAT systems
capable of label-free high-throughput imaging of circulating melanoma tumor cells in patients in
vivo.

4

Chapter 2 Photoacoustic Elastography
In this chapter, I introduce the development of photoacoustic elastography techniques.
Elastography is a medical imaging technique can noninvasively map the elastic properties of
biological tissue. Photoacoustic elastography combines the elasticity imaging capability with the
unique advantages of PAT. In the first section, I developed the vascular elastic PAT (VE-PAT)
system that can measure the blood vessel compliance. Then, in the second section, I demonstrated
photoacoustic elastography using a linear-array-based PACT system. Last, I report quantitative
photoacoustic elastography (QPAE) capable of measuring Young’s modulus of biological tissue
in vivo in humans.

2.1 Vascular Elastic Photoacoustic Tomography
2.1.1 Background
Mechanical properties of biological tissue are directly related to its underlying structure and can
be altered by pathological states such as tumors and arteriosclerosis. Particularly, the elastic
properties of blood vessels are strongly affected by hemodynamic changes in the circulation
system and may indicate the presence of thrombosis and vessel occlusion, which can lead to severe
conditions such as stroke, acute heart attack, and pulmonary embolism27. Partially or fully clogged
blood vessels under thrombosis usually are harder to compress28. Thus, characterizing the elastic
properties of blood vessels under different hemodynamic states can potentially contribute to the
detection of thrombosis, and help prevent it from developing into acute life-threatening conditions.

Inspired by manual palpation, medical imaging technologies have been applied to image the elastic
properties of biological tissue24. By measuring the tissue’s deformation under loading, elasticity
5

imaging techniques usually map the mechanical properties of biological tissue onto an image
called an elastogram. An elastogram conveys the local variations of stiffness in the region of
interest and adds a new dimension of information that may help clinical diagnosis and therapy.
Besides its primary application in breast cancer diagnosis, elasticity imaging techniques also find
applications in blood vessel stiffness characterization29,30. Vascular elasticity imaging was first
implemented invasively by using endovascular imaging catheters31,32. Based on various imaging
modalities, noninvasive vascular elasticity imaging was later achieved, including ultrasound
elastography (USE), magnetic resonance elastography (MRE), and optical coherence elastography
(OCE)33–35. USE can image blood vessels in deep regions, but the poor ultrasonic scattering
contrast between blood and extravascular tissue makes it insensitive to the deformations of small
blood vessels36. MRE can potentially penetrate the whole human body, but its spatial resolution
(~1–3 mm) is sufficient for assessing the stiffness of large blood vessels only37. Benefiting from
the high spatial resolution of optical coherence tomography, OCE has a typical spatial resolution
of 1–10 μm and can detect displacement at the sub-micrometer level. Thus, it is capable of mapping
small blood vessel elasticity38. However, OCE suffers from strong optical scattering in biological
tissue, limiting its penetration depth to ~1 mm, which is insufficient for assessing elastic properties
of blood vessels in the optical diffusive regime in tissues.

With strong optical absorption contrast provided by hemoglobin in red blood cells, PAT has
achieved structural and functional imaging of vasculature in both animals and humans39–41. PAT
has also been applied to measure the elastic properties of biological tissue ex vivo. However, by
measuring the phase delay between the dominant frequency photoacoustic wave and the reference
signal, the current photoacoustic technique is able to detect only the viscosity-elasticity ratio
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instead of the elasticity, which is not applicable to assessing the vascular elastic properties in
humans in vivo42.

In this section, I report my work on developing VE-PAT, which is capable of measuring blood
vessel compliance changes at depths in humans. Because PAT is highly sensitive to blood, the
term “blood vessel” in this section specifically refers to blood perfused vessels. By measuring the
compliance changes of blood vessel phantoms with and without simulated thrombosis, we
demonstrated the feasibility of VE-PAT in characterizing blood vessel elasticity. We further
applied this technique to humans and detected a decrease of blood vessel compliance after
downstream vessel occlusion, demonstrating the potential of VE-PAT in clinical thrombosis
detection.

2.1.2 Methods
Experimental system
In VE-PAT, the major device is a linear-array-based photoacoustic imaging probe43,44. The probe
consisted of a linear array ultrasonic transducer (Visualsonics Inc. LZ250, 21 MHz center
frequency, 78% one-way bandwidth, 256 elements, 23 mm × 3 mm array size) with two optical
fiber bundle strips (20 mm × 1.25 mm) mounted on each side (Fig. 2.1a). The laser beams coming
out of the two optical fiber bundle strips had an angle of incidence of 30° with respect to the
imaging plane. The two optical fiber bundles were bifurcated from a single optical bundle that was
incorporated into the probe together with an ultrasound signal cable. A tunable optical parametric
oscillator laser (680 nm to 970 nm, 20 Hz pulse repetition rate) was coupled into the single fiber
optical bundle for photoacoustic excitation. The wavelength was set to 850 nm to achieve deep
penetration for vascular elasticity imaging. In our experiments, the fluence on the sample surface
7

was 10 mJ/cm2, well within the safety limit set by the American National Standards Institute (20
mJ/cm2). Each element of the transducer array was cylindrically focused with a focal length of 15
mm. For each of four laser pulses, photoacoustic signals were captured sequentially on one quarter
(i.e., 64 elements) of the transducer array elements. After all data was acquired from the four
segments, we reconstructed a two-dimensional photoacoustic image using the filtered backprojection algorithm45. The reconstructed two-dimensional photoacoustic image was referred to
hereafter as the B-scan photoacoustic image. An imaging station (Vevo LAZR, Visualsonics Inc.)
displayed the reconstructed B-scan photoacoustic images at 5 frames/second, as determined by the
20 Hz laser repetition rate and the four-to-one multiplexing in the image acquisition system. The
VE-PAT system has spatial resolutions of 119 μm in the lateral direction, 86 μm in the axial
direction, and 1237 μm in the elevational direction44. The minimum displacement that can be
resolved is 18.3 μm, which is determined by the data acquisition sampling rate of 84 MHz and the
average speed of sound in biological tissue of 1540 m/s. The typical signal-to-noise ratios (SNRs)
of the VE-PAT system were around 25 dB in the following phantom experiments and 20 dB in the
in vivo experiments in humans.

To implement VE-PAT, a customized compression stage was developed and incorporated into the
probe. The compression stage had an aluminum plate controlled by a three-dimensional translation
stage, which could position the plate in the x-y plane and induce precise displacements along the
z-axis for accurate sample compression (Fig. 2.1b). Above the compression plate, a water tank
held water for acoustic coupling. An imaging window slightly larger than the probe was machined
in the center of the compression plate. To ensure the compression force applied to the sample was
normal and uniaxial, a piece of fully stretched polymethylpentene (TPX) plastic membrane was
attached to the bottom of the compression plate, which allowed the transmission of both the optical
8

excitation light and generated photoacoustic wave. An aluminum block on an optical table held
the sample against compression.

Figure 2.1. Schematic of VE-PAT. (a) Photoacoustic imaging probe. (b) VE-PAT setup for a blood vessel phantom
imaging. The imaging probe is incorporated with a customized compression stage.

Phantom preparation

Silicone microtubes with 0.3 mm (60985-700, VWR) and 3.4 mm inner diameters (ID) (60985720, VWR) perfused with bovine blood (905, Quad-Five) mimicked small and large blood vessels,
respectively. Blood was pumped into the microtubes through a syringe, and the flow speed was
controlled by a syringe pump (BSP-99M, Braintree Scientific). The thrombosis was simulated by
injecting a small drop of glue into the microtube downstream from the measurement point, which
hardened on the tube wall and partially blocked the flow. The microtube was then embedded in
tissue-mimicking gelatin phantoms 3 mm deep (Fig. 2.2a). To achieve stiffness similar to that of
soft tissue, the gelatin concentration in the phantoms was 100 g/L46. To achieve similar optical
scattering as in biological tissue, 1% intralipid was added to the gelatin phantoms.
9

Sample compression and photoacoustic image acquisition

Elastic property changes induced by simulated thrombosis were investigated in both the large and
small blood vessel phantoms. As shown in Figure 2.1b, the axis of the phantom blood vessel was
perpendicular to the imaging plane. A cross section of the phantom was first imaged right after the
compression plate contacted the sample with a minimum load. For the big vessel (ID = 3.4 mm),
we applied ten small steps of compression with a step size of 50 μm and two large steps of
compression with a step size of 500 μm. For the small vessel phantom (ID = 0.3 mm), only one 50
μm step compression was applied instead of twelve steps. For all the compression steps,
corresponding photoacoustic images were acquired when the phantom had stabilized. The same
compression and imaging procedure was performed in both conditions with and without simulated
thrombosis.

In vivo blood vessel elasticity was assessed on the middle finger of the right hand of a 29-year-old
male volunteer. All of the experiments were conducted in accordance with the human studies
protocols approved by the Institutional Review Board at Washington University in St. Louis. The
right hand was placed on the object holder, and the middle finger was fixed in position and imaged
by the VE-PAT system. Similar to the procedures in our phantom experiments, a cross section of
the finger was first imaged just after the compression plate contacted the finger with a minimum
load. Then, we applied five small steps of compression with a step size of 50 μm and two large
steps of compression with a step size of 300 μm. Photoacoustic images were acquired after each
step of compression. To simulate thrombosis, a vessel occlusion was created on the near end of
the middle finger. The same compression and imaging procedure was repeated to obtain the elastic
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property changes of a finger vessel due to the occlusion. The occlusion time was short enough (60
seconds) to avoid any potential harm.

Strain calculation

Strain values of the blood vessel phantoms and the finger blood vessels under compression were
obtained via analyzing the reconstructed B-scan photoacoustic images before and after
compression based on the following method. First, the photoacoustic images at preload were
segmented based on a threshold of 6 dB with respect to the noise level, and the original distances
𝐿 between the top and bottom boundaries of the blood vessels were calculated at each reconstructed
A-line. Then, corresponding reconstructed A-lines in the photoacoustic images before and after
compression were analyzed with a sliding-window cross-correlation method24. The sliding
window was set slightly larger than the visible vessel boundaries in the photoacoustic images. By
doing cross-correlation between the corresponding signals within the window before and after
compression, axial displacements of the top and bottom boundaries, denoted as 𝑑𝑡 and 𝑑𝑏 , were
estimated. The strain 𝜀 was then calculated by

𝜀=

𝑑𝑡 − 𝑑𝑏
.
𝐿

(2.1)

As the compliance 𝐶 is proportional to the strain 𝜀, the ratio of the compliances 𝐶1 and 𝐶2 of two
samples under the same stress equals the ratio of their strains 𝜀1 and 𝜀2 :
𝐶1
𝜀1
= .
𝐶2
𝜀2
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(2.2)

2.1.3 Results
Standard compression test of the large blood vessel phantom

Figure 2.2. Characterization of a large blood vessel phantom. (a) Diagram of the large blood vessel phantom
embedded 3 mm deep in gelatin. (b) Stress–strain response measured for the large blood vessel phantom with and
without simulated thrombosis. Stress–strain curves with strain smaller than 10% were fitted to linear functions to
calculate the compliances as shown by the dashed lines.

Before the microtubes were embedded into tissue-mimicking gelatin phantoms, the compliances
of the perfused large blood vessel phantoms with and without simulated thrombosis were measured
with a standard compression test. In the standard compression test, the large blood vessel phantom
was placed on a high-precision digital weighing scale (S200, Ohaus) and compressed using the
customized compression stage. The compression stress was calculated based on the difference in
the scale readings before and after compression. The axial displacement of the top boundary was
read from the translation stage that moved the compression plate along the z-axis for precise
sample compression. Because the bottom boundary did not move, the strain was calculated as the
12

deformation over the original diameter of blood vessel phantom (Eq. 2.1). Consistent with the
previous elasticity imaging studies47, the stress–strain relationship appeared linear with the
coefficient of determination (R2) of 0.993 and 0.987 when the strain was smaller than 10% (Fig.
2.2b). The ratio of the compliances between with and without simulated thrombosis was 0.64.

VE-PAT of large blood vessel phantom

Photoacoustic images of a cross section of the large blood vessel phantom before and after ten
small steps of compression with a step size of 50 μm are shown in Figure 2.3. The diameter of the
large blood vessel phantom before compression was measured to be 3513.6 μm. The axial
displacements of the top and bottom boundaries and the strain values of the large blood vessel
phantom are summarized in Table 2.1. Under the same stress, the blood vessel phantom without
simulated thrombosis (Fig. 2.3a and b) underwent larger deformation than that with simulated
thrombosis (Fig. 2.3c and d). The strain values of the large blood vessel phantom with and without
simulated thrombosis were plotted at each compression step (Fig. 2.3i). During the ten small steps
of compression, the stress–strain response still appeared linear, as shown in Figure 2.3i. We
quantified the relative compliance by fitting the two data sets to linear functions. Compliance ratio
between the two states was estimated to be 0.67, which is close to the ratio 0.64 measured in the
standard compression test.

Figure 2.3e–h show B-scan photoacoustic images of a cross section of the large blood vessel
phantom before and after two large steps of compression with a step size 500 μm, during which
the strain reached the apparent nonlinear stress–strain response regime. The blood vessel phantom
became harder to compress in the presence of simulated thrombosis (Fig. 2.3g and h), akin to the
linear stress–strain response result. The strain values at the first compression state for the blood
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vessel phantom with and without simulated thrombosis were 12.9 ± 1.3% and 16.3 ± 1.1%,
respectively. At the second compression state, they were 15.8 ± 1.4% and 22.4 ± 1.7%, respectively
(Fig. 2.3i). Since the same compression forces were applied to the blood vessel phantom with and
without simulated thrombosis at each state, the smaller strains indicated that a decrease in
compliance of the blood vessel phantom was induced by the simulated thrombosis.

Figure 2.3. VE-PAT of a large blood vessel phantom. Photoacoustic images of a cross section in the large blood vessel
phantom, without thrombosis before (a), after ten small steps of compression (b), and after two large steps of
compression (e-f). Photoacoustic images of the cross section in the large blood vessel phantom with simulated
thrombosis before (c), after ten small steps of compression (d), and after two large steps of compression (g-h). (i)
Strain curves under twelve steps of compression for the large blood vessel phantom with and without simulated
thrombosis. Dashed lines: linear fits with the coefficient of determination (R2) of 0.998 and 0.995 for ≤13% strain.
Error bars: standard deviation.
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Table 2.1. VE-PAT of axial displacements and strains of the large blood vessel phantom. The linear compression is
the result from 10 total compression steps.

Without
thrombosis

With
thrombosis

Linear
compression

Nonlinear
compression
step 1

Nonlinear
compression
step 2

Top boundary
displacement (μm)

475.8

732.0

1006.5

Bottom boundary
displacement (μm)

43.9

161.0

219.6

Deformation (μm)

431.9

571.0

786.9

Strain (%)

12.3

16.3

22.4

Standard deviation
of strain (%)

0.9

1.1

1.7

Top boundary
displacement (μm)

320.3

567.3

695.4

Bottom boundary
displacement (μm)

34.8

113.4

139

Deformation (μm)

285.5

453.9

556.4

Strain (%)

8.1

12.9

15.8

Standard deviation
of strain (%)

0.6

1.3

1.4

VE-PAT of small blood vessel phantom

Photoacoustic images of a cross section of the small blood vessel were acquired before and after
compression, with and without simulated thrombosis (Fig. 2.4a–d). The diameter of the small
blood vessel phantom before compression was measured to be 329.4 μm. The axial displacements
of the top and bottom boundaries and the strain values of the small blood vessel phantom are
summarized in Table 2.2. Similar to the large blood vessel phantom, the small blood vessel
phantom was harder to compress with the simulated thrombosis. The strain for the small blood
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vessel phantom without simulated thrombosis was 13.3 ± 0.9% while the strain with simulated
thrombosis was only 6.7 ± 0.4% (Fig. 2.4e). Under the same compression force, the decrease in
strain indicated a decrease in compliance due to the simulated thrombosis.

Figure 2.4. VE-PAT of a small blood vessel phantom. Photoacoustic images of a cross section of the small blood
vessel phantom, without simulated thrombosis before (a) and after compression (b), and with simulated thrombosis
before (c) and after compression (d). (e) Strain values for the small blood vessel phantom with and without thrombosis.
Statistics: paired student’s t-test. P values: **<0.05.

Table 2.2. VE-PAT of axial displacements and strains of the small blood vessel phantom.

Without thrombosis

With thrombosis

Top boundary displacement (μm)

71.4

45.8

Bottom boundary displacement (μm)

27.5

23.8

Deformation (μm)

43.9

22.0

Strain (%)

13.3

6.7

Standard deviation of strain (%)

0.9

0.4
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VE-PAT of blood vessel in a human

Figure 2.5 shows the VE-PAT results of the middle finger blood vessels of the human subject with
and without vessel occlusion. The diameter of the blood vessel in the human finger before
compression was measured to be 786.9 μm. The axial displacements of the top and bottom
boundaries and the strain values of the finger blood vessel are summarized in Table 2.3. During
five small steps of compression with a step size of 50 μm, the blood vessel in the finger underwent
smaller deformation with vessel occlusion downstream (Fig. 2.5a–d). Strain values for the blood
vessels at each step of compression were calculated for both normal and vessel occlusion
conditions (Fig. 2.5e). Since the largest deformation was still within the linear stress–strain
response regime, we estimated a relative decrease of compliance as 30.0% when the vessel was
occluded.

Figure 2.5. VE-PAT of a human finger in the linear stress–strain response regime. Photoacoustic images of a cross
section of the human finger, without vessel occlusion before (a) and after compression (b), and with vessel occlusion
before (c) and after compression (d). (e) Strain curves under five steps of compression for the human finger with and
without vessel occlusion. Dashed lines: linear fits with the coefficient of determination (R2) of 0.993 and 0.987. Error
bars: standard deviation.
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Table 2.3. VE-PAT of axial displacements and strains of the finger blood vessel in vivo. The linear compression is
the result from 5 total compression steps.

Without
vessel
occlusion

With vessel
occlusion

Linear
compression

Nonlinear
compression
step 1

Nonlinear
compression
step 2

Top boundary
displacement (μm)

234.2

456.1

585.6

Bottom boundary
displacement (μm)

155.5

161.0

208.7

Deformation (μm)

78.7

295.1

376.9

Strain (%)

10.0

37.5

47.9

Standard deviation
of strain (%)

2.8

5.8

6.1

Top boundary
displacement (μm)

165.6

259.9

475.7

Bottom boundary
displacement (μm)

113.4

128.1

295.5

Deformation (μm)

52.2

131.8

180.2

Strain (%)

6.6

16.7

22.9

Standard deviation
of strain (%)

0.8

3.4

4.5

The finger was then compressed with two 300 μm steps, during which the blood vessels underwent
larger deformation that the stress–strain response became nonlinear (Fig. 2.6a–f). Again, the blood
vessels with occlusion underwent smaller deformation than that without occlusion under the same
load. Strain values for blood vessels without occlusion at the two steps were 37.5 ± 5.8% and 47.9
± 6.1%, while they were 16.7 ± 3.4% and 22.9 ± 4.5% with vessel occlusion (Fig. 2.6g). These
results demonstrated that VE-PAT can detect the decrease of vessel compliance in the human
finger due to vessel occlusion in both the linear and nonlinear stress–strain response regimes.
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Figure 2.6. VE-PAT of a human finger in the nonlinear stress–strain response regime. Photoacoustic images of a cross
section of the human finger without vessel occlusion before compression (a), after compression step 1 (b), and after
compression step 2 (c). Photoacoustic images of the same cross section of the human finger with vessel occlusion
before compression (d), after compression step 1 (e), and after compression step 2 (f). (g) Strain values for the blood
vessels with and without thrombosis in two compression steps. Statistics: paired student’s t-test. P values: **<0.05.

2.1.4 Discussion
VE-PAT detected vascular compliance changes due to simulated thrombosis in large and small
blood vessel phantoms at depths and in blood vessels in a finger of a human subject in vivo. In the
large blood vessel phantom, the compliance ratio between the two states with and without
simulated thrombosis measured by VE-PAT agreed with the value measured in the standard
compression test. By imaging the small blood vessel phantom embedded 3 mm deep in the gelatin
phantom, VE-PAT demonstrated its capability to detect elasticity changes of small blood vessels
at depths that are difficult for either USE or OCE to image. In addition, VE-PAT was applied to
assess blood vessel elasticity changes due to vessel occlusion in the human finger, demonstrating
its potential for clinical vessel elasticity characterization.
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The detection sensitivity of the VE-PAT system is limited by the minimum detectable
displacement, i.e., 18.3 μm. First, the minimum detectable displacement limits the minimum
diameter of blood vessels whose elasticity can be assessed by VE-PAT in the linear stress–strain
response regime, which is usually considered to be less than 10% strain in biological tissue. To
stay within the linear stress–strain response regime, the blood vessel diameter should be at least
183 μm, i.e., 10 times (reciprocal of 10%) the minimum detectable displacement. For blood vessels
with diameters smaller than 183 μm and larger than the minimum detectable displacement of 18.3
μm, their elasticity can still be assessed, but only in the nonlinear stress–strain response regime.
For blood vessels with diameters smaller than 18.3 μm, their deformation cannot be resolved,
which is the ultimate detection limit of the current VE-PAT system.

To the best of our knowledge, this is the first time that PAT has been applied for quantitative
assessment of blood vessel elastic properties in humans in vivo. In addition to the information
including structure, flow velocity, molecule concentration, and oxygen saturation level of
hemoglobin, that photoacoustic imaging can provide21,48–50, VE-PAT adds important elasticity
information.

2.2 Quasi-static Photoacoustic Elastography
2.2.1 Background
Elastography was first performed using ultrasound imaging in 199151. Later, elastography was
implemented using magnetic resonance imaging, namely magnetic resonance elastography, at the
whole-body level with a spatial resolution of ~1–3 mm52. Elastography was also implemented in
optical coherence tomography (OCT), which has greatly improved the spatial resolution to ~1–10
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μm, but OCT has limited imaging depth (~1 mm in the skin) due to the strong optical scattering in
biological tissue38.

PAT is a hybrid imaging technique that combines rich optical absorption contrast and high
ultrasonic spatial resolution3. PAT has proven capable of imaging anatomical, functional,
molecular, and metabolic information of biological tissue14,40,53,54. There have been several
photoacoustic studies on measuring the elastic properties of biological tissue. In one study, the
viscoelasticity of biological tissues was imaged by photoacoustic technique, but the elasticity could
not be measured because the detected photoacoustic signal phase delay was related to the viscosityelasticity ratio instead of the elasticity alone42,55. In a second study, the volume-averaged Young’s
modulus of soft tissue was measured by a photoacoustic sensing technique, which, however,
possessed no spatial resolution56. Yet another study introduced speckles in photoacoustic images
for sample displacement estimation but demonstrated the concept only with simulation data57. So
far, elastography has not been successfully implemented using photoacoustic imaging. Here, we
demonstrate photoacoustic elastography, capable of high-resolution strain imaging of biological
tissue based on the contrast of Young’s modulus. Implemented using PACT, photoacoustic
elastography can map the mechanical contrast in biological tissue while maintaining high spatial
resolution and excellent penetration depth.

2.2.2 Methods
The photoacoustic elastography was developed based on a linear-array PACT system43, which is
capable of high-resolution imaging of the elasticity distribution in tissue in vivo. A 10 ns pulsed
laser beam at 680 nm was used for photoacoustic excitation with a 20 Hz pulse repetition rate.
Light was first coupled into a fiber bundle. The fiber bundle was then split into two rectangular
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light bars mounted on each side of a linear ultrasonic transducer array (LZ250, VisualSonics Inc.,
21 MHz center frequency, 256 elements), which detected the generated photoacoustic waves.
Photoacoustic signals were sampled at 84 MHz. For each laser pulse, one quarter of the 256
ultrasonic array elements were used for detecting photoacoustic signals. Acquired with four laser
pulses, the full data set was used to reconstruct a cross-sectional photoacoustic image, yielding a
frame rate of 5 Hz. The spatial resolutions of the PACT system were 119 μm in the lateral direction,
86 μm in the axial direction, and 1.2 mm in the elevational direction58.

In our photoacoustic elastography system, an aluminum compression plate larger than the object
exerted a small axial compressive force on the object (Fig. 2.7a). An imaging window slightly
larger than the ultrasonic transducer probe was opened at the center of the compression plate (Fig.
2.7b). A piece of fully stretched polymethylpentene (TPX) plastic membrane was attached to the
bottom of the compression plate to provide uniform and uniaxial force to the object while passing
the illumination laser beam. Ultrasound gel was used for acoustic coupling between the
compression plate and the object, without changing the elasticity of the gelatin phantoms.
Ultrasound gel is also convenient for in vivo animal imaging and potential clinical applications.
For acoustic coupling between the probe and the compression plate, water was chosen as the
medium. The compression plate was adjusted by a manual translation stage to provide precise
compression to the object against a rigid object holder. The total displacement of the object surface
was read from the translation stage. The object and the object holder were placed on a highprecision digital weighing scale (S200, Ohaus). The compression stress applied to the object was
calculated from the difference in the scale readings before and after compression:
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𝜎=

𝑔(𝑚𝑎 − 𝑚𝑏 )
.
𝐴

(2.3)

Here, 𝜎 is the compression stress, 𝑔 is the acceleration of gravity, 𝑚𝑎 and 𝑚𝑏 are the scale readings
before and after compression, and 𝐴 is the area on which the compression force is applied.

Figure 2.7. Schematic of the photoacoustic elastography system. (a) Side view of the photoacoustic elastography
system. (b) Top view of the compression plate with the imaging window at the center.

2.2.3 Results
Photoacoustic elastography of homogeneous gelatin phantoms
To demonstrate quantitative elasticity measurement, photoacoustic elastography was first used to
image four homogeneous gelatin phantoms with respective gelatin concentration of 40, 60, 80, and
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100 g/L. To provide absorption contrast for photoacoustic imaging, 50 μm microspheres were
mixed in the gelatin phantoms at a concentration of ~5 microspheres per mm 3. Each gelatin
phantom was imaged with the photoacoustic elastography system before and after compression
with an external stress of 53 Pa (Fig. 2.8a and b). The maximum surface displacement in the
experiments was 120 μm, and the maximum strain was 4%, which was considered to be within the
linear strain response regime of the phantom46. Time-resolved A-line signals before and after
compression were cross-correlated to calculate the axial displacement due to compression59,
generating a cross-sectional map of displacements after compression (Fig. 2.8c). Here, shortwindow cross-correlation between corresponding A-lines was computed. We slid a 90-µm-wide
window along the A-lines acquired before and after compression and computed the crosscorrelations to find the displacement between the A-lines at each window position. Displacements
were then averaged among the microspheres at each depth (Fig. 2.8d). The slope of the linear
fitting of the displacements versus depths—i.e., the magnitude of the average gradient of the
displacement—quantified the average strain of each gelatin phantom. The same data processing
was performed on 20 measurements, 5 each for four gelatin phantoms (Fig. 2.8e). The measured
strains were then fitted by the model below46:

𝜀=

𝜎 1
.
𝐾 𝐶2

(2.4)

Here, 𝜀 is the strain of the gelatin phantom, 𝜎 is the stress applied to the phantom, 𝐾 is a constant
factor, and 𝐶 is the gelatin concentration. Note 𝐾 is affected by the equilibrium temperature, the
temperature and duration of the gelatin mixing process, and the molecular weight of gelatin.
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Figure 2.8. Photoacoustic elastography of a single-lay gelatin phantom. (a-b) Cross-sectional PA images of a gelatin
phantom (40 g/L gelatin concentration) mixed with 50 μm microspheres acquired (a) before and (b) after compression.
(c) Displacement image obtained from (a) and (b). (d) Average displacement versus the depth. The strain of the
phantom was estimated as the slope of the linear fitting. (e) Measured strains of gelatin phantoms with 4%, 6%, 8%,
and 10% concentration in weight. The data was fitted to a quadratic model that describes the relationship between the
strain and the gelatin concentration (Equation 2.4).

Photoacoustic elastography of a bilayer gelatin phantom
Photoacoustic elastography was then used to image a bilayer gelatin phantom with different gelatin
concentrations in each layer. The top layer had a gelatin concentration of 50 g/L and a thickness
of 2.5 mm. The bottom layer had a gelatin concentration of 100 g/L and a thickness of 2.0 mm.
Again, 50 μm microspheres were mixed in the gelatin phantom at the concentration of 5
microspheres per mm3. The bilayer phantom was imaged by the photoacoustic elastography system
before and after compression with a stress of 98 Pa (Fig. 2.9a and b). A displacement image was
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generated using the same method as above (Fig. 2.9c). Displacements of the microspheres were
averaged at each depth and fitted by a linear function for each layer (Fig. 2.9 d). The slopes of the
two linear fittings reflect the strains in the two layers. The strain ratio between the two layers is
4.0 ± 0.2, which agrees with the theoretical value of 4.

Figure 2.9. Photoacoustic elastography of a bilayer gelatin phantom. (a-b) PA images of a bilayer gelatin phantom
mixed with 50 μm microspheres acquired (a) before and (b) after compression. (c) Displacement image obtained from
(a) and (b). (d) Average displacement versus depth. The data was fitted by a linear function for each layer.

Photoacoustic elastography of a mouse leg in vivo
A mouse leg was then imaged in vivo by photoacoustic elastography. All experimental animal
procedures were carried out in conformity with laboratory animal protocols approved by the
Animal Studies Committee at Washington University in St. Louis. The mouse leg was imaged
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before and after applying an external compression force of 12 mN (Fig. 2.10a and b). A
displacement image was obtained by cross-correlating the photoacoustic images before and after
compression, using the image pixels with photoacoustic signal amplitudes above the noise level.
A raw strain image was then obtained by numerically differentiating the axial displacements,
assuming that the applied stress was uniaxial (Fig. 2.10c). The raw strain image was then
superimposed on the structural photoacoustic image (Fig. 2.10e). The regions of tissue with larger
strains were softer than regions with smaller strains, and thus were thought to have more fat. The
photoacoustic elastography was validated by USE using the same linear-array imaging probe,
which showed a similar distribution of strains (Fig. 2.10d and f). In USE, structural ultrasound
images were acquired simultaneously with structural photoacoustic images before and after the
compression. The displacement and strain images in the USE were computed using the same data
processing method as in the photoacoustic elastography. The average strains over the entire crosssectional image were 0.84 ± 0.49% in photoacoustic elastography and 0.82 ± 0.29% in USE. Here
it is worth noting that there were differences between the strain distribution measured by
photoacoustic elastography and USE. Although both methods measured the elastic property of the
tissue, they were based on different contrast mechanisms. Within each resolution voxel (~119 μm
by 86 μm by 1.2 mm) of the strain image, optical-absorption-based photoacoustic elastography
measured the integrated elasticity of the tissue only through the displacement of the vasculature,
while acoustic-scattering-based USE mapped the integrated elasticity through the displacement of
more tissue components, including vasculature, muscle fibers, and fat. Under compression, there
may be more relative displacements between vasculature and other tissue components in the soft
regions, resulting in higher strain values than those in USE. Another possible reason for the
discrepancy between the measured strain images is the different number of useful pixels in
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photoacoustic and ultrasound elastography images. Lacking speckles and imaging only the blood
vasculature, photoacoustic elastography has fewer useful pixels than USE, resulting in fewer
effective pixels for interpolation, especially in the tissue region with less blood.

Figure 2.10. Photoacoustic elastography of a mouse leg in vivo. (a-b) PA images of a mouse leg in vivo before and
after compression. (c) A strain image of the mouse leg obtained by photoacoustic elastography in vivo. (d) A strain
image of the mouse leg obtained by USE in vivo. (e) The strain image of the mouse leg obtained by photoacoustic
elastography superimposed on the structural PA image. (d) The strain image of the mouse leg obtained by USE on the
structural ultrasound image.

2.2.4 Discussion
Compared to previous studies, our photoacoustic elastography technique based on a linear-array
PACT has the following distinctive features. First, photoacoustic elastography maps the Young’s
modulus of biological tissue, but previous photoacoustic viscoelasticity studies are based on the
contrast of the viscosity-elasticity ratio. Second, photoacoustic elastography is able to provide
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cross-sectional strain images of biological tissue with high axial resolution, while viscosityelasticity ratio measurement has no axial resolution. Third, photoacoustic viscoelasticity imaging
is based on an intensity-modulated continuous-wave laser excitation, yielding a much lower signal
to noise ratio than that in photoacoustic elastography using a pulsed laser excitation60. Fourth,
photoacoustic elastography is implemented on a commercial linear-array-based PACT system,
which can measure other biological parameters including vasculature density, tumor volume,
oxygen saturation of hemoglobin, and blood flow velocity61.
We would like to point out that the motivation of this work is not to prove that photoacoustic
elastography is superior to USE. Instead, the major motivation is to demonstrate the feasibility of
elasticity measurement by using PAT as an independent device: Not all the photoacoustic imaging
systems have the capability of ultrasound transmission, and thus USE is not always available.
Photoacoustic elastography can be implemented on existing photoacoustic imaging systems, as an
additional function, to provide more comprehensive information about the tissue’s mechanical and
functional information.
Further, PAT can potentially measure elasticity concurrently with other functional parameters,
including the oxygen saturation of hemoglobin, which may provide more comprehensive
information for disease diagnosis and treatment evaluation9. Noninvasive imaging of elasticity
distribution expands the functionality of PAT and is expected to find potential applications in
clinical practice, such as cancer detection and arterial plaque assessment. To advance the current
photoacoustic elastography technique for clinical applications, several challenges remain to be
solved. One challenge is to apply normal uniform compression force in vivo. A special
compression mechanism needs to be developed for curved tissue surface. Another challenge is to
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achieve 3D volumetric strain imaging. To achieve this, the current linear-array photoacoustic
probe can be linearly scanned orthogonally.

2.3 Quantitative Photoacoustic Elastography
2.3.1 Background
To quantify the elastic properties of biological tissue, elastography has been developed in various
modalities including USE51, MRE37, OCE38, and photoacoustic elastography62. In elastography,
tissue deformation is induced by a static or dynamic load and imaged. If the stress distribution is
known, the deformation can be converted to an image of elasticity called elastogram. However,
unless the stress is known in absolute values, elastography techniques can image elasticity only in
relative values, which are not sufficient for longitudinal monitoring.

Various methods have been developed to achieve absolute elastography. By measuring shear wave
propagation, USE and MRE can quantify the shear modulus of biological tissue52,63. Although the
Young’s modulus 𝐸 is directly related to the shear modulus 𝐺 in soft tissue by

𝐸 = 2𝐺(1 + 𝑣).

(2.5)

It is also affected by the Poisson's ratio 𝑣 of soft tissue, which can vary from 0.46 to 0.4964. Thus,
the absolute Young’s modulus is still unknown without the knowledge of both the shear modulus
and Poisson’s ratio. OCE has achieved quantitative measurement of absolute Young’s modulus.
In one study, compression OCE was combined with a stress sensor to measure both strain and
stress, from which the absolute Young’s modulus of biological tissue was calculated65. In another
study, the absolute Young’s modulus was obtained from the phase velocity of the surface acoustic
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wave, which was measured by phase-sensitive optical coherence tomography66. However, both
methods suffer from limited imaging depth (~1 mm) due to strong optical scattering in biological
tissue.

By acoustically detecting optical absorption, PAT achieves high sensitivity, multicontrast imaging
of biological tissue with highly scalable spatial resolution and penetration depth3,40,67. PAT has
successfully measured the elastic properties of biological tissue53,55,62, including strain, the
viscosity-elasticity ratio, and vascular compliance. Yet, all the aforementioned photoacoustic
elastic imaging techniques measure only relative elastic properties. Here, we report QPAE capable
of measuring the absolute Young’s modulus in vivo in humans. By introducing a stress sensor into
photoacoustic elastography, QPAE measures the local stress and strain simultaneously and
quantifies the absolute Young’s modulus.

2.3.2 Methods
To implement QPAE, a linear-array-transducer based photoacoustic imaging system (Vevo LAZR
Imaging System, VisualSonics Inc., Toronto, Canada) was modified to be combined with a
customized compression system43 (Fig. 2.11). A Nd:YAG laser pumped a tunable optical
parametric oscillator laser to provide illumination with wavelengths from 680 nm to 970 nm at a
repetition rate of 20 Hz. An excitation wavelength of 850 nm was chosen to achieve deep
penetration for QPAE. The laser beam was then coupled into an optical fiber bundle that was
incorporated into the photoacoustic imaging probe. The optical fiber bundle bifurcated into two
rectangular fiber bundles (20 mm × 1.25 mm). Laser beams emerging from the two rectangular
fiber bundle strips illuminated the object to be imaged at an angle of incidence of 30° with respect
to the imaging plane. The fluence on the tissue surface was about 10 mJ/cm2, below the 20 mJ/cm2
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safety limit set by the American National Standards Institute. The generated photoacoustic waves
were detected by a linear array ultrasonic transducer (23 mm × 3 mm), which was placed coaxially
and confocally with the illuminating fiber bundles to maximize the system’s sensitivity. The linear
array ultrasonic transducer had 256 elements, a central frequency of 21 MHz, and a one-way
bandwidth of 78%. For each laser pulse, ultrasonic signals from 64 out of the 256 elements in the
linear array were acquired by the data acquisition system. Thus, to obtain a two-dimensional image
with full width, four laser pulses were needed, which reduced the two-dimensional imaging frame
rate to 5 Hz, corresponding to one fourth of the laser pulse repetition rate of 20 Hz. The full data
set from all the elements in the linear array ultrasonic transducer was then used to reconstruct a
two-dimensional photoacoustic image, referred as a B-scan photoacoustic image, by using the
filtered back-projection algorithm45.

Figure 2.11. Schematic of QPAE system. (a) Photoacoustic imaging probe at lateral and elevational view. FB, fiber
bundle; IP, imaging probe; LB, laser beam; SC, signal cable; TA, transducer array. (b) QPAE system setup. CP,
compression plate; O, object to be imaged; OH, object holder; SS, stress sensor; TM, TPX membrane; WT, water
tank.
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The compression system consisted of an aluminum compression plate with an open imaging
window at the center. A translation stage moved the compression stage along the z-axis to exert a
small axial compression force on the object to be imaged. To ensure the compression force was
normal, a piece of fully stretched polymethylpentene (TPX) plastic membrane was attached to the
bottom of the compression plate. A stress sensor made of translucent silicone rubber was placed
between the TPX plastic membrane and the object to be imaged to measure the local stress68. The
stress sensor had a Young’s modulus of 30 kPa. An object holder held the object to be imaged
against compression. To provide acoustic coupling, the photoacoustic imaging probe head was
submerged in a water tank above the compression plate. Ultrasound gel maintained good acoustic
contact between the compression plate and the sensor, and between the sensor and the object.
To obtain the Young’s modulus of the object, both the local stress and strain were measured in
each experiment. After the compression plate contacted the stress sensor with a minimum load, a
B-scan photoacoustic image of both the sensor and the object was first obtained, from which the
baseline thickness of the stress sensor 𝑙𝑏 (𝑥) was measured. Then we exerted a small axial
compression by moving the compression plate along the z-axis. After the object had stabilized, we
obtained another B-scan photoacoustic image of the same cross section of the sensor and the object,
from which the compressed thickness of the stress sensor 𝑙𝑐 (𝑥) was measured. The strain of the
stress sensor 𝜀𝑠𝑠 (𝑥) at each lateral location was then calculated by

𝜀𝑠𝑠 (𝑥) =

𝑙𝑏 (𝑥) − 𝑙𝑐 (𝑥)
.
𝑙𝑏 (𝑥)

(2.6)

The local stress 𝜎(𝑥) at each lateral position was obtained from the stress–strain curve of the sensor
material (Fig. 2.12a), which was generated by an independent compression test. A two33

dimensional short-window cross-correlation between the two B-scan images was calculated to
obtain a map of displacement. By numerically differentiating the displacement map, we obtained
a strain image of the object 𝜀𝑠𝑎 (𝑥, 𝑧). The Young’s modulus value at each location 𝐸𝑠𝑎 (𝑥, 𝑧) was
then calculated by

𝐸𝑠𝑎 (𝑥, 𝑧) =

𝜎(𝑥)
.
𝜀𝑠𝑎 (𝑥, 𝑧)

(2.7)

Figure 2.12. Characterization of the stress sensor. (a) Stress–strain curve of the stress sensor material. (b) Validation
of the stress measurement by the stress sensor. The measured stress (black dots) agreed well with the applied stress.

To ensure the accuracy of the Young’s modulus measurement, we first validated the stress
measurement by the stress sensor. Placed on a high-precision digital weighing scale (S200, Ohaus),
the stress sensor was imaged by QPAE before and after compression. The applied stress was
calculated by

𝜎𝐴 (𝑥) =

𝑔(𝑚𝑎 − 𝑚𝑏 )
.
𝐴
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(2.8)

Here, 𝜎𝐴 (𝑥) is the compression stress, 𝑔 is the acceleration of gravity, 𝑚𝑎 and 𝑚𝑏 are the scale
readings before and after compression, and 𝐴 is the area on which the compression force is applied.
The local compression stress was also obtained by analyzing the photoacoustic images before and
after compression with the method described above and averaged over the entire cross section. The
stress measured by the stress sensor agreed well with the applied stress (Fig. 2.12b).

2.3.3 Results
QPAE of agar phantoms

We first demonstrated the feasibility of QPAE by imaging agar phantoms with different
concentrations. A small portion of black ink was mixed with the agar to provide optical absorption.
Agar phantoms with concentrations of 20 g/L, 25 g/L, 30 g/L, 35 g/L, and 40 g/L were embedded
in gelatin at a concentration of 100 g/L. To mimic optical scattering in biological tissue, 1%
intralipid was added to the agar phantoms and the gelatin background. The five phantoms were
imaged by QPAE, and maps of Young’s modulus were obtained using the method described above
(Fig. 2.13a-e). The entire cross-sections of the five agar phantoms, with depths between 2.5 mm
and 3.0 mm, were all clearly resolved by QPAE. Then the Young’s modulus at each agar
concentration was calculated by averaging over all the pixels with signal to noise ratios (SNRs)
above 6 dB in the entire Young’s modulus map. Two methods were adopted to validate the
Young’s modulus measurement in the phantoms. First, the average Young’s modulus values were
fitted to the following empirical relationship based on the agar concentrations46 (Fig. 2.13f)
𝐸 = 𝑘𝐶 1.87 .
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(2.9)

Here, 𝐸 is the Young’s modulus at a given concentration 𝐶, and 𝑘 is a factor related to several
parameters, including the molecular weight of agar used in the experiments and the agar mixing
duration and temperature. The fitting results show a good agreement between the Young’s
modulus measurement by QPAE and the empirical relationship based on the agar concentrations,
with an R2 value of 0.99. Second, the Young’s modulus measurements of the agar phantoms were
validated by an independent standard compression test (SCT). In the SCT, stress–strain curves of
the agar phantoms fabricated with the same procedure as above were generated. Young’s modulus
values were calculated based on stress–strain curves with strain ˂ 0.1 69. The Young’s modulus
values of agar phantoms measured by QPAE agree well with those measured by SCT, further
demonstrating the accuracy of QPAE in quantifying the absolute elasticity (Fig. 2.13g).

Figure 2.13. QPAE of agar phantoms. (a-e) QPAE images of agar phantoms at agar concentrations of 20 g/L, 25 g/L,
30 g/L, 35 g/L, and 40 g/L, respectively. (f) Young’s modulus measured by QPAE as a function of agar concentration.
The results were fitted by Equation 2.8. (g) Validation of Young’s modulus measurement by SCT. The Young’s
modulus values of the agar phantoms measured by the two methods agreed well.
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QPAE of a human arm in vivo
To demonstrate quantitative measurement of Young’s modulus in vivo, we imaged the right arm
of a healthy human volunteer. All of the experiments were conducted in accordance with the
human study protocols approved by the Institutional Review Board at Washington University in
St. Louis. The biceps muscle was chosen because the volunteer would have sufficient control of
the arm to avoid motion artifacts and could maintain the same arm position and same elbow angle
of 90° throughput the experiment. The right arm was chosen to reduce the possible motion artifacts
induced by the movement of the chest wall and the heart. During the experiments, the volunteer
was asked to place his arm as flat as possible on the object holder. Then he held a hand grip
attached to a cable with different loadings pulling his arm straight but was tasked with keeping his
elbow at a 90° angle during imaging. The stress sensor was placed on the biceps with ultrasound
gel in between to keep good acoustic contact. The compression system and the photoacoustic
imaging probe were on top of the stress sensor. Different loadings of 0.0 kg, 2.5 kg, 5.0 kg, 7.5 kg,
and 10.0 kg were applied. At each loading, a B-scan photoacoustic image of a cross section of the
stress sensor and arm was obtained first. In the B-scan photoacoustic image, three layers of
structures were resolved, including the skin layer, the blood vessels, and a muscle layer (Fig.
2.14a). Then an axial compression force was exerted by moving the compression plate down along
the z-axis. Another B-scan photoacoustic image of the same cross section of the stress sensor and
arm was obtained. At each loading, a map of Young’s modulus was calculated based on the method
described above (Fig. 2.14 a–e). With QPAE, we were able to obtain the Young’s modulus values
of the bicep up to 6 mm deep, within which the SNR was sufficiently high to calculate the
displacements. We also calculated the average Young’s modulus values for each layer (Fig. 2.14f).
The skin had an average Young’s modulus value of 15.9 kPa, and we found that it stayed invariant
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with increasing loadings of the arm. The Young’s modulus of the muscle layer increased linearly
with the loading applied. The result indicated that the elastic modulus of the biceps muscle has a
linear relationship with the loading applied, which agrees with previous shear modulus
measurements by MRE70. A slight increase of the Young’s modulus was also observed in the
cephalic vein, which possibly resulted from the increased blood supply to the arm due to repeated
loading applied during the experiments. The in vivo results in human arm further demonstrated the
capability of QPAE in measuring the Young’s modulus quantitatively.

Figure 2.14. QPAE of a human biceps muscle in vivo. QPAE images of the human biceps muscle in vivo at different
loadings: 0.0 kg (a), 2.5 kg (b), 5.0 kg (c), 7.5 kg (d), and 10.0 kg (e). The skin layer, blood vessel boundaries, and
skeletal muscle can be observed. (f) Young’s modulus value averaged in each layer as a function of loading.

2.3.4 Discussion
Note that in the phantom and in vivo experiments above, the maximum deformation of the phantom
and the biological tissue was controlled to be smaller than 0.1. This ensures that the stress–strain
38

response stayed in the linear range, so the Young’s modulus calculation was valid69. However, this
requirement was not necessary for the stress sensor because we had characterized its stress–strain
behavior with stain up to 0.5. The Young’s modulus was calculated only on the pixels with SNRs
above 6 dB because the displacement calculation based on the cross-correlation was only valid for
pixels with SNRs above 6 dB.
The spatial resolutions of QPAE are 86 μm in the axial direction, 119 μm in the lateral direction,
and 1237 μm in the elevational direction, determined by the linear-array-based photoacoustic
imaging probe. The minimum detectable displacement is 18.3 μm, which is determined by the data
acquisition sampling rate of 84 MHz and the average speed of sound in biological tissue of 1540
m/s. The range of Young’s modulus measurement by QPAE depends on two factors. One is the
range of strain measurement by PAE. The other is the ratio of the elasticity of the stress sensor to
that of the object to be imaged. The maximum measurable Young’s modulus is determined by the
maximum stress measured by the stress sensor and the minimum strain of the object to be imaged,
and vice versa for the minimum measurable Young’s modulus. For a given stress sensor and PAE
system, the maximum measurable Young’s modulus 𝐸𝑚𝑎𝑥 is

𝐸𝑚𝑎𝑥 =

𝜎𝑚𝑎𝑥
𝜎𝑚𝑎𝑥
=
.
𝜀𝑚𝑖𝑛
𝑑𝑚𝑖𝑛 ⁄𝑙

(2.10)

Here, 𝑑𝑚𝑖𝑛 represents the minimum detectable displacement in PAE, which is 18.3 μm in our
system. The original object thickness 𝑙, is around 6 mm in the above experiments. The maximum
measurable stress 𝜎𝑚𝑎𝑥 is theoretically limited to the stress at which the sensor breaks down. In
practice, if the stress sensor works in the linear stress–strain response range (strain < 0.1), the
maximum measurable stress for the sensor would be 3 kPa, resulting in a maximum measurable
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Young’s modulus of 983 kPa. If we reach a strain of 0.4 for the stress sensor, the maximum
measurable Young’s modulus would be 28.3 MPa. The minimum measurable Young’s modulus
Emin can be calculated by

𝐸𝑚𝑖𝑛 =

𝜎𝑚𝑖𝑛
𝑑𝑚𝑖𝑛 ⁄𝑙𝑠𝑠
=
.
𝜀𝑚𝑎𝑥
𝜀𝑚𝑎𝑥

(2.11)

Here, 𝑙𝑠𝑠 represents the thickness of stress sensor and 𝜀𝑚𝑎𝑥 is the maximum strain of the object.
For valid Young’s modulus calculation, the stress–strain response of the object needs to stay in the
linear range, thus the maximum strain of the object should be 0.1. For a 2-mm-thick stress sensor
in our QPAE system, the minimum measurable Young’s modulus would be 3.2 kPa.

To the best our knowledge, this is the first quantitative imaging of absolute elasticity in biological
tissue by PAT. QPAE achieves mapping of the absolute Young’s modulus in vivo up to 6 mm
deep, which is in the optical diffusive regime, and thus enables longitudinal imaging of tissue
elasticity. QPAE can be exploited for potential clinical applications, especially for long term
measurement of tissue elasticity such as monitoring softening of the cervix during pregnancy.
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Chapter 3 Advanced Photoacoustic
Microscopy Techniques
In this chapter, I introduce the development of advanced PAM techniques. In the first section, I
report NIR-OR-PAM. By utilizing NIR light for photoacoustic excitation, we have achieved
greater penetration depth and finer lateral resolution in the deeper regions. Then, in the second
section, I demonstrated a high-speed functional OR-PAM (HF-OR-PAM) system for epilepsy
imaging in mouse brain in vivo with high spatial-temporal resolution. Last, I developed a singlecell metabolic PAM (SCM-PAM) capable of label-free high-throughput single-cell oxygen
consumption rate measurements. By improving the current single-cell metabolism measurement
throughput limit by two orders of magnitude, from ~30 cells over 15 minutes to ~3000 cells over
15 minutes, SCM-PAM enables imaging and quantification of intratumoral metabolic
heterogeneity with single-cell resolution.

3.1 Near-infrared Optical-resolution Photoacoustic
Microscopy
3.1.1 Background
With 100% sensitivity to optical absorption, OR-PAM can provide both anatomical and functional
information with high spatial resolution71–73. In OR-PAM, the high lateral resolution is achieved
by tightly focusing the laser beam into a diffraction-limited spot20. In a highly scattering medium
such as biological tissue, the focusing capability of OR-PAM degrades with the imaging depth74.
In previous OR-PAM studies, ultraviolet (UV) or visible (VIS) light was used for illumination,
mainly because of the strong absorption of DNA/RNA, cytochromes, hemoglobin, and melanin in
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these wavelength regions75,76. However, the strong optical scattering limits the penetration depth
of OR-PAM in biological tissue.

To improve the imaging depth, we propose NIR-OR-PAM. Compared with visible illumination,
NIR illumination yields several benefits. First, NIR-OR-PAM can penetrate deeper in tissue for a
given SNR, primarily due to weaker absorption of NIR light by blood77. Second, with weaker
scattering of NIR light, NIR-OR-PAM can maintain its lateral resolution at greater depths. Third,
NIR-OR-PAM can image other tissue components, such as water and lipid78,79. The optical
absorption spectra of four tissue components from 250 nm to 1150 nm are shown in Figure
3.1a80,81. Fourth, the American National Standard Institute (ANSI) permits stronger NIR light
intensity on the tissue surface82. Here, we applied NIR light in OR-PAM and demonstrated these
advantages.

3.1.2 Methods
In the NIR-OR-PAM system (Fig. 3.1b), an Nd:YLF laser (INNOSAB, Edgewave, GmbH)
generates laser pulses at its fundamental wavelength of 1046 nm. The laser pulses then pass
through a second harmonic generator to generate 523 nm laser pulses. After the second harmonic
generator, 523 nm and residual 1046 nm laser beams are split by a dichroic mirror. A dye laser
(CBR-D, Sirah, GmbH) is pumped by the 523 nm beam and emits laser pulses with tunable
wavelengths. We selected 570 nm for photoacoustic imaging, referred as VIS-OR-PAM, to
compare with NIR-OR-PAM. A flip mirror is used to select either the 570 nm or the 1046 nm laser
beam. After this, the laser beam is reshaped by an iris (ID25SS, Thorlabs) and then attenuated by
a neutral density filter (NDC-50C-2M, Thorlabs). A condenser lens (LA1131, Thorlabs) and a 50
μm diameter pinhole (P50C, Thorlabs) spatially filter the beam further. The laser beam is then
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focused into the sample by an objective (AC127-050-A, Thorlabs; numerical aperture: 0.1 in air).
A high-frequency ultrasonic transducer is placed confocally with the objective to detect the
generated photoacoustic waves. The acoustic-optical coaxial alignment is achieved by using a
beam combiner composed of a thin layer of silicone oil sandwiched between a right-angle prism
(NT32-545, Edmund Optics) and a rhomboid prism (NT49-419, Edmund Optics). Each laser pulse
generates a one-dimensional photoacoustic image (A-line) by recording the time course of the
photoacoustic signal. Volumetric imaging is provided by two-dimensional motor scanning.

3.1.3 Results
Penetration depth of NIR-OR-PAM
To measure the penetration depth of the NIR-OR-PAM, we imaged a 50 μm diameter black human
hair obliquely inserted into a piece of fresh chicken breast tissue. To conform to the ANSI safety
limit, the light fluences on the tissue surface at 570 nm and 1046 nm were adjusted to 20 mJ/cm2
and 100 mJ/cm2, respectively. NIR-OR-PAM was able to image the black hair 3.2 mm beneath the
skin surface with an SNR of 6 dB compared to only 2.3 mm by VIS-OR-PAM with the same SNR
(Fig. 3.2a and b). NIR-OR-PAM can penetrate deeper than VIS-OR-PAM: First, NIR light
undergoes weaker optical attenuation than VIS light, which allows it to penetrate deeper; Second,
ANSI permits stronger NIR light fluence on tissue surface, which also gives us larger penetration
depth. The same time-gain compensation (TGC, 0.75 dB/MHz/cm) for acoustic attenuation was
applied to improve the visibility in both cases.
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Figure 3.1. Absorption spectra and the schematic of NIR-OR-PAM. (a) Absorption spectra of oxy-hemoglobin
(HbO2) (150 g/L or 2.3 mM in blood), deoxy-hemoglobin (HbR) (150 g/L or 2.3 mM in blood), water (80% by volume
in tissue), and lipid (20% by volume in tissue) from 250 nm to 1150 nm. (b) Schematic of the NIR-OR-PAM system.
ConL, condenser lens; CorL, correction lens; DC, dye cell; DM, dichroic mirror; FM, flip mirror; M1, M2, and M3,
mirrors; ND, neutral density filter; OL, objective lens; PH, pinhole; PL, pump laser; RAP, right-angle prism; RhP,
rhomboid prism; SHG, second harmonic generator; SOL, silicone oil layer; UT, ultrasonic transducer; WT, water
tank.
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Figure 3.2. Penetration depths of the two OR-PAM systems. VIS-OR-PAM (a) and NIR-OR-PAM (b) images of a
black human hair inserted obliquely into a piece of fresh chicken breast tissue. The hair was imaged with an SNR of
≥ 6 dB up to 3.2 mm deep in the tissue by NIR-OR-PAM and 2.3 mm deep in the tissue by VIS-OR-PAM.

Figure 3.3. Lateral resolutions of the two OR-PAM systems. (a-b) Line spread functions (black dotted lines) extracted
from the fitted edge spread functions (solid red lines) of VIS-OR-PAM (a) and NIR-OR-PAM (b) acquired in water.
Here, the lateral resolution was quantified as the FWHM of the line spread functions. The lateral resolution of NIROR-PAM in water is 6.2 μm, while the lateral resolution of VIS-OR-PAM is 2.9 μm. (c) Lateral resolution of NIROR-PAM and VIS-OR-PAM as a function of imaging depth in scattering media. Here, the lateral resolution was
quantified as the FWHM of the numerical first-derivative of the measured edge spread function.
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Lateral resolution of NIR-OR-PAM

To measure the lateral resolution of the NIR-OR-PAM system in clear media, a sharp metal edge
was imaged with a step size of 0.625 μm and a scanning range of 100 μm along the x-axis. By
fitting the measured data to an edge spread function, the full width at half maximum (FWHM) of
the corresponding line spread function was estimated as the lateral resolution. The lateral
resolution of NIR-OR-PAM in a clear medium was estimated to be 6.2 μm (Fig. 3.3b), and that of
VIS-OR-PAM was estimated to be 2.9 μm (Fig. 3.3a), both of which are close to the theoretical
lateral resolutions of OR-PAM, which are determined by the focal diameters of the laser beams.
The axial resolution of NIR-OR-PAM was estimated to be ~27 μm, based on the transducer
bandwidth and the speed of sound in tissue83. In scattering media such as biological tissue, both
the lateral and axial resolutions decrease with imaging depth due to optical scattering and
frequency-dependent acoustic attenuation in tissue.

The lateral resolutions of NIR-OR-PAM and VIS-OR-PAM at different imaging depths were
measured in scattering media. A sharp metal edge obliquely inserted into a piece of fresh chicken
breast tissue was imaged at different depths while the optical focus was maintained on the metal
edge. As optical focusing deteriorated in tissue, the line spread functions were no longer Gaussian
functions, thus the lateral resolution could no longer be estimated by fitting the edge spread
functions using error functions, as we did for the clear medium. Therefore, we estimated the lateral
resolution as the FWHM of the numerical first-derivative of the measured edge spread function.
Figure 3.3c shows the lateral resolutions of both NIR-OR-PAM and VIS-OR-PAM as functions
of imaging depth. Due to optical scattering in the chicken tissue, the optical focusing degrades
with depth, deteriorating the lateral resolution of OR-PAM. At 1046 nm, scattering in chicken
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breast tissue is weaker than that at 570 nm. With weaker optical scattering, NIR light can focus
better than VIS light after traveling through a certain depth, which results in finer lateral resolution
in NIR-OR-PAM over VIS-OR-PAM. For VIS-OR-PAM, the lateral resolution is finer than 40
μm up to ~1.6 mm depth, while for NIR-OR-PAM the lateral resolution is finer than 40 μm up to
~2 mm depth. Close to the tissue surface (<0.6 mm), NIR-OR-PAM has a worse lateral resolution
than VIS-OR-PAM due to the longer wavelength; at ~0.6 mm depth, NIR-OR-PAM and VIS-ORPAM show similar resolutions. As the imaging depth goes beyond 0.6 mm, NIR-OR-PAM has
finer lateral resolutions than VIS-OR-PAM, until the optical focusing becomes so ineffective that
OR-PAM turns into acoustic-resolution PAM, where the acoustic focusing of the 50 MHz
ultrasonic transducer (~43 μm) determines the lateral resolution.

NIR-OR-PAM of a mouse ear in vivo

A mouse ear was imaged in vivo with NIR-OR-PAM. All experimental animal procedures were
carried out in conformity with the laboratory animal protocol approved by the Animal Studies
Committee at Washington University in St. Louis. A 2 × 2 mm2 area of the mouse ear was imaged
by both VIS-OR-PAM and NIR-OR-PAM (Fig. 3.4a and b). VIS-OR-PAM is able to image only
the blood vessels (Fig. 3.4a). NIR-OR-PAM, however, is able to image more contrasts (Fig. 3.4b).
In addition to blood vessels, the circular structures imaged by NIR-OR-PAM are suspected to be
fat cells surrounding sebaceous glands84,85. Close-up images and B-scan images (Fig. 3.4c and d)
further demonstrate the improvement of NIR-OR-PAM in lipid contrast and imaging depth in vivo.

NIR-OR-PAM of a mouse brain in vivo
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We also imaged a mouse brain in vivo with NIR-OR-PAM. The same area of the mouse brain was
imaged by VIS-OR-PAM and NIR-OR-PAM. The scalp was removed but the skull was intact.
Due to the strong blood absorption and brain tissue scattering, few blood vessels deeper than 0.5
mm can be imaged by VIS-OR-PAM (Fig. 3.5a and b). However, NIR-OR-PAM can detect signals
from blood vessels deeper than 0.5 mm (Fig. 3.5c and d).

Figure 3.4. Comparison of mouse ear images by the two OR-PAM systems. (a) A maximum amplitude projection
(MAP) image of a mouse ear acquired by VIS-OR-PAM in vivo within depths up to 300 μm. Two close-ups show the
PA signals from blood vessels, as indicated by the dashed boxes. (b) An MAP image of the same mouse ear acquired
by NIR-OR-PAM in vivo within depths up to 300 μm. (c-d) B-scan images along the dashed lines in (a) and (b),
respectively, on a logarithmic scale after acoustic attenuation compensation with an acoustic attenuation coefficient
of 1 dB/MHz/cm.

NIR-OR-PAM can not only penetrate deeper than VIS-OR-PAM but also image structures in deep
regions with finer resolution. As shown in Figure 3.6a and b, at both illumination wavelengths,
OR-PAM was able to clearly image the cortical vascular network. However, close-ups of the
vessels more than 200 μm deep in figure 3.6a and b show that the vessels are less blurred in the
NIR-OR-PAM images than in the VIS-OR-PAM images, as shown in figure 3.6c. The lateral
resolution improvement for in vivo imaging by NIR-OR-PAM was estimated by comparing the
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apparent diameters of vessels at the same depths. The apparent diameters of two representative
vessels were 120 μm and 160 μm in VIS-OR-PAM, while they were 50 μm and 80 μm in NIROR-PAM, respectively (Fig. 3.6d). The apparent diameters of blood vessels were ~2 times smaller
in NIR-OR-PAM.

Figure 3.5. Comparison of in vivo imaging depths in a mouse brain. (a) x-z projection of a VIS-OR-PAM image of
the mouse brain acquired in vivo. (b) x-y projections of the mouse brain at different depths. No structure can be
detected at depths beyond 500 µm. (c) x-z projection of a NIR-OR-PAM image of the same mouse brain acquired in
vivo. (d) x-y projections of the mouse brain at different depths. Structures can be detected at depths up to 750 µm.
The dashed lines in the x-z projections mark the approximate location of the skull.

Due to strong absorption, an overlying blood vessel may shadow vessels underneath in VIS-ORPAM. At 1046 nm, the optical absorption of hemoglobin is about 40 times less than that at 570 nm
(Fig. 3.1a). Therefore, 1046 nm NIR light has a 1/e penetration depth of 1.2 mm in blood, and is
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able to image multiple layers of blood vessels. This advantage was demonstrated by imaging a
bleeding area in a mouse brain. The bleeding layer appears weaker in NIR-OR-PAM than in VISOR-PAM (Fig. 3.7a and b). By peeling off the bleeding layer in data processing, we can clearly
see that the optical shadowing from the bleeding layer is weaker in NIR-OR-PAM, and the vascular
network underneath can thus be better resolved with greater SNR. However, due to the strong
absorption, nearly all of the VIS light is absorbed by the blood pool and generated strong
photoacoustic signals that were reverberated by other underlying brain structures, showing as a
‘ghost’ image of the blood pool.

Figure 3.6. Comparison of in vivo lateral resolutions in the mouse brain. (a-b) In vivo mouse brain MAP images
acquired by VIS-OR-PAM (a) and NIR-OR-PAM (b), respectively. (c) Close-ups of the dashed boxes in (a) and (b)
show that more blood vessels can be imaged by NIR-OR-PAM. (d) Normalized PA amplitudes across two selected
blood vessels at 225 μm (solid lines) and 330 μm (dashed lines) depths in (c), respectively. Both vessels have smaller
apparent diameters in the NIR-OR-PAM image than in the VIS-OR-PAM image, because they are less blurred.
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Figure 3.7. Comparison of penetrations in blood. (a) Top: a VIS-OR-PAM MAP image of a mouse brain acquired in
vivo within depths up to 300 μm, in which blood vessels were covered by a bleeding layer. Bottom: a VIS-OR-PAM
MAP image of the same area in the mouse brain acquired in vivo within depths from 100 μm to 300 μm after digitally
peeling off the bleeding layer. The underneath blood vessels can barely be resolved. (b) Top: an NIR-OR-PAM MAP
image of the same region as (a) within depths up to 300 μm. The signal strength from the bleeding layer is weaker
than that from the VIS-OR-PAM counterpart. Bottom: an NIR-OR-PAM MAP image of the same area in the mouse
brain acquired in vivo within depths from 100 μm to 300 μm after digitally peeling off the bleeding layer. The
underneath blood vessels can be clearly resolved.

3.1.4 Discussion
It is worth pointing out that lower optical absorption in the NIR region allows deeper penetration
but results in weaker photoacoustic signals. However, with nanosecond pulse excitation, the tissue
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damage mechanism is mainly photothermal86. Therefore, lower absorption allows for stronger
excitation fluence, which can partially compensate for the reduced signal strength.

3.2 High-speed Functional Photoacoustic Microscopy
3.2.1 Background
Epilepsy is a neurological disorder characterized by recurring seizures that affects more than 50
million people worldwide87. Imaging and characterizing the neurovascular coupling during
epileptic seizure can help understand the disease88,89. To study the highly localized correlation
between the metabolic demands of neural activities and the cerebral hemodynamics, capillarylevel spatial resolution is needed90. To investigate the propagation of epileptic seizures through the
cerebral hemodynamic responses, high temporal resolution is also needed.

Modern functional brain imaging has enabled better understanding of epilepsy and contributed to
its diagnosis and treatment91–95. However, functional magnetic resonance imaging (fMRI), the
major clinical functional brain imaging method, lacks the required spatial and temporal resolutions
for documenting complex paroxysmal brain activities during epileptic seizures96. Functional
ultrasound (fUS) imaging has imaged the cross-sectional propagation of epileptic seizure with
greatly improved temporal resolution at adequate depths, but still lacks the required spatial
resolution for studying capillary-level hemodynamics97. Optical imaging methods have also
played a major role in understanding epilepsy. Voltage-sensitive dye (VSD) imaging provides
information of neural behaviors during epileptic seizure with sufficient temporal resolution but
suffers from tissue toxicity98,99. Optical coherence tomography (OCT) has reported a significant
decrease in the backscattering of light in the mouse brain during seizure progression but is
insensitive to changes in blood perfusion100.
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PAT has gained great attention for biomedical imaging by providing structural, functional,
molecular, mechanical, and metabolic information8,9,101,102. PACT was previously applied for
imaging epileptic seizure in the mouse brain, but the spatial resolution was insufficient to resolve
capillary-level hemodynamic changes103,104. OR-PAM, a major microscopic implementation of
PAT, is well suited for cerebral hemodynamic imaging because of its excellent contrast between
blood vessels and background tissues105. Given the deficiencies of the current brain imaging
modalities, we report an HF-OR-PAM system capable of imaging epileptic seizure propagation in
the mouse brain with sufficiently high spatial and temporal resolutions. This HF-OR-PAM system,
with high speed (~0.5 Hz volumetric frame rate) and high spatial resolution (~3 μm lateral
resolution), was able to image the spread of microvascular hemodynamic responses to the
propagation of epileptic seizure. We observed increased blood perfusion along the propagation
path of the seizure, reflected by increases in total hemoglobin concentration and blood vessel
diameters.

3.2.2 Methods
Animal preparation

Female ND4 Swiss Webster mice (n = 3) between 16 to 20 g and 4 to 6 weeks old (Harlan
Laboratory, Inc) were used for this study. All experimental animal procedures were carried out in
conformity with the laboratory animal protocols approved by the Animal Studies Committee at
Washington University in St. Louis. Before the experiment, each mouse was first treated with
1.5% vaporized isoflurane for scalp removal and 4-AP injection. Anesthetic depth was assessed
by periodically checking the toe pinch withdrawal reflex. The mouse was mounted on a custombuilt animal holder for HF-OR-PAM. The scalp of each mouse was removed. For epilepsy
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induction, a 500 μm skull opening with the dura intact was created by using a dental drill (Fine
Science Tools) about 2 mm posterior and 1.5 mm lateral to the Bregma point. A dosage of 10 μL
4-aminopyridine (4-AP; Sigma-Aldrich) solution at a concentration of 1.5 mM was injected
through a 150-μm-diameter cannula, which was inserted 0.2 to 0.3 mm below the dura mater
surface. Note that the 4-AP solution used in our study had a ten times lower concentration but a
10 times larger volume than that used in the previous study. After the 4-AP injection, each mouse
was carefully treated with an intraperitoneal dose of 400 mg/kg chloral hydrate for a smooth
transition from isoflurane to chloral hydrate, an anesthetic selected for its relatively mild effect on
cerebral hemodynamics106. The animal’s temperature was kept at 37 ºC by a heating pad during
the entire experiment.

Electroencephalogram recording

To monitor the neural activity that induced the hemodynamic changes during epileptic seizures,
we applied a single-channel electroencephalogram (EEG) recording through an electrode attached
on top of the skull. A reference electrode was mounted on the tooth bar that was in direct contact
with the nasal bone. The EEG signals were amplified by an AC/DC differential amplifier (A-M
Systems, Model 3000), lowpass filtered with a cut-off frequency of 200 Hz, and concurrently
sampled with the photoacoustic signals.

Propagation map construction

X-y projected photoacoustic images were formed by taking the MAP along the depth direction.
Photoacoustic images were then analyzed by comparing the images with the baseline image and
taking the fractional change. The propagation map at the 𝑖 𝑡ℎ frame (𝑖 ≥ 2) was calculated by
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∆𝐴𝑖 = (

𝐴𝑖−1 +𝐴𝑖 +𝐴𝑖+1
3

−

𝐴1 +𝐴2 +𝐴3
3

)/(

𝐴1 +𝐴2 +𝐴3
3

).

(3.1)

Here 𝐴𝑖 is the 𝑖 𝑡ℎ frame. The propagation map was then superimposed onto the corresponding
structrual image to show the spatio–temporal propagation of epileptic seizure. Here, because three
consecutive frames were used in computing the activation map, the effective temporal sampling
rate of the activation map was about 0.17 Hz, which was still sufficiently high to monitor the
seizure propagation.

Blood vessel segmentation and vessel diameter quantification

To distinguish blood vessels from the background, photoacoustic amplitudes were first extracted
by taking the Hilbert transform of the raw photoacoustic signals. The threshold for distinguishing
blood vessels from background was set to be 3 dB above the noise level. The photoacoustic images
were then converted into a binary image based on the threshold, and the blood vessels were
segmented automatically34. The cross sections of the blood vessels were then identified, and the
transverse pathlengths across the vessels were calculated at different angles. The shortest
transverse pathlength was used as the vessel diameter.

3.2.3 Results
HF-OR-PAM of mouse brain vasculature

To image mouse brain vasculature, we updated an OR-PAM system enhanced by a waterimmersible microelectromechanical systems (MEMS) scanning mirror107. HF-OR-PAM is capable
of simultaneously providing high spatial and temporal resolutions. The schematic of HF-OR-PAM
is shown in Figure 3.8a. The system employs a 3-ps pulsed laser (APL-4000-1064, RPMC Lasers,
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Inc.) emitting at 532 nm wavelength with a 200 kHz pulse repetition rate. The laser beam is first
attenuated by a neutral density filter. After being spatially filtered by a condenser lens (LA1131,
Thorlabs, Inc.) and a 50-μm-diameter pinhole (P50C, Thorlabs, Inc.), the laser beam is focused by
an optical objective lens (AC127-050-A, Thorlabs, Inc.; NA: 0.1 in air). The laser beam is then
directed to the sample by a beam combiner and a MEMS scanning mirror. The fluence on the tissue
surface was 5 mJ/cm2, well within the safety limit (20 mJ/cm2) set by the American National
Standards Institute (ANSI). The beam combiner is composed of an aluminum-coated prism (NT32331, Edmund, Inc.) and an uncoated prism (NT32-330, Edmund, Inc.), and provides acousticoptical coaxial alignment. The two prims are glued together. Here, the thin aluminum coating
reflects light but transmits sound. The loss of the acoustic signal crossing the interface of the two
glass prisms is approximately 25%, which depends on the acoustic impedance mismatch at the
interface and the thickness of the glue layer. An optical correction lens is attached to the top surface
of the combiner to correct aberration due to the prism. An acoustic lens with an NA of 0.25 (NT45010, Edmund, Inc.) is attached to the right surface of the combiner. The generated photoacoustic
signal is reflected by the MEMS scanning mirror and detected by an ultrasonic transducer (V214BB-RM, Olympus-NDT, Inc.; 50 MHz central frequency; 100% one-way bandwidth), which is
placed confocally with the objective lens. Both the excitation laser beam and generated
photoacoustic beam are scanned confocally by the MEMS scanning mirror, providing high
detection sensitivity within a large field of view (FoV).
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Figure 3.8. HF-OR-PAM of mouse brain vasculature. (a) Schematic of HF-OR-PAM with a fast-scanning waterimmersible MEMS mirror. AC, aluminum coating; AL, acoustic lens; CorL, correction lens; ConL, condenser lens;
FSM, fast scanning MEMS mirror; ND, neutral density filter; OL, objective lens; UT, ultrasonic transducer; WT,
water tank. (b) Scanning scheme of HF-OR-PAM. 3D imaging is achieved by fast MEMS mirror scanning along the
x axis and slow motor-stage scanning along the y axis. (c) A representative x-y projected brain vasculature image
acquired by MEM-OR-PAM through an intact skull. (d) The depth-enhanced x-z projected brain vasculature image
of the red dashed box in (c). The location of the skull is indicted by the yellow dashed lines.

The scanning scheme of HF-OR-PAM for 3D imaging is shown in Figure 3.9b. The MEMS mirror
is driven by electromagnetic force and submerged in water for ultrasound coupling. A onedimensional photoacoustic image (A-line) is formed by recording the time course of the
photoacoustic signal generated by one single laser pulse. A two-dimensional photoacoustic image
(B-scan) is formed by scanning the laser pulses along the x-axis with the MEMS mirror at 400 Hz.
A three-dimensional photoacoustic image (C-scan) is formed by stacking the B-scans acquired
57

with slow linear step-motor scanning of the object along the y-axis. Bi-hemispheric and unihemispheric imaging were performed to provide comprehensive epileptic seizure propagation
patterns (Fig. 3.9).

Figure 3.9. Photographs of mouse brains with skull intact showing the scanning protocols for bi-hemispheric (blackdashed box) (a) and uni-hemispheric imaging (red-dashed box) (b) of epileptic seizure in the mouse brain, where the
fast MEMS mirror scanning directions are marked by the arrows. (c) The position of the EEG recording electrode and
the imaging FoV (shown by the blue dashed box).

A 4 × 3 mm2 area in the mouse cortex was imaged by HF-OR-PAM with a volumetric frame rate
of 0.5 Hz (Fig. 3.8c and d). The axial resolution of HF-OR-PAM was ∼27 μm, estimated from the
transducer bandwidth (50 MHz) and the speed of sound in tissue (1540 m/s). Photoacoustic signals
acquired at 532 nm, which is close to an isosbestic point of oxyhemoglobin and deoxyhemoglobin,
reflected the relative total hemoglobin concentration.

HF-OR-PAM of epileptic seizure propagation in mouse brain

We performed photoacoustic imaging in a mouse epilepsy model (n = 3). We induced acute
ictogenesis by focal injection of a potassium channel blocker (4-aminopyridine, 4-AP) at 0.2 mm
depth in the mouse cortex, and then performed PAM imaging and electroencephalography (EEG)
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recordings simultaneously (Fig. 3.10a). We imaged the dynamics of total hemoglobin
concentration in response to epileptic seizures (Figs. 3.11 and 3.12). The total hemoglobin
concentration increased along the propagation path of epileptic seizure. The increase in the total
hemoglobin concentration started first at the injection site and then propagated bilaterally to
adjacent areas.

Figure 3.10. HF-OR-PAM of epileptic seizure in a mouse brain. (a) Schematic setup for epilepsy imaging by HF-ORPAM. Red-dashed box shows the imaging area in the mouse cortex. 4-AP was injected locally in the cortex, and an
electrode was attached to the skull surface for EEG recording. (b) Comparison of the EEG signals (blue line) and the
PA signals (red line) recorded simultaneously, showing the correlation between neural activities and hemodynamic
changes. (c) Baseline structural PA image showing the brain vasculature. (d) Fractional changes in PA amplitude
during epileptic seizure. (e) Superposition of the fractional change image (d) on the structural PA image (c) mapping
the wave propagation.

We observed different propagation patterns, including waves of photoacoustic signal changes
along one or both daughter branches of blood vessels, local activations, and waves spreading
bilaterally in both hemispheres (Figs. 3.11 and 3.12). In one representative experiment, during 12
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minutes after 4-AP injection, five groups of waves were observed, with an average duration of
69.6 ± 34.5 seconds. The duration was defined as the time interval during which PA signal increase
was 3 dB above the noise level. Two groups of waves propagated along both daughter vessels of
a mother vessel until they exited the FoV. Two other waves propagated along only one daughter
vessel of the mother vessel. Another wave quickly diminished after entering the FoV. The
propagation delay maps were computed using the same method by Macé et al. for representative
ictal events to show the propagation path and time course (Figs. 3.11d, 3.11h, and 3.12f).

Figure 3.11. HF-OR-PAM of epileptic seizure propagation in one hemisphere. (a-c) Snapshots of representative wave
of PA signal changes propagating along both daughter branches of a blood vessel. (d) Propagation delay map of the
waves shown in (a-c), where the propagation delay in seconds is color encoded and the propagation direction is
indicated by arrows. (e-g) Snapshots of representative wave of PA signal changes propagating along only one daughter
branch of the same blood vessel. (h) Propagation delay map of the wave shown in (e-g). The timestamps are correlated
with the EEG signal shown in Figure 3.10b.

To detect the neural activities that induced the changes in total hemoglobin concentration observed
by HF-OR-PAM, we performed simultaneous EEG signal recording. The PA signal increase was
highly correlated with the EEG signal showing the occurrences of epileptic seizures (Fig. 3.10b).
The correlation coefficient was 0.95 between the PA signal change and the envelope of the EEG
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signal. We also found that the seizure durations measured by PAM and EEG were highly
correlated, with a correlation coefficient of 0.89.

Figure 3.12. HF-OR-PAM of epileptic seizure propagation in bi-hemispheres. (a-f) One representative wave of high
fractional PA signal changes propagated bilaterally in both hemispheres. The timestamps are correlated with the EEG
signal shown in (g). (h) Propagation delay map of the wave in (a-f). Propagation delay in seconds is color encoded.
Arrows represent the wave propagation direction.

We then investigated the propagation speed of epileptic seizures by measuring the arrival time of
the wave of PA signal changes traveling from a reference location (Fig. 3.13a-c). By using a set of
30 spatial points along the blood vessel, we found the epileptic seizure propagation speed was 3.42
mm/min on average (n = 3 mice, 21 blood vessels, 90 total seizures) (Fig. 3.13d), similar to that
reported in previous studies.
61

Figure 3.13. HF-OR-PAM of epileptic seizure propagation speed. (a) Fractional changes in PA amplitudes are plotted
for two different pixels chosen along a blood vessel in the representative ictal seizure event shown in Figure 3.11. (b)
Cross-correlation function between the two signals. The propagation delay is given by the peak position of the crosscorrelation function. (c) Measurement of epileptic seizure propagation speed. A set of 30 points are selected along the
blood vessel. The delay time is linear with the distance from a reference point, and the data is fitted by a linear function.
The slope of the linear function provides the epileptic seizure propagation speed. (d) Histogram of 90 measurements
of epileptic seizure propagation speed.

HF-OR-PAM of blood vessel diameter change in response to epileptic seizure

Vessel diameter changes play a key role in regulating cerebral blood flow for neurovascular
coupling during transient brain activities like epileptic seizure108. HF-OR-PAM was applied to
measure the blood vessel diameter change in response to epileptic seizure (n = 3). After the
injection of 4-AP, HF-OR-PAM was used to image the mouse cortex vasculature with a frame rate
of 0.5 Hz (Fig. 3.14a). We applied a customized vessel segmentation algorithm to distinguish the
blood vessels from the background. Because the transverse resolution of HF-OR-PAM (~3 μm) is
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finer than the axial resolution (~27 μm), the vessel diameter was calculated along the transverse
direction.

Figure 3.14. HF-OR-PAM of blood vessel dilation in response to epileptic seizures. (a) A representative HF-ORPAM image of the mouse brain vasculature. (b) The diameter changes of a representative vessel highlighted by the
red-dashed box in (a). Green dashed lines indicate the resting-state blood vessel boundaries at 10 s. The timestamps
are correlated with the EEG signal shown in (c). (c) Upper panel: time course of the vessel diameters indicated by the
white box in (b) during epileptic seizures. Lower panel: EEG signals acquired simultaneously. (d) Fractional change
in vessel diameter as a function of distance from the injection site. (n = 3 mice, 35 blood vessels, 117 total seizures).
Blue line: running average over 3 sampling points.

HF-OR-PAM monitored the blood vessel diameter changes in response to epileptic seizures (Fig.
3.14b). The change in blood vessel diameters correlated well with the envelope of the EEG signals
(Fig. 3.14c), with a correlation coefficient of 0.91. The distances of the responding vessels relative
to the injection site were measured from the structural image. We found that the magnitudes of
blood vessel diameter changes decreased with increasing distance from the 4-AP injection site (n
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= 3 mice, 35 blood vessels, 117 total seizures) (Figs. 3.14d and 3.15). Within a 1 mm radius of the
injection site, blood vessel diameters increased by an average of 67.1 ± 15.8% during epileptic
seizures.

Figure 3.15. Fractional changes of vessel diameter in response to epileptic seizures. Histogram of 117 measurements
of fractional changes of vessel diameter.

3.2.4 Discussion
In this study, a 4-AP induced epilepsy model was used to demonstrate the feasibility of HF-ORPAM of hemodynamic responses to epileptic seizure propagation with high spatial and temporal
resolution. The 4-AP model is commonly used as an acute model of epileptic ictal seizure109. We
believe HF-OR-PAM of 4-AP induced epilepsy will be of great interest to the epilepsy research
community.
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Although the hemodynamic response imaged by HF-OR-PAM was highly correlated and localized
with the neural activities, it only provided information about the metabolic need during epileptic
seizures. Further development of PAM based on direct sensing of neural activity using membrane
potential or calcium sensitive contrast agents would provide new insights into the disease. In
addition, by applying multi-wavelength measurements in HF-OR-PAM, we can quantify oxygen
saturation of hemoglobin (sO2) and target specific biomarkers19,21. HF-OR-PAM can measure
blood flow by using photoacoustic Doppler effect or cross-correlation methods49,110. With sO2 and
blood flow information, HF-OR-PAM can further quantify the cerebral metabolic rate of oxygen
(CMRO2) during brain activities111. HF-OR-PAM can also be used to study vascular compliance
and the functional connectivity in the mouse brain during epileptic seizures53,112. With high
detection sensitivity, a large FoV, high spatio–temporal resolution, and functional imaging
capabilities, HF-OR-PAM has the potential to become a powerful tool for epilepsy studies.

3.3 Single-cell Metabolic Photoacoustic Microscopy
3.3.1 Background
Tumors consist of heterogeneous populations of cancer cells that have distinct genetic and
phenotypic profiles. The heterogeneity within a tumor, namely intratumoral heterogeneity, has
become the greatest challenge to effective cancer therapy113. It exists among almost all the
hallmarks of cancer, including acquired cell motility that leads to metastasis, elevated angiogenic
potential that leads to angiogenesis, and altered cellular metabolism114. Tumor cells are well known
to have significantly altered metabolic profiles compared to normal cells, and many treatment
methodologies target the cellular metabolism of tumor115. Assessing intratumoral metabolic
heterogeneity would greatly contribute to the understanding of tumor growth, invasion, and drug
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resistance. It will also help design effective and personalized treatment strategies116. While
advances in genome sequencing have revealed intratumoral metabolic heterogeneity on the genetic
level117, little is known about its phenotypic landscape.

With greatly improved biomedical imaging tools, the phenotypic landscape of intratumoral
metabolic heterogeneity now can be studied directly on bulk populations of cells118. However, the
limitations of the current methods usually prevent us from understanding intratumoral metabolic
heterogeneity on a single-cell level. Metabolic heterogeneity has been directly visualized by
positron emission tomography (PET) in vivo in humans119. However, PET lacks the spatial
resolution to study metabolic heterogeneity at the single-cell level. Fluorescence-based methods
have also been used, but the required labelling may perturb the original microenvironments of
tumor cells120. Optical imaging techniques based on endogenous contrasts, such as nicotinamide
adenine dinucleotide (NADH) and flavin adenine dinucleotide (FAD), can assess metabolic states
without labeling121. However, these techniques can only quantify heterogeneous cell populations,
they cannot provide metabolic information for single cells122.
The oxygen consumption rate (OCR) of a cell is directly related to its metabolism123. The
distribution of the single-cell OCRs within a tumor would be an important indicator of its
metabolic heterogeneity. To date, most OCR measurements have been performed on bulk
populations of cells, and they provide little information on cell-to-cell metabolic heterogeneity. To
measure single-cell OCR accurately, each cell must be sealed into a small oxygen-diffusionlimited environment, where the temporal change of oxygen content can be monitored. To create
such an environment, microwell arrays are usually designed to trap a single cell in each microwell
for OCR measurement124. Previously, single-cell OCR measurements have been performed by
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electrical and fluorescent methods, which require microscale oxygen sensors to monitor the
oxygen content change125. To perform single-cell OCR measurements on a large population of
cells with these methods, a massive array of microscale oxygen sensors has to be embedded into
the microwell array, making it extremely difficult to fabricate and use. Moreover, the embedded
microscale oxygen sensors may adversely affect the normal metabolism of the cells, rendering the
OCR measurement inaccurate. Limited by these issues, single-cell OCR measurement has been
demonstrated with only ~30 cell capability126. However, to obtain statistically sound data for
intratumoral metabolic heterogeneity studies, single-cell OCRs of a large number of cells need to
be measured without altering the normal metabolism of the cells. To better understand intratumoral
metabolic heterogeneity and improve cancer therapy, new high-throughput methods are needed to
provide label-free single-cell OCR measurements of a large population of cells.

With 100% relative sensitivity to optical absorption (i.e., a given percentage change in the optical
absorption coefficient yields the same percentage change in the photoacoustic amplitude),
photoacoustic imaging can provide anatomical, functional, molecular, mechanical, and metabolic
information about biological tissues8,13,21. OR-PAM, the major microscopic implementation of
photoacoustic imaging, achieves diffraction-limited lateral resolution, which is sufficient for single
cell imaging20. By employing two excitation wavelengths, OR-PAM can measure the oxygen
saturation of hemoglobin (sO2) in blood127. Further, by temporally monitoring sO2, photoacoustic
imaging can detect changes in blood oxygen content and quantify oxygen metabolism without
labeling111. Here, we developed SCM-PAM by combining a high-density microwell array with
wide-field fast-scanning functional OR-PAM. SCM-PAM provides label-free high-throughput
single-cell OCR measurements for a large population of cells. Each target cell is trapped in a
microwell that constitutes a small oxygen-diffusion-limited environment. By using hemoglobin as
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both an oxygen supplier and sensor, SCM-PAM continuously monitors the sO2 in each microwell
to detect oxygen content changes and quantify the OCR of each target cell. With the capability of
fast-scanning over a wide FoV, SCM-PAM can monitor thousands of microwells, thus achieving
label-free high-throughput single-cell OCR measurements for a large population of cells.

3.3.2 Methods
SCM-PAM system

To achieve label-free high-throughput single-cell metabolic imaging, we combined a functional
OR-PAM system with a high-density microwell array (Fig. 3.16). For sO2 measurement, the
system employs a solid-state laser at 532 nm (SPOT, Elforlight) and a dye laser (CBR-D, Sirah)
at 559 nm. The combined laser beam is reshaped by a 2 mm aperture iris (ID25SS, Thorlabs) and
attenuated by a neutral density filter (NDC-50C-2M, Thorlabs). A pair of condenser lenses
(LA1131, Thorlabs) and a pinhole (P50C, Thorlabs; diameter: 50 μm) are used to spatially filter
the laser beam. A beam sampler (BSF10-A, Thorlabs) and a photodiode are used to monitor the
laser intensity fluctuation. The filtered laser beam is then coupled into a single-mode photonic
crystal fiber (LMA-10, NKT Photonics). The output of the single-mode fiber is collimated by an
objective lens (RMS4×, Thorlabs), reflected by a mirror, and focused on the object by another
identical objective lens. A beam combiner, composed of a thin layer of silicone oil sandwiched by
a rhomboid prism (NT49-419, Edmund Optics) and a right-angle prism (NT32-545, Edmund
Optics), provides acoustic-optical coaxial alignment. The generated photoacoustic waves are
detected by an ultrasonic transducer with a central frequency of 50 MHz (V214-BB-RM,
Olympus-NDT) placed confocally with the objective lens.
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Figure 3.16. System schematic and working modes of SCM-PAM. a, System schematic of SCM-PAM. b, Highresolution mode of SCM-PAM, with optical diffraction limited lateral resolution. c, High-throughput mode of SCMPAM, with single-cell metabolism measurement throughput of ~3000 cells over 15 minutes.

Lateral resolution of SCM-PAM

The lateral resolution of the SCM-PAM system was measured by imaging a sharp metal edge with
a scanning step size of 0.625 µm and a scanning range of 100 µm along the x axis (Fig. 3.17). The
measured data were fitted to an edge spread function (ESF), and the line spread function (LSF)
was calculated based on the fitted ESF. The full width at half maximum (FWHM) of the LSF was
quantified as the lateral resolution. The experimentally measured lateral resolution of SCM-PAM
was 2.71 µm, close to the theoretical value of 2.66 µm.

High-density microwell array

To achieve label-free high-throughput single-cell metabolic imaging, we designed and fabricated
a high-density microwell array capable of trapping a single cell in each microwell. To ensure
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trapping at most one cell, each microwell was designed to be 40 μm in diameter and 50 μm in
depth, and the microwells were set 80 μm apart. SU-8 50 (NANO™) resist was used for fabrication
of the microwell array. To enable effective loading of cells and blood without trapping air in the
microwells, the array was fabricated on an anodisc inorganic filter membrane (Whatman®). To
improve adhesion between the SU-8 substrate and the anodisc inorganic filter membrane, a 400
nm thick layer of aluminum was deposited between them.

Figure 3.17. Lateral resolution of SCM-PAM. The measured data (blue circles) were fitted to deduce an edge spread
function (ESF, red solid line). The line spread function (LSF, black dotted line) was calculated by differentiating the
fitted ESF. The lateral resolution was quantified as the full width at half maximum (FWHM) of the LSF.

The detailed fabrication process was as follows (Fig. 3.18). First, a 400 nm thick layer of aluminum
was deposited on one side of a 60 μm thick anodisc inorganic filter membrane by an e-beam
evaporator (Kurt J. Lesker®). Second, SU-8 50 was spin coated on the aluminum layer at 500 rpm
for 10 seconds in the spread cycle and at 4000 rpm for 30 seconds in the spin cycle to generate a
50 μm thick layer of SU-8 substrate. The entire substrate was then soft baked in an oven at 90°C
for 3 hours, after which the SU-8 was exposed to near ultraviolet light at 200 mJ/cm2. After post70

exposure baking, microwells were developed in an SU-8 developer. The entire microwell array
was then immersed in aluminum etchant, during which the aluminum layer beneath the microwells
was etched away, while the remaining part of the aluminum layer was kept.

Figure 3.18. Fabrication and operation of the high-density microwell array. a-d, Fabrication process of the highdensity microwell array. a, A 400 nm thick layer of aluminum (gray) was deposited on one side of a 60 μm thick
Anodisc inorganic filter membrane (black and white). b, A 50 μm layer of SU-8 (blue) was coated on top of the
aluminum layer. c, Microwells were developed in the SU-8 substrate. d, The aluminum layer beneath the microwells
was etched away, while the remaining part of the aluminum layer was kept. e-h, Operation of the high-density
microwell array. e, Single-cell suspension mixed with blood was spread on the surface of the microwell array. f,
Blood-cell mixture settled in the microwells. The blood was able to enter the Anodisc while the target cells could only
enter the microwells because of the size. g, The cells and blood outside the microwells were removed by flushing the
microwell array with blood and fresh cell culture medium and drawing a small rubber squeegee across the flat surface.
h, The microwell array was sealed by immersing it into silicone oil (yellow).
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Cell culture

Three types of cells, the B16 mouse melanoma cell line, the RAW264.7 murine macrophage cell
line, and the A549 human epithelial lung cancer cell line, were obtained from the Tissue Culture
and Support Center at the Washington University School of Medicine. The B16 mouse melanoma
cells and the RAW264.7 murine macrophage cells were cultured in Dulbecco’s Modified Eagle’s
Medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen) at 37° C in 5% CO2.
The A549 human epithelial lung cancer cells were cultured in F-12K Medium at 37° C in 5% CO2.
At 75% to 80% confluence, cells were harvested with 0.25% trypsin-EDTA solution (Invitrogen)
to generate a single-cell suspension at a concentration of 1×106 cells/mL.

Cells from patient specimens

After informed consent was obtained, breast cancer and normal tissues were collected from women
with newly diagnosed clinical stage I/II breast cancer undergoing breast-conserving surgery. The
protocol was approved by the Institutional Review Board at Washington University in St. Louis.
After excision, the breast tissue was transported in saline immediately from the operating room to
the lab and dissociated to a single-cell suspension with gentleMACS Dissociator (Miltenyi Biotec)
with minimal ischemia time.

Label-free high-throughput single-cell OCR measurement by SCM-PAM

To achieve label-free high-throughput single-cell OCR measurement, 0.1 mL of the single-cell
suspension containing ~10,000 single cells was mixed with the same volume of fully oxygenated
blood and loaded into the high-density microwell array. After waiting for the cells to settle into
the microwells, the high-density microwell array was gently flushed with fully oxygenated blood
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and fresh cell culture medium to remove cells outside the microwells and subsequently a small
rubber squeegee was drawn across the flat surface. After gently immersing the microwell array in
silicone oil for oxygen sealing, the entire assembly was transferred to SCM-PAM for OCR
measurement. During the OCR measurement, a lab-made heating pad maintained the temperature.

Because the amount of oxygen dissolved in blood is negligible compared to its counterpart bound
to hemoglobin, the sO2 change in a microwell can be considered reflective of the oxygen content
change in the microwell. The OCR of a single cell in a microwell can be calculated by:

OCR =

∆O2
.
∆𝑡

(3.2)

Here ∆O2 represents the amount of oxygen change in the microwell over a certain time period ∆𝑡.
The oxygen change in a microwell can be calculated by:
∆𝑛 = 𝑉b × ∆𝐶bO2 .

(3.3)

Here 𝑉b is the volume of blood in the microwell, which is 4.9 × 104 fL, and ∆𝐶bO2 is the change of
oxygen concentration in the blood, which is proportional to the sO2 change ∆sO2 :
∆𝐶bO2 = 4 × ∆sO2 × 𝐶Hb .

(3.4)

Here 𝐶Hb is the concentration of hemoglobin in blood, and the factor 4 is the bonding ratio between
oxygen and hemoglobin. Combining the above three equations, the OCR can be calculated by:

OCR =

4 × 𝑉b × ∆sO2 × 𝐶Hb
.
∆𝑡
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(3.5)

Coefficient of variation and chi-squared goodness-of-fit
The coefficient of variation, Cv, is defined as the ratio of the standard deviation σ to the mean µ of
a distribution:
𝜎

𝐶v = µ .

(3.6)

It is a normalized measure of the dispersion of the single-cell OCR distribution and thus a
parameter to quantify and compare intratumoral metabolic heterogeneity.

The chi-squared goodness-of-fit is used to assess how close the single-cell OCR distribution was
to a normal distribution. The data is first grouped into bins, and the observed and expected counts
for the bins are then calculated. The chi-squared value χ2 is then calculated by
𝑁
2

𝜒 =∑
𝑖=1

(𝑂i − 𝐸i )2
.
𝐸i

(3.7)

Here 𝑂i denotes the observed counts, and 𝐸i denotes the expected counts based on the normal
distribution. A smaller chi-squared value indicates a better fit to the normal distribution and a lower
level of intratumoral cellular metabolic heterogeneity.

3.3.3 Results
SCM-PAM of single-cell trapping and oxygen sealing in a high-density microwell array

The system schematic of SCM-PAM is shown in Figure 3.16a. In brief, the laser beams are focused
on the high-density microwell array, and the generated photoacoustic signals are detected by an
ultrasonic transducer. By recording the time course of the photoacoustic signal from each laser
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pulse, a one-dimensional photoacoustic image (A-line) is acquired. Cross-sectional images (Bscans) or volumetric images (C-scans) can be obtained by linear or raster motor scanning. To
provide comprehensive single-cell metabolic information, we operate SCM-PAM in two modes,
high-resolution mode and high-throughput mode. In the high-resolution mode (Fig. 3.16b), the
microwell array is placed at the optical and acoustic focal plane of the SCM-PAM. With a scanning
step size of 1.25 μm, a photoacoustic image with a FoV of 1 mm × 1 mm (corresponding to 100
microwells) is acquired by SCM-PAM in 400 seconds. In the high-resolution mode, we achieve
optical diffraction limited lateral resolution, which is 2.71 μm for the current system (Fig. 3.17).
Multiple parameters, including the cell size and the well filling ratio, can be quantified in the highresolution mode. In the high-throughput mode (Fig. 3.16c), the laser beam is slightly defocused so
that the laser spot size on the microwell array is 10 μm. A photoacoustic image with a FoV of 7.2
mm × 7.2 mm (corresponding to 3600 microwells) is then acquired by SCM-PAM with a scanning
step size of 20 μm. Each image in the high-throughput mode takes 720 seconds to acquire. In the
high-throughput mode, four spots in each microwell are sampled to provide accurate measurement
of sO2 within the microwell. The throughput can be further improved by sampling only one spot
in each microwell, at the expense of sO2 measurement accuracy within the microwell.

We first imaged the high-density microwell array with the SCM-PAM in high-resolution mode.
Because the aluminum layer generates strong photoacoustic signals, each microwell can be clearly
identified in the photoacoustic images as a negative contrast (Fig. 3.19a). The microwell diameters
estimated from the photoacoustic images were ~40 μm, which agreed well with the values set
during fabrication. To test the single cell trapping efficiency of the microwell array, we imaged it
loaded with B16 melanoma cells. Individual B16 melanoma cells were clearly identified in the
microwells (Fig. 3.19b). By optimizing the cell trapping procedure, we achieved a cell trapping
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efficiency of 73%. We then imaged the microwell array loaded with fully oxygenated blood (sO2
= 100%) and fully deoxygenated blood (sO2 = 0%). The sO2 maps of the high-density microwell
arrays were obtained by employing two wavelengths (532 and 559 nm) for photoacoustic
excitation (Fig. 3.19c and d). The sO2 values were measured accurately, and the microwells were
clearly distinguished from the background based on the sO2 values.

To ensure that the OCR for each single cell was measured accurately, we verified the oxygen
sealing of the microwell array. We first studied the oxygen diffusion between the blood in the
microwells and the outside air by monitoring the sO2 in the microwells. The array was loaded with
blood with sO2 values of 0%, 25%, 50%, 75%, and 100%, and the sO2 values in the microwells
were monitored for 300 minutes, which is 20 times as long as the 15 minute time interval between
two sO2 measurements in later experiments. The sO2 remained unchanged for 300 minutes during
the imaging (Fig. 3.19g), showing that the microwells were fully sealed.

To avoid crosstalk between single-cell OCR measurements in adjacent microwells, we then tested
the oxygen diffusion between microwells. First, we induced differences in adjacent microwells by
selectively heating the microwells, because a temperature change can shift the oxygen–
hemoglobin dissociation curve and thus change the sO2 in the microwells. The baseline sO2 of the
blood loaded in the array was ~60%, at which value a small shift of the oxygen–hemoglobin
dissociation curve can yield a relatively large change in sO2. Then, every other column of
microwells was heated by scanning a continuous-wave (CW) laser (532 nm wavelength; MLL-III532, General Optoelectronic) along the column. During heating, the maximum photoacoustic
amplitude increase at 532 nm was ~8.5%, corresponding to a temperature rise of 1.9°C. To ensure
that only the blood in the microwells was heated, the CW laser spot size was 15 μm and the
76

scanning step size was 80 μm. The laser spot size was smaller than the microwell diameter of 40
µm, and the scanning step size matches the spacing between microwells of 80 µm. After heating,
the array was sealed immediately with silicone oil, and the sO2 in the microwells was monitored
for 300 minutes (Fig. 3.19e and f). At the beginning of the monitoring period, an average decrease
of 12% in sO2 was observed, which was due to heating. During the 300 minute monitoring, the
sO2 in microwells with and without heating stayed unchanged, demonstrating that there was no
oxygen diffusion between the microwells in the high-density microwell array (Fig. 3.19h).

Figure 3.19. Single-cell trapping and oxygen sealing of the high-density microwell array. a, SCM-PAM of a microwell
array without loading. Each well can be clearly identified. b, SCM-PAM of a microwell array loaded with a single
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B16 melanoma cell per well. c, SCM-PAM of a microwell array loaded with fully oxygenated blood (sO2 = 100%).
d, SCM-PAM of a microwell array loaded with fully deoxygenated blood (sO 2 = 0%). e, SCM-PAM of a microwell
array loaded with blood immediately after heating the selected columns. f, SCM-PAM of the microwell array loaded
with blood 300 minutes after heating the selected columns. The columns with heating are labelled with “H”, and the
columns without heating are labelled with “N”. g, Oxygen sealing of an array from the outside air with various initial
sO2 values. The sO2 of the blood in the microwells remained unchanged during 300 minute monitoring, showing that
the microwell array was fully sealed and there was no oxygen diffusion between the microwells and the outside air.
h, Oxygen sealing of an array between microwells. The sO2 of the blood in the microwells remained unchanged during
300 minute monitoring after heating the selected columns, showing that the array was fully sealed and there was no
oxygen diffusion between the microwells.

SCM-PAM of metabolic cellular heterogeneity in cultured cells

To validate the basic capability to image cellular metabolic heterogeneity, we first applied SCMPAM to image cultured normal and cancer cells. Two cell lines, RAW264.7 murine macrophage
(a normal cell line) and A539 human epithelial lung cancer (a cancer cell line) were used. The
single-cell OCRs of RAW264.7 cells were first measured in high-resolution mode (Fig. 3.20a). Of
100 microwells, 92 were filled with a single RAW264.7 cell each well. The sO2 in each microwell
was monitored for 45 minutes to measure the oxygen consumed by the RAW264.7 cell (Fig.
3.20b). Based on the oxygen consumed in 45 minutes, the OCR of each cell was calculated. The
average OCR of the 92 RAW264.7 cells was 0.84 ± 0.08 fmol/min. Then we switched to the highthroughput mode and monitored the sO2 in 3600 microwells. Among the 3600 microwells, 2746
showed significant changes in sO2 within 45 minutes of monitoring (Fig. 3.20c), indicating that
each of these microwells was loaded with a single living RAW264.7 cell. For the remaining
microwells, it could be that RAW264.7 cells were either not loaded or not alive. The oxygen
consumed in each microwell was calculated based on the sO2 change (Fig. 3.20d), and the OCRs
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of the 2746 RAW264.7 cells were calculated accordingly. The average OCR of the 2746
RAW264.7 cells was 0.81 ± 0.11 fmol/min.

Figure 3.20. SCM-PAM of cellular metabolic heterogeneity in cultured cells. a-d, SCM-PAM of single-cell oxygen
consumption rates (OCRs) of cultured RAW264.7 murine macrophage cells. a, SCM-PAM of sO2 changes in the
microwells in high-resolution mode. b, Oxygen consumption curves of 92 RAW264.7 cells measured by SCM-PAM
in high-resolution mode. c, SCM-PAM of sO2 changes in the microwells in high-throughput mode. d, Oxygen
consumption curves of 2746 RAW264.7 cells measured by SCM-PAM in high-throughput mode. e-h, SCM-PAM of
single-cell OCRs of cultured A539 human epithelial lung cancer cells. e, SCM-PAM of sO2 changes in the microwells
measured in high-resolution mode. f, Oxygen consumption curves of 86 A539 cells measured by SCM-PAM in highresolution mode. g, SCM-PAM of sO2 changes in the microwells in high-throughput mode. h, Oxygen consumption
curves of 2761 A539 cells measured by SCM-PAM in high-throughput mode. i, Single-cell OCR distributions of the
above two cell lines measured by SCM-PAM in high-throughput mode.
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Similarly, the single-cell OCRs of A539 cells were first measured in high-resolution mode (Fig.
3.20e). Of 100 microwells, 86 were filled with a single A539 cell each. As before, the sO2 in each
microwell was monitored for 45 minutes, and the oxygen consumed were calculated (Fig. 3.20f).
The OCR of each cell was then calculated based on the oxygen consumed, and the average OCR
of the 86 A539 cells was 1.86 ± 0.43 fmol/min. In the high-throughput mode, among the 3600
microwells, 2761 showed significant changes in sO2 within 45 minutes of monitoring (Fig. 3.20g),
indicating that a single A539 cell was loaded in each of these wells. The oxygen consumed in each
microwell was calculated based on the sO2 change (Fig. 3.20h), and the OCRs of the 2761 A539
cells were calculated accordingly. The average OCR was 1.82 ± 0.47 fmol/min. To show the
cellular metabolic heterogeneity, the distributions of the single-cell OCRs of the above two cell
lines are shown in a histogram (Fig. 3.20i). The cancer cell line (A539 human epithelial lung
cancer) showed a broader and more irregular distribution of single-cell OCRs, indicating a higher
level of cellular metabolic heterogeneity compared to the normal cell line (RAW264.7 murine
macrophage). The initial results in cultured cells demonstrate SCM-PAM’s ability to perform
label-free high-throughput single-cell OCR measurements and show its potential for imaging
intratumoral metabolic heterogeneity.

SCM-PAM of intratumoral metabolic heterogeneity in breast cancer patients

To fully demonstrate its potential in imaging intratumoral metabolic heterogeneity, we applied
SCM-PAM to measure single-cell OCR distributions of normal and cancerous breast tissues from
3 breast cancer patients. After surgical excision, the normal and cancerous breast tissues were
dissociated into single-cell suspensions and placed into the device. The single-cell OCRs of normal
breast tissue cells from patients were first measured in high-resolution mode (Fig. 3.21a). Of 100
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microwells, 87 were each filled with a single cell. We monitored the sO2 in each microwell for 45
minutes to quantify the oxygen consumed and calculate the OCR of the cell in the microwell (Fig.
3.21b). The average OCR of the 87 normal cells was 1.40 ± 0.22 fmol/min. Then we switched to
the high-throughput mode. Among the 3600 microwells imaged, 2438 showed significant changes
in sO2 within 45 minutes of monitoring (Fig. 3.21c), indicating that a single cell was loaded in
each of these wells. The oxygen consumed in each microwell was calculated based on the sO 2
change (Fig. 3.21d), and the OCR of each single cell was calculated accordingly. The average
single-cell OCR of the 2438 cells from the normal breast tissues was 1.41 ± 0.23 fmol/min.

Similarly, we measured the single-cell OCRs of the breast cancer cells from patients (Fig. 3.21eh). In high-resolution mode, the measured average OCR of 93 single cancer cells was 2.27 ± 0.42
fmol/min. In high-throughput mode, the measured average OCR of 2463 single cancer cells was
2.21 ± 0.45 fmol/min. To illustrate the cellular metabolic heterogeneity in breast cancer patients,
the distributions of single-cell OCRs of the normal and cancer cells were plotted (Figs. 3.21i, 3.22,
and 3.23). Even though tumors contain multiple populations of cells beside the cancer cells, the
cancer specimen had a significantly higher average OCR, due to its higher rate of metabolism and
cell proliferation than those of the normal specimen. Paralleling the results in cultured cells, the
cells from the cancer tissue also showed a broader and more irregular distribution of single-cell
OCRs, indicating a higher degree of cellular metabolic heterogeneity than the normal cells. The
results from breast cancer patients fully prove the capability of SCM-CAM in imaging intratumoral
metabolic heterogeneity and show its potential for clinical translation.
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Figure 3.21. SCM-PAM of intratumoral metabolic heterogeneity in a breast cancer patient. a-d, Single-cell OCRs of
normal breast tissue cells measured by SCM-PAM. a, SCM-PAM of sO2 changes in the microwells in high-resolution
mode. b, Oxygen consumption curves of 87 normal cells measured by SCM-PAM in high-resolution mode. c, SCMPAM of sO2 changes in the microwells in high-throughput mode. d, Oxygen consumption curves of 2438 normal cells
measured by SCM-PAM in high-throughput mode. e-h, Single-cell OCRs of cancerous breast tissue cells measured
by SCM-PAM. e, SCM-PAM of sO2 changes in the microwells in high-resolution mode. f, Oxygen consumption
curves of 93 cancer cells measured by SCM-PAM in high-resolution mode. g, SCM-PAM of sO2 changes in the
microwells in high-throughput mode. h, Oxygen consumption curves of 2463 cancer cells measured by SCM-PAM in
high-throughput mode. i, SCM-PAM of single-cell OCR distributions of normal and cancer cells from the patient in
high-throughput mode.
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Figure 3.22. Single-cell OCR distributions in Patient 2 measured by SCM-PAM.

Figure 3.23. Single-cell OCR distributions in Patient 3 measured by SCM-PAM.

Quantifications of elevated cellular metabolic heterogeneity in cancer

To show the full capability of SCM-PAM in quantitatively characterizing intratumoral metabolic
heterogeneity, we calculated and compared several key parameters of single-cell OCR
distributions of both cultured cells and cells from three breast cancer patients. Using cultured cells,
we first calculated the coefficients of variation (CoVs) of the single-cell OCR distributions in
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normal (RAW264.7 murine macrophage) and cancer (A539 human epithelial lung cancer) cells.
The cancer cells showed a significantly higher CoV than the normal cells (n = 5 groups; 14,055
normal cells; 13,257 cancer cells; *p < 0.05), indicating an elevated level of cellular metabolic
heterogeneity (Fig. 3.24a). To quantify how close the single-cell OCR distributions are to normal
distributions, we calculated the chi-squared goodness-of-fit to normal distributions for the cultured
cells (Methods). The cancer cells had a significantly higher chi-squared value than the normal cells
(n = 5 groups; 14,055 normal cells; 13,257 cancer cells; *p < 0.05), indicating a lower similarity
to normal distributions (Fig. 3.24b). In other words, there was a higher level of chaotic cellular
metabolic heterogeneity in the cancer cells than in the normal cells.

In subsequent tests using cells from three breast cancer patients, the cancer cells had a higher
average single-cell OCR, showing an increase in oxygen consumption compared to normal cells
(Fig. 3.24c). We also measured the CoVs and chi-squared values of the single-cell OCR
distributions of the normal and cancer cells. The cancer cells showed a significantly higher CoV
than the normal cells (n = 3 patients; 7,549 normal cells; 6,807 cancer cells; *p < 0.05), indicating
an elevated level of cellular metabolic heterogeneity (Fig. 3.24d). In addition, the cancer cells also
had a significantly higher chi-squared value than the normal cells (n = 3 patients; 7,549 normal
cells; 6,807 cancer cells; *p < 0.05), indicating a lower similarity to normal distributions, thus a
higher level of chaotic cellular metabolic heterogeneity (Fig. 3.24e). Quantitative characterization
of the intratumoral metabolic heterogeneity further shows the capability of SCM-PAM and its
potential as a tool for both preclinical cancer research and clinical cancer therapy.
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Figure 3.24. Elevated and chaotic cellular metabolic heterogeneity in cancer by SCM-PAM. a-b, SCM-PAM of
elevated cellular metabolic heterogeneity in cultured cells. a, Coefficients of variation (CoVs) of single-cell OCR
distributions in cultured normal (RAW264.7 murine macrophage) and cancer (A539 human epithelial lung cancer)
cells (n = 5 groups; 14,055 normal cells; 13,257 cancer cells; *p < 0.05). b, Chi-squared goodness-of-fit to normal
distributions of single-cell OCR distributions in cultured normal and cancer cells (n = 5 groups; 14,055 normal cells;
13,257 cancer cells; *p < 0.05). c, Average single-cell OCRs of normal and cancerous breast tissue cells from three
breast cancer patients. In all three patients, the cancer cells consumed oxygen faster than the normal cell on average
(Patient 1: *p < 0.05; Patient 2: *p < 0.05; Patient 3: *p < 0.05;). d-e, SCM-PAM of elevated cellular metabolic
heterogeneity in breast cancer patients. d, CoVs of single-cell OCR distributions in normal and cancer cells from
breast cancer patients (n = 3 patients; 7,549 normal cells; 6,807 cancer cells; *p < 0.05). e, Chi-squared goodness-offit to normal distributions of single-cell OCR distributions in normal and cancer cells from breast cancer patients (n =
3 patients; 7,549 normal cells; 6,807 cancer cells; *p < 0.05).

SCM-PAM of oxygen consumption of cancer and normal cells in hypoxia

To show the versatility of SCM-PAM as a research tool, we applied it to study the oxygen
consumption of single cells in hypoxia, an important hallmark of cancer. By changing the sO 2 of
the blood (i.e., the oxygen supplier and sensor) in the microwells, we measured how the OCRs of
normal and cancer cells depend on the environmental oxygen levels. In cultured cells, both the
cancer and normal cells showed decreases in average OCRs in hypoxia, due to the lower oxygen
supply (Fig. 3.25a). The cancer cells, however, showed a smaller relative decrease than normal
cells, indicating better adaptation to hypoxia. We also studied how cellular metabolic
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heterogeneity changes in hypoxia by measuring the CoVs and chi-squared values of single-cell
OCR distributions. The CoVs of both normal and cancer cells increased in hypoxia, indicating
more diverse metabolism of single cells under a lower oxygen supply. The cancer cells had an
even higher relative change in CoVs, showing a greater increase in cellular metabolic
heterogeneity (Fig. 3.25b). The chi-squared values of both normal and cancer cells also became
larger in hypoxia, showing that the chaotic levels of cellular metabolic heterogeneity increased
under a lower oxygen supply (Fig. 3.25c).

Figure 3.25. Oxygen consumption of cancer and normal cells in hypoxia by SCM-PAM. a-c, Oxygen consumption
of cultured cells in hypoxia measured by SCM-PAM. a, Normalized OCRs of cultured normal (RAW264.7 murine
macrophage) and cancer (A539 human epithelial lung cancer) cells at different sO 2 levels. b, Normalized CoVs of
single-cell OCR distributions in cultured normal and cancer cells at different sO 2 levels. c, Normalized chi-squared
values of single-cell OCR distributions in cultured normal and cancer cells at different sO 2 levels. d-f, Oxygen
consumptions of normal and cancer cells from breast cancer patients in hypoxia measured by SCM-PAM. d,
Normalized OCRs of normal and cancer cells from breast cancer patients at different sO2 levels. e, Normalized CoVs
of single-cell OCR distributions in normal and cancer cells from breast cancer patients at different sO 2 levels. f,
Normalized chi-squared values of single-cell OCR distributions in normal and cancer cells from breast cancer patients
at different sO2 levels.
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An interesting observation is that the normal cells had a higher relative change in chi-squared
values, showing a greater relative increase in the chaotic levels of cellular metabolic heterogeneity.
This could be due to two reasons. First, the cancer cells started with a higher baseline level of
chaos in cellular metabolic heterogeneity. Second, the cancer cells better adapted to hypoxia than
the normal cells, leading to smaller further increases in the chaotic levels of cellular metabolic
heterogeneity (Fig. 3.26). Similar results were obtained in cells from breast cancer patients (Fig.
3.25d-f), further validating the results and showing the additional potential of SCM-PAM as an
important research tool.

Figure 3.26. Absolute changes of oxygen consumption in hypoxia by SCM-PAM. a-c, Absolute changes in oxygen
consumption of cultured cells in hypoxia measured by SCM-PAM. a, Average single-cell OCRs of cultured normal
(RAW264.7 murine macrophage) and cancer (A539 human epithelial lung cancer) cells at different sO2 levels. b,
CoVs of single-cell OCR distributions in cultured normal and cancer cells at different sO2 levels. c, Chi-squared values
of single-cell OCR distributions in cultured normal and cancer cells at different sO 2 levels. d-f, Absolute changes in
oxygen consumption of normal and cancer cells from breast cancer patients in hypoxia measured by SCM-PAM. d,
Average single-cell OCRs of normal and cancer cells from breast cancer patients at different sO 2 levels. e, CoVs of
single-cell OCR distributions in normal and cancer cells from breast cancer patients at different sO 2 levels. f, Chisquared values of single-cell OCR distributions in normal and cancer cells from breast cancer patients at different sO 2
levels.
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3.3.4 Discussion
By ultrasonically probing the optical absorption of hemoglobin, which acts as both an oxygen
supplier and sensor for single cells, photoacoustic imaging achieves label-free OCR
measurements. Without the need for exogenous oxygen sensors or labelling, a large population of
cells can be screened for single-cell OCR measurement by creating an oxygen-diffusion limited
microenvironment for each cell, using a high-density microwell array. Combining photoacoustic
imaging with the high-density microwell array, SCM-PAM successfully overcomes all the major
challenges in high-throughput single-cell OCR measurements and enables metabolic imaging of
cellular heterogeneity in cancer. In addition, by mixing cancer cells with blood, SCM-PAM avoids
possible adverse effects on normal cell functioning that might be caused by embedded oxygen
sensors or labelling, such as oxygen consumption by electrode sensors
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or photo-toxicity by

fluorescent sensors129. We initially proved the capability of SCM-PAM in label-free highthroughput single-cell OCR measurement by imaging cultured normal and cancer cells. We further
showed the full potential of SCM-PAM for clinical translation by imaging the intratumoral
metabolic heterogeneity in breast cancer patients. By measuring and comparing the key parameters
of single-cell OCR distributions of normal and cancer cells, we demonstrated the capability of
SCM-PAM to quantify intratumoral metabolic heterogeneity. In addition, we showed other
potential applications of SCM-PAM as a powerful research tool to study oxygen consumptions of
single cells in hypoxia. More importantly, we characterized the chaotic feature of intratumoral
metabolic heterogeneity for the first time with and without hypoxia.

Both elevated and chaotic metabolic heterogeneity was observed in cancer cells by SCM-PAM in
our results. The elevated cellular metabolic heterogeneity can be attributed to the genomic
instability in cell cloning and propagation130, the high potency in cell differentiation—
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characteristic of cancer stem cells131, and the presence of mixed cell populations in the patient
specimens. First, cancer cell propagation results in constant mutation acquisitions from unstable
genome replications, resulting in genomic diversity within a single tumor132. Second, cancer stem
cells produce a variety of cell types in a tumor through a differentiation hierarchy133. Third, tumors
are comprised of multiple populations of cells beside the cancer cells themselves, such as
inflammatory cells, which may contribute to the metabolic heterogeneity. The genomic diversity,
distinct cancer cell types, and mixed cell populations within a single tumor result in elevated
intratumoral metabolic heterogeneity. Further, the gene expression unpredictability within one
cancer cell type leads to chaotic cellular metabolic heterogeneity. The high unpredictability of
gene expression yields different mitochondrial contents at different times, creating a chaotic
metabolic system even within a single cancer cell134. Together, these factors contribute to the
elevated and chaotic intratumoral metabolic heterogeneity observed by SCM-PAM.

The OCR of an individual cell is the sum of the OCRs of all the subcellular mitochondria, which
are responsible for aerobic glycolysis, i.e., oxygen consumption. Mathematically, we have
𝑛

𝑆𝑛 = ∑ 𝑀𝑖 .

(3.8)

𝑖=1

Here, 𝑆𝑛 denotes the single-cell OCR, 𝑀𝑖 represents the ith mitochondrion OCR, and n denotes the
virtual number of mitochondria in the cell. Within one cell type, because n is highly consistent135,
it can be treated as a constant. According to the central limit theorem, 𝑆𝑛 follows a normal
distribution if 𝑀𝑖 follows the same distribution regardless of its shape. By sampling a massive
number of single cells simultaneously, we can accurately model the distributions of 𝑆𝑛 and
compare them to a normal distribution using the chi-squared test. We found that cancer cells, both
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in the cultured cell lines as well as the patient tumors, deviated farther from normal distributions,
i.e., with greater chi-squared values, than normal cells, probably due to the aforementioned factors.
First, both the genomic diversity and the multiple types of cancer cells within a tumor generate
distinct n values and 𝑀𝑖 distributions. Second, even within one cancer cell type, the
unpredictability of gene expression produces incongruent distributions of 𝑀𝑖 . This observation
characterized the chaotic feature of intratumoral metabolic heterogeneity for the first time at the
mitochondrial level.

In an effort to further understand the contributions of distinct cancer cell subclones to intratumoral
metabolic heterogeneity, we tried to calculate the number of distinct cell subclones within the
cancer cells sampled. By assuming that the single-cell OCR of each cell type follows a normal
distribution, we fitted the single-cell OCR distributions of the cancer cells to the sum of multiple
normal distributions (Fig. 3.27). The number and weight of the normal distributions were obtained
during fitting. The fitting results showed that the single-cell OCR distributions of the cancer cells
were the sum of multiple normal distributions, indicating that there may be several cell subclones
or types within the cancer cell population examined.

The functionality of SCM-PAM can be further enhanced in two aspects. First, the imaging
throughput can be further improved by using an array with more microwells and increasing the
imaging speed. To make an array with more microwells, more robust fabrication materials and
processes are required. To increase the imaging speed, new scanning mechanisms, such as
microelectromechanical system mirror based scanning, can be used9. Second, additional
parameters can be measured to provide more information on single-cell metabolism. Cell sizes can
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be more accurately quantified in three dimensions by using the photobleaching effect71, and pH
values can be measured with a pH-sensitive fluorescent dye136.

Figure 3.27. Fitting of single-cell OCR distributions. a, The single-cell OCR distribution of cancer cells in Patient 1
was fitted to the sum of two normal distribution with an R2 value of 0.92, indicating that there may be two major types
of cancer cells (indicated by the cyan dashed line and blue dotted line) within the cell population examined. b, The
single-cell OCR distribution of cancer cells in Patient 2 was fitted to the sum of two normal distribution with an R2
value of 0.84, indicating that there may be two major types of cancer cells (indicated by the cyan dashed line and blue
dotted line) within the cell population examined. c, The single-cell OCR distribution of cancer cells in Patient 3 was
fitted to the sum of two normal distribution with an R2 value of 0.88, indicating that there may be two major types of
cancer cells (indicated by the cyan dashed line and blue dotted line) within the cell population examined.
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SCM-PAM holds great potential for clinical translation, especially in the emerging area of
targeting hypoxia, understanding metabolic diversity within and between tumors, and investigating
the effect this heterogeneity on tumor aggressiveness. By utilizing excised tumor tissue and
quickly dissociating it into single-cell suspension for high-throughput single-cell OCR
measurements, SCM-PAM can be conveniently adopted for clinical use. Although in this paper
we have focused on breast cancer, SCM-PAM can be applied to image intratumoral metabolic
heterogeneity of virtually all solid tumors that can be sampled. The microwell size can be adjusted
to better accommodate different cancer cells of varying size. The obtained single-cell metabolism
information and intratumoral metabolic heterogeneity will be particularly valuable to cancer
therapy137. Single-cell metabolism information about cancer cells can be used for therapy response
monitoring and evaluation138, which can help screen drug combinations and develop personalized
cancer therapy strategy139. Apart from cancer therapy, by measuring the single-cell OCR
distributions of different tumors in one patient, SCM-PAM can also study intertumoral
heterogeneity and response to hypoxia. Moreover, SCM-PAM is particularly suitable for studying
the metabolic states of CTCs, the key determinants of cancer metastatic propensity, because blood
is the original biological environment for CTCs140.

In summary, we have developed and optimized SCM-PAM, which combines a wide-field fastscanning functional OR-PAM with a high-density microwell array, for label-free high-throughput
single-cell imaging of intratumoral metabolic heterogeneity. We have demonstrated its capability
by measuring the single-cell OCR distributions of cultured cells and showed its potential for
clinical translation by imaging intratumoral metabolic heterogeneity in breast cancer patient
specimens. In addition, with rich optical absorption contrast, the wide-field fast-scanning
functional OR-PAM subsystem of SCM-PAM can provide multiple dimensions of information
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about tumors, including angiogenesis, metastasis, and drug responses, along with intratumoral
heterogeneity141–143. With its unique capability for label-free high-throughput single-cell OCR
measurement and the potential of providing multidimensional information about tumors, SCMPAM is a promising tool for both fundamental cancer research and clinical personalized cancer
therapy.
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Chapter 4 Photoacoustic Tomography of
Circulating Melanoma Tumor Cells
In this chapter, I introduce the development of linear-array-based PAT systems for label-free highthroughput circulating melanoma tumor cell detection. In the first section, I report a linear-arraybased PAT (LA-PAT) system to detect and quantify circulating melanoma tumor cell clusters,
which greatly elevate the metastatic potential of cancer compared to single circulating melanoma
tumor cells. Then, in the second section, I demonstrated label-free high-throughput PAT of
circulating melanoma tumor cells in patients in vivo. Taking advantage of the strong optical
absorption of melanin, we maximized the contrast between circulating melanoma tumor cells and
blood by picking the optimal excitation wavelength and successfully imaged circulating melanoma
tumor cells in patients in vivo.

4.1 Label-free High-throughput Detection and
Quantification of Circulating Melanoma Tumor Cell
Clusters by Linear-array-based Photoacoustic Tomography
4.1.1 Background
Metastasis, the spread of cancer cells from a primary site to distant organs leading to the growth
of new tumors there, accounts for the majority of cancer deaths144. Blood-borne metastasis
comprises multiple steps, including intravasation, survival in the blood circulation, extravasation,
and secondary growth in the distant organs, in which the rare CTCs are the key determinants of
metastatic propensity145. While most CTCs survive in the blood circulation in the form of single
cells, CTC clusters also exist and elevate the metastatic potential by 23 to 50 folds146. Detection
and quantification of CTC clusters will provide valuable insights into metastasis as well as cancer
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therapy. Because the presence of CTCs is positively correlated with metastatic propensity147, the
detection and enumeration of rare CTCs will help to better evaluate the melanoma stage and predict
metastatic potential during the diagnosis. In addition, tracking the concentration of CTCs in the
circulatory system during treatment will likely be valuable indicators of both tumor responses to
therapy and melanoma progression.

Taking advantage of tumor-specific physical and biological properties, such as sizes and surface
biomarkers, multiple technologies have been developed to capture and isolate single CTCs and
CTC clusters124,148. However, most of these existing technologies require blood to be drawn to
isolate and capture CTCs ex vivo, reducing the effective CTC detection sensitivity. Optical imaging
technologies, such as confocal microscopy, in vivo flow cytometry, and optical coherence
tomography, have been applied to detect CTCs in vivo149–151. However, suffering from strong
optical scattering in biological tissue, these techniques have shallow penetration, limiting them to
imaging only small blood vessels, which results in low throughput for CTC detection.

By integrating optical excitation with acoustic detection, PAT combines rich optical absorption
contrasts with high ultrasonic spatial resolution at depths3. With 100% relative sensitivity to optical
absorption, i.e., a given percentage change in the optical absorption yields the same percentage
change in the photoacoustic signal, PAT8,40,62,111 achieves structural, functional, metabolic, and
mechanical imaging of biological tissue. Taking advantage of the strong optical absorption of
melanin, photoacoustic techniques have been successfully used for imaging and sensing melanoma
CTCs. Photoacoustic flowmetry successfully detected circulating melanoma cells in human
blood152,153. Photoacoustic flow cytometry enables long term monitoring of melanoma CTCs in
vivo. However, these sensing techniques provide inadequate spatial resolution to further
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characterize melanoma CTCs154. The microscopic implementation of PAT, OR-PAM, images
single melanoma CTCs in the blood flows with high spatial-temporal resolution155. While
providing valuable insights into CTCs on a single cell level, OR-PAM suffers from low
throughput.

Here, we apply a LA-PAT system for label-free high-throughput melanoma CTC cluster detection
and quantification in vivo. Exploiting the strong optical absorption of melanin in the melanoma
tumor cells, LA-PAT can achieve label-free detection of melanoma CTC clusters in vivo. By
analyzing the contrast-to-noise ratios (CNRs) of the photoacoustic signals, LA-PAT can quantify
the number of cells in the CTC clusters and study their circulating kinetics in the bloodstream.

4.1.2 Methods
Linear-array-based photoacoustic tomography system

To image melanoma CTC clusters, we applied an LA-PAT system based on a handheld probe and
improved the image reconstruction43. A tunable optical parametric oscillator laser (680 to 970 nm,
20-Hz pulse repetition rate) was used for illumination. An excitation wavelength of 680 nm was
chosen to achieve the optimal contrast between melanoma tumor cells and blood (Fig. 4.1a). The
laser beam was coupled into a fiber optical bundle that bifurcated into two optical fiber bundles.
Laser beams coming out of the two optical fiber bundle strips (20 mm × 1.25 mm) excited the
object at an angle of incidence of 30 degrees relative to the imaging plane (Fig. 4.1b and c). During
the experiments, the fluence on the tissue surface was about 10 mJ/cm2, well within the 20 mJ/cm2
safety limit set by the American National Standards Institute. The generated photoacoustic waves
were detected by a linear array ultrasonic transducer (Visualsonics, Inc., LZ250, 21 MHz center
frequency, 78% one-way bandwidth, 256 elements, 23 mm × 3 mm array size). The spatial
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resolutions of the system were 119 μm in the lateral direction, 86 μm in the axial direction, and
1237 μm in the elevational direction53. Because there were only 64 channels in the data acquisition
unit, four-to-one multiplexing was applied during image acquisition. For each laser pulse, the
generated photoacoustic signals were captured sequentially by a quarter segment of the linear array
(i.e., elements 1–64, 65–128, 129–192, and 193–256). Once the data were acquired from all four
quarter segments, a two-dimensional photoacoustic image was reconstructed with the universal
back-projection algorithm developed by our group45. The reconstructed photoacoustic images
were displayed in an imaging station (Vevo LAZR, Visualsonics, Inc.). Determined by the 20 Hz
laser repetition rate and the four-to-one multiplexing in image acquisition, the frame rate was 5
frames/second.

Tumor cell culture and cluster preparation
B16F10 melanoma tumor cells obtained from ATCC® were cultured in Dulbecco’s modified
Eagle’s medium (Invitrogen) supplemented with 10% fetal bovine serum (Invitrogen) at 37 °C in
air with 5% CO2. Upon reaching 80% confluence, cells growing in a monolayer were incubated
with 0.25% trypsin-EDTA solution (Invitrogen) to generate floating cell clusters of various sizes.
After adding serum-containing medium to neutralize trypsin, the floating cell clusters were
handled in two ways. To mimic melanoma CTC clusters of various sizes, floating cell clusters
totaling 1×106 cells were directly suspended in 1 mL of bovine blood for ex vivo experiments or
in 1 mL of collected rat blood for tail vein injection. To generate melanoma cell clusters of a certain
size for CNR analysis, instead of directly suspending the floating cell clusters in blood, the clusters
were mechanically dissociated by pipetting to generate a single-cell suspension. The single cells
were then suspended in a blood-agar mixture at a desired concentration and then cooled to become
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solid. The concentration was controlled so that within each resolution voxel of LA-PAT there was
a certain number of melanoma cells, i.e., 5, 10, 20, 30, 40, or 50. The solid mixture was then
mechanically dissociated into particles smaller than the resolution voxel of LA-PAT to generate
cell clusters of a certain size. The particles were then suspended in 1 mL of bovine blood for CNR
analysis.

Figure 4.1. Absorption spectra and views of the hand-held probe for LA-PAT. (a) Absorption spectra of melanin
(black dashed line), oxyhemoglobin (red solid line), and deoxyhemoglobin (blue dotted line). (b) Lateral view of the
hand-held probe. (c) Elevational view of the hand-held probe with a zoomed-in view.

Phantom preparation
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Silicone microtubes with 0.76 mm inner diameter (11-189-15C, Fisher Scientific) were perfused
with bovine blood (905, Quad-Five) to mimic blood vessels. The microtubes were embedded 3
mm deep in tissue-mimicking gelatin phantoms. Optical scattering similar to that in biological
tissue was achieved by adding 1% intralipid to the gelatin phantoms. Melanoma tumor cell clusters
suspended in bovine blood were pumped through the microtubes with a syringe. A syringe pump
(BSP-99M, Braintree Scientific) controlled the blood flow speed.

Experimental animals and CTC cluster injection

All experimental animal procedures were carried out in conformity with the laboratory animal
protocol approved by the Animal Studies Committee at Washington University in St. Louis. Male
nude rats (Hsd:RH-Foxn1rnu/Foxn1+, Harlan Co.; 12–13 weeks old; ~330−350 g body weight)
were used for all in vivo experiments. Throughout the experiments, the rats were kept under
anesthesia with 2% vaporized isoflurane. A home-made animal holder immobilized the rats during
the experiments.

4.1.3 Results
CNR analysis of melanoma tumor cell clusters

To detect and quantify CTC clusters, we first used LA-PAT to image melanoma tumor cell clusters
of known sizes and analyzed their CNRs. Clusters with an average of 5, 10, 20, 30, 40, and 50
cells were suspended in blood and imaged by LA-PAT. The CNR for each cluster was calculated
(Fig. 4.2a). The average CNRs were plotted as a function of the number of cells in the clusters, as
measured with an optical microscope (Eclipse TS100, Nikon) (Fig. 4.2b). The experimental data
were fitted to a linear function:
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𝐶𝑁𝑅 = 0.46 × 𝑁.

(4.1)

Figure 4.2. CNR analysis of melanoma tumor cell clusters. (a) CNR distributions measured with LA-PAT for
melanoma tumor cell clusters of different sizes. (b) Average CNRs in LA-PAT as a function of the numbers of cells
in melanoma tumor cell clusters. (c) The numbers of cells in melanoma tumor cell clusters measured by LA-PAT
agreed well with those measured by an optical microscope (OM).

Here 𝑁 represents the number of cells in a melanoma tumor cell cluster. Based on a 6 dB CNR
threshold, a minimum of four cells can be resolved although this minimum was not directly
observed. To verify the relationship between the CNR and the number of cells in the clusters,
another independent experiment was performed. Melanoma tumor cell clusters consisting of a
uniform but unknown number of cells were equally divided into six groups. Three randomly
chosen groups were suspended in blood and imaged by LA-PAT. The numbers of cells in the
clusters were calculated based on the CNRs and the relationship above. The other three groups
were examined with an optical microscope to determine the numbers of cells in the clusters. The
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number of cells in the melanoma tumor cell clusters measured by LA-PAT and optical microscopy
agreed well with each other (Fig. 4.2c), confirming the relationship between the numbers of cells
in the clusters and the CNRs in LA-PAT.

LA-PAT of CTC clusters ex vivo

We then demonstrated the ability of LA-PAT to detect and quantify CTC clusters ex vivo. A
mixture of melanoma tumor cell clusters of various sizes was equally divided into six groups.
Three randomly chosen groups were suspended in blood, pumped through microtubes to mimic
flowing melanoma CTC clusters, and imaged by LA-PAT. Each melanoma tumor cell cluster was
captured by LA-PAT multiple times, and the average CNR was used to calculate the number of
cells in the cluster. Based on the calculated number of cells in the clusters, the melanoma tumor
cell clusters were divided into three categories: ≤10, 11–20, and ≥21. Typical photoacoustic
images of the three categories are shown in Figure. 3a–c. The other three groups were measured
with an optical microscope to determine the numbers of cells in the clusters and were divided into
the same three categories. The size distributions of the clusters measured by LA-PAT and optical
microscopy agreed well with each other with a correlation coefficient of 0.96 (Fig. 4.3d), and the
results further demonstrated the ability of LA-PAT to detect and quantify melanoma CTC clusters.

LA-PAT of CTC clusters in vivo

To demonstrate the feasibility of LA-PAT in vivo, we imaged melanoma CTC clusters injected
into rats. Melanoma tumor cell clusters suspended in 1 mL of rat blood at a concentration of 1×106
cells/mL were injected into the same rat from which the blood was collected a few minutes earlier.
The rat tail vein was then monitored by LA-PAT for 45 minutes to study the circulation kinetics
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and the clearance rates of CTC clusters. CTC clusters were detected by LA-PAT immediately after
injection and during circulating in the rat bloodstreams (Fig. 4.4a and b). The numbers of cells in
the CTC clusters were calculated based on the CNRs. The CTC clusters were categorized into
three groups based on the calculated number of cells and the clearance curves of the three groups
are shown in Figure 4.4c. Larger CTC clusters showed faster clearance rates from the bloodstream
than smaller CTC clusters.

Figure 4.3. LA-PAT of CTC clusters ex vivo. LA-PAT of a flowing melanoma tumor cell cluster with (a) 7 cells, (b)
14 cells, and (c) 29 cells. The cell numbers are calculated based on the CNR curve in Figure 4.2. (d) Distributions of
the numbers of cells in melanoma tumor cell clusters, as measured by LA-PAT and OM.
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Figure 4.4. LA-PAT of CTC clusters in rat tail veins in vivo. (a) LA-PAT of CTC clusters in a rat tail vein in vivo
immediately after injection. (b) LA-PAT of CTC clusters in the rat tail vein in vivo 45 min after injection. (c) Clearance
curves of small (≤10 cells), medium (11–20 cells), and large (≥21 cells) CTC clusters in rat bloodstreams.

4.1.4 Discussion
Compared to single CTCs, CTC clusters are rarer, but have a higher metastatic potential. CTC
clusters have a faster clearance rate, i.e., a shorter lifetime, in the bloodstream than single CTCs,
making them even more difficult to detect. The melanoma CTC detection sensitivity of LA-PAT
is determined by the CNR. Because the noise is dominated by the fluctuating counts of red blood
cells in each resolution voxel, the detection sensitivity is largely dependent on the spatial
resolutions of LA-PAT. On one hand, to achieve single cell sensitivity in CTC detection, a higher
frequency ultrasonic transducer could be used, at the expense of penetration depth. On the other
hand, to achieve deeper imaging, a lower frequency ultrasonic transducer can be employed, at the
expense of CTC detection sensitivity. The CTC detection sensitivity can be further improved by
performing spectral unmixing using multi-wavelength illumination. To achieve multi-wavelength
imaging of flowing CTCs, a second laser with a different wavelength needs to be incorporated into
the system.
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It is worth pointing out that currently LA-PAT detects only CTCs originating from primary tumors
in which cells express melanin. To detect CTCs originating from amelanotic melanoma tumors,
other tumor-specific physiological properties, such as sizes and surface biomarkers, can be
utilized. The quantification of CTC cluster sizes is indeed based on the assumption that the melanin
content is relatively uniform in the tumor cells. This assumption often holds true for tumor cells
originating from the same primary tumor. However, if there are several primary tumors, it may
affect the accuracy of quantifying CTC cluster sizes.

LA-PAT has the potential to be a powerful tool for both preclinical tumor metastasis study and
clinical cancer diagnosis and therapy. As a useful technique for researchers and scientists to better
understand the relationship between CTCs and tumor metastasis, LA-PAT can employ ultrasonic
transducers of different frequencies for target vessels at various depths and different animal
models. Other physiological parameters, including vessel diameter and blood flow speed, can be
measured concurrently for further understanding of CTC flow dynamics. LA-PAT can also be used
by clinicians to monitor the changes of CTC concentrations in patients’ circulatory systems and to
evaluate the outcome of cancer therapy. To further improve LA-PAT for such clinical applications,
an automatic CTC detection and counting algorithm should be developed.

Metastasis is a complex biological process that involves multiple steps and many parameters.
Photoacoustic imaging, with the ability to quantify numerous parameters at multiple scales based
on the same optical absorption contrast, can provide comprehensive information about tumor
metastasis. OR-PAM can study CTCs on a single cell level. LA-PAT has been demonstrated to
detect and quantify CTC clusters. In addition, photoacoustic imaging can measure other important
biological parameters, including the oxygen saturation of hemoglobin, metabolic rate, and tumor
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stiffness21,102,156, all of which are closely related to metastasis142,157,158. With the capability to detect
and quantify CTC clusters and the potential to provide multidimensional information on tumor
metastasis, LA-PAT is a promising tool for both preclinical cancer metastasis study and clinical
tumor therapy.

4.2 Label-free High-throughput Photoacoustic
Tomography of Circulating Melanoma Tumor Cells in
Patients in Vivo
4.2.1 Background
More than 90% of cancer-associated mortality are caused by metastasis25, which refers to the
process of cancer cells spreading from primary tumor site to surrounding tissues and distant organs
to form new tumors. During the entire metastatic process, a cancer cell needs to execute multiple
steps, including acquiring the invasive phenotype at the primary tumor, invading the surrounding
tissue, enter the local blood or lymphatic vessel (intravasation), surviving and circulating in the
blood stream, exiting through microvessels to distant tissues (extravasation), adapting to the new
microenvironment, and growing into metastases26. In this metastatic cascade, the rare CTCs are
the key determinants to the metastatic propensity159,160. Considered as the “seeds” to metastases,
the presence and concentration of CTCs are closely correlated with the tumor progression,
metastases, and survival rates in patients145. Thus, efficient detection and characterization of CTCs
will make critical contributions to cancer diagnosis and staging, therapy response assessment, and
residual disease evaluation after surgery.

Recent advances in biomedical techniques have enabled intensive study on the presence of CTCs
in the bloodstream to gain further insights of metastasis161. These techniques usually utilize tumor105

specific physical and biological properties to detect, capture, or isolate CTCs from the
bloodstream. However, they all encounter certain limits that prevent effective detection of CTCs
in patients. Most ex vivo CTC detection assays, including the CTC microchip and the FDAapproved CellSearch (CELLSEARCH®), rely on epithelial markers as the tumor biomarker148,162.
A critical subpopulation of CTCs could be missed in such assays because some CTCs can shield
their epithelial markers or express fewer markers after transitions. A new generation of microchip
was developed to isolate CTC clusters based on size124. However, it stills suffers from very limited
blood sample volume in the ex vivo assays relative to the patient’s entire blood volume, which
significantly reduces the effective sensitivity of CTC detection, and thus leads to inaccurate
diagnosis. To improve the detection sensitivity, in vivo optical CTC imaging techniques have also
been developed149, including in vivo flow cytometry151, multiphoton microscopy163, and inverse
spectroscopic optical coherence tomography164. However, most of these techniques requires CTC
labelling using targeted nanoparticles or fluorescent probes, the toxicity of which impedes their in
vivo clinical translation. More importantly, strong optical scattering in biological tissue severely
limits the imaging depth of these optical imaging techniques165, restricting the imaging targets to
only small vessels, resulting in low throughput for CTC detection.

By ultrasonically imaging optical absorption contrast, PAT achieves label-free imaging of
biological tissue in vivo beyond the optical diffusion limit and has significantly advanced cancer
imaging3,7,166,167. The unique combination of optical excitation and acoustic detection allows PAT
to break all the aforementioned limits for effective CTC detection. First, the weak ultrasonic
scattering in soft tissue provides PAT the access to bigger vessels with greater flow rates at depths,
thus achieving much higher throughput for CTC detection than pure optical techniques. Second,
the rich endogenous optical absorption contrast enables high-sensitivity imaging of CTCs in vivo
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by proper excitation wavelength selection and/or robust spectral unmixing, without the need of
exogenous labelling agents. In this work, we focus on CTC detection in melanoma, the most fatal
type of skin cancer with more than 87,000 new diagnoses and 10,000 deaths each year168.
Melanoma has a high tendency of metastasis, after which the 5-year survival rate decreases from
98.5% to less than 20%. Effective detection of melanoma CTC is critical for understanding
melanoma metastasis and improving its therapy. PAT is particularly suitable for melanoma CTC
detection owing to the strong optical absorption of the highly expressed melanin, which serves as
a perfect intrinsic contrast169. Photoacoustic sensing techniques, including photoacoustic
flowmetry and flow cytometry, has successfully infer the appearances of melanoma tumor cells by
identifying the peaks in the 1D signal, but they do not provide the spatial resolution to visualize
and characterize them152,154.

Here, we developed a PAT system based on a linear ultrasonic transducer array (LA-PAT) and
achieved label-free high-throughput imaging of melanoma CTCs in patient in vivo for the first
time. We first imaged flowing melanoma tumor cells in microtubes to initially demonstrate the
capability of LA-PAT. Then, 16 Stage III and IV melanoma patients were imaged by LA-PAT and
we successfully detected melanoma CTCs in 3 of them. The CTC imaging results were validated
with CNR analysis compared to healthy volunteers and CTC-negative patients and the clinical
relevance of CTC detection was studied by follow-up monitoring of the patients imaged.

4.2.2 Methods
Optimal excitation wavelength for photoacoustic imaging of circulating melanoma tumor
cells
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Figure 4.5. Optimal excitation wavelength for photoacoustic imaging of melanoma CTCs. a, Optical absorption
spectra of melanin (major absorber in melanoma CTCs) and hemoglobin (major absorber in blood). HbO2,
oxyhemoglobin; HbR, deoxyhemoglobin. b, Absorption coefficient ratio of melanin and venous blood with an oxygen
saturation level of 85%. An excitation wavelength of 680 nm was chosen to maximize the melanoma CTC detection
sensitivity.

To achieve the highest detection sensitivity of melanoma CTCs in blood, an excitation wavelength
that maximizes the contrast between melanoma CTCs (target) and blood (background) should be
chosen. We compared the optical absorption spectra of melanin, the major optical absorber in
melanoma CTCs, and hemoglobin, the major optical absorber in blood (Fig. 4.5a). Based on the
absorption spectra, we calculated the optical absorption coefficient ratio of melanin and venous
blood (oxygen saturation level of 85%) to select the wavelength that maximizes the contrast.
Venous blood was used as the background here because veins, with shallow depth in tissue and
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large blood volume, are ideal imaging targets in patients for melanoma CTC detection in patients.
Based on the optical absorption coefficient ratio, an excitation wavelength of 680 nm was chosen
to maximize the contrast between melanoma CTCs and blood and achieve the highest detection
sensitivity (Fig. 4.5b).

Linear-array-based photoacoustic tomography system for circulating melanoma tumor cell
imaging

To achieve label-free high-throughput imaging of melanoma CTCs, we developed a PAT system
based on a linear array ultrasonic transducer (LA-PAT) (Fig. 4.6). After careful analysis, an
excitation wavelength of 680 nm was chosen to maximize the contrast between melanoma CTCs
and blood and another excitation wavelength of 850 nm was chosen to locate blood vessels in
melanoma patients. To provide excitation wavelengths of 680 nm and 850 nm, a tunable optical
parametric oscillator laser (680 to 970 nm, 20-Hz pulse repetition rate) was used and the excitation
wavelength can be manually switched. To ensure the safety of patients, the laser beam was coupled
into a fiber optical bundle. The optical fiber bundle bifurcated into two and laser beams coming
out of the optical fiber bundles illuminate the imaging area at an angle of incidence of 30 degree
relative to the imaging plane. The fluence on the tissue surface during the experiments was ~11
mJ/cm2, well within the 20 mJ/cm2 safety limit set by the American National Standards Institute.
The generated photoacoustic waves were detected by a linear array ultrasonic transducer
(Visualsonics, Inc., MS550D, 40 MHz center frequency, 33 MHz bandwidth, 256 elements). A
four-to-one multiplexing was used in image acquisition because there were 256 elements in the
linear array transducer and 64 channels in the data acquisition unit. In detail, for each laser pulse,
the generated photoacoustic signals were captured sequentially by a quarter segment of the linear
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array (i.e., elements 1 to 64, 65 to 128, 129 to 192, and 193 to 256). A 2D photoacoustic image
was reconstructed with the universal back-projection algorithm after the data were acquired from
all four quarter segments. The linear array ultrasonic transducer was connected to an imaging
platform (Visualsonics Inc., Vevo LAZR), where the reconstructed photoacoustic images were
displayed. The imaging frame rate was 5 frames/second, determined together by the 20 Hz laser
repetition rate and four-to-one multiplexing in image acquisition. The frame rate can be adjusted
by utilizing fewer elements in the linear array transducer, at the expense of smaller imaging FoV.

Figure 4.6. System schematic of LA-PAT for melanoma CTC imaging in patients.

Spatial resolutions of LA-PAT system

The spatial resolutions of the LA-PAT system were quantified by imaging a carbon fiber with a
diameter of 6 µm. First, the carbon fiber was placed perpendicular to the imaging plane and a cross
section image of the carbon fiber was acquired by LA-PAT (Fig. 4.7a). The photoacoustic
amplitude profile of the carbon fiber along the axial direction was fitted to a Gaussian function
and the full width half maximum (FWHM) of 43 µm was quantified as the axial resolution of the
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LA-PAT system (Fig. 4.7b). The LA-PAT system was then scanned along the elevational direction
with a step size of 20 µm. To quantify the lateral resolution, the MAP image along the axial
direction of the carbon fiber was obtained (Fig. 4.7c). Similarly, the photoacoustic amplitude
profile of the carbon fiber along the lateral direction was fitted to a Gaussian function and the
FWHM of 94 µm was quantified as the lateral resolution of the LA-PAT system (Fig. 4.7d). To
quantify the elevation resolution, the carbon fiber was placed along the lateral direction of the LAPAT system. The LA-PAT system was then scanned along the elevational direction with a step
size of 20 µm and an MAP image along the axial direction of the carbon fiber was obtained (Fig.
4.7e). The photoacoustic amplitude profile of the carbon fiber along the elevational direction was
fitted to a Gaussian function and the FWHM of 633 µm was quantified as the elevational resolution
of the LA-PAT system (Fig. 4.7f).

Phantom preparation

To mimic blood vessels of different diameters, silicone microtubes (Fisher Scientific) with various
inner diameters of 0.3 mm, 0.5 mm, 0.64 mm, 0.76 mm, 1 mm, 1.5 mm, 2 mm, 2.64 mm, and 3.35
mm were perfused with bovine blood (905, Quad-Five). The microtubes were embedded at
different depths in tissue-mimicking gelatin phantoms. To achieve optical scattering similar to that
in biological tissue, 1% intralipid was added to the gelatin phantoms. Melanoma tumor cells
suspended in bovine blood were pumped through the microtubes with a syringe. A syringe pump
(BSP-99M, Braintree Scientific) controlled the blood flow speed.
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Figure 4.7. Quantification of spatial resolutions of LA-PAT system. a, A cross section image of a carbon fiber by LAPAT. b, The photoacoustic amplitude profile along the green dashed line in (a). The profile was fitted to a Gaussian
function and the full width half maximum (FWHM) of 43 µm was quantified as the axial resolution of the LA-PAT
system. c, An MAP image along the axial direction of the carbon fiber by LA-PAT. d, The photoacoustic amplitude
profile along the green dashed line in (c). The profile was fitted to a Gaussian function and the FWHM of 94 µm was
quantified as the lateral resolution of the LA-PAT system. e, An MAP image along the axial direction of the carbon
fiber by LA-PAT. f, The photoacoustic amplitude profile along the green dashed line in (e). The profile was fitted to
a Gaussian function and the FWHM of 633 µm was quantified as the elevational resolution of the LA-PAT system.
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Catching efficiency calculation

To quantify the melanoma tumor cell catching efficiency of LA-PAT, ~1000 single melanoma
tumor cells were suspended in 10 mL bovine blood and pumped through a microtube with a
syringe. The melanoma tumor cells and blood were collected at the other end of the microtube.
After ~50 melanoma tumor cells were captured by LA-PAT, the collected melanoma tumor cells
and blood mixture were examined with an optical microscope to count the number of melanoma
tumor cells pumped through the microtube. The catching efficiency E is defined as

𝐸=

𝑛
.
𝑁

(4.2)

Here, n stands for the number of melanoma tumor cells capture by LA-PAT and N stands for the
number of melanoma tumor cells pumped through the microtube.

Imaging procedure for melanoma patients and healthy volunteers

After informed consent was obtained, the patients and volunteers were asked to sit down or lie
down in a comfortable position on the patient chair or bed. The protocol was approved by the
Institutional Review Board at Washington University in St. Louis. Depending on the location of
primary melanomas, either the cephalic veins or the small saphenous veins were imaged. First, an
excitation wavelength of 850 nm was used to locate the target vein and proper imaging segment.
Then, we switched to 680 nm to detect the melanoma CTCs and each patient was usually imaged
for 20 minutes. During the entire imaging session, laser safety glasses with optical density greater
than 5 at 680 nm and 850 nm were required to ensure the safety of patients.

Flow speed of melanoma tumor cells
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Figure 4.8. Estimation of the melanoma CTC flow speed. a, A representative photoacoustic image of a single
melanoma CTC in a patient. b, A representative photoacoustic image of a melanoma CTC cluster in the patient. c, The
time trace plot of each pixel along the yellow dashed line in (a) in the space-time domain. The slope of the red solid
line, computed by linear fitting as 10.3 mm/s, represents the flow speed of the single melanoma CTC. d, The time
trace plot of each pixel along the yellow dashed line in (b) in the space-time domain. The slope of the red solid line,
computed by linear fitting as 5.4 mm/s, represents the flow speed of the melanoma CTC cluster.

To make robust measurement of the flow speed of melanoma tumor cells, we converted their
motions to the space-time domain. The time traces of each pixel along the yellow dashed line in
Figure. 4.8a and b were extracted and the signals were shown as an image in the space-time domain
(Fig. 4.8a and b). The data were fitted to a linear function and the slope of the linear function in
the space-time domain was used to calculate the speed of the melanoma CTC.

Detection sensitivity of melanoma CTC by LA-PAT
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The ability to visualize a melanoma tumor cell in blood depends on the CNR, defined as

CNR =

∆𝑃𝐴
.
𝜎𝑃𝐴

(4.3)

Here, ∆𝑃𝐴 stands for the photoacoustic amplitude variation due to the strong optical absorption by
the single melanoma CTC, and 𝜎𝑃𝐴 stands for the standard deviation of the varying background
photoacoustic amplitude due to the fluctuation of RBC numbers.
The photoacoustic amplitude variation ∆𝑃𝐴 is defined as the photoacoustic amplitude difference
between two adjacent voxels with and without a melanoma CTC
∆𝑃𝐴 = 𝑃𝐴𝑤 − 𝑃𝐴𝑤𝑜 .

(4.4)

∆𝑃𝐴 = 𝑃𝐴𝐶𝑇𝐶 + 𝑃𝐴𝑅𝐵𝐶 ∗ [𝑅𝐵𝐶]𝑤 − 𝑃𝐴𝑅𝐵𝐶 ∗ [𝑅𝐵𝐶]𝑤𝑜 .

(4.5)

And it can be further expressed as

Here 𝑃𝐴𝐶𝑇𝐶 stands for the photoacoustic signal from one melanoma CTC and 𝑃𝐴𝑅𝐵𝐶 stands for
the photoacoustic signal from one RBC. [𝑅𝐵𝐶]𝑤 and [𝑅𝐵𝐶]𝑤𝑜 stand for the number of RBCs in a
resolution voxel with and without a melanoma CTC.

Because the fluctuation of RBC number in each resolution voxel follows Passion distribution, the
noise 𝜎𝑃𝐴 can be expressed as
𝜎𝑃𝐴 = 𝑃𝐴𝑅𝐵𝐶 ∗ √[𝑅𝐵𝐶]𝑤𝑜 .
Combining equations (3) and (4), the CNR can be expressed as
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(4.6)

CNR =

𝑃𝐴𝐶𝑇𝐶 + 𝑃𝐴𝑅𝐵𝐶 ∗ [𝑅𝐵𝐶]𝑤 − 𝑃𝐴𝑅𝐵𝐶 ∗ [𝑅𝐵𝐶]𝑤𝑜
𝑃𝐴𝑅𝐵𝐶 ∗ √[𝑅𝐵𝐶]𝑤𝑜

.

(4.7)

It can be further simplified by canceling 𝑃𝐴𝑅𝐵𝐶

CNR =

𝑃𝐴𝐶𝑇𝐶 ⁄𝑃𝐴𝑅𝐵𝐶 +[𝑅𝐵𝐶]𝑤 − [𝑅𝐵𝐶]𝑤𝑜
√[𝑅𝐵𝐶]𝑤𝑜

.

(4.8)

The photoacoustic amplitude ratio between one melanoma CTC and one RBC is determined by
two factors, the absorption volume and absorption coefficient at the excitation wavelength. The
volume ratio between a melanoma CTC and a RBC is typically ~10. By careful analysis of the
absorption spectra of melanin (major optical absorber in melanoma CTCs) and hemoglobin (major
optical absorber in RBCs), the maximum absorption coefficient ratio is ~150 (Fig. 4.5). So the
typical value for 𝑃𝐴𝐶𝑇𝐶 ⁄𝑃𝐴𝑅𝐵𝐶 is ~1500. Because a melanoma CTC only takes up the space for
~10 RBCs, the difference between [𝑅𝐵𝐶]𝑤 and [𝑅𝐵𝐶]𝑤𝑜 is ~10, less than 1% of 𝑃𝐴𝐶𝑇𝐶 ⁄𝑃𝐴𝑅𝐵𝐶 ,
and can be neglected. So the CNR can be further expressed as

CNR =

𝑃𝐴𝐶𝑇𝐶 ⁄𝑃𝐴𝑅𝐵𝐶
√[𝑅𝐵𝐶]𝑤𝑜

.

(4.9)

The [𝑅𝐵𝐶]𝑤𝑜 is determined by the density of RBCs in blood and the resolution voxel size. The
CNR, i.e. melanoma CTC detection sensitivity, can be enhanced by reducing the resolution voxel
size using an ultrasonic transducer with higher frequency, at the expense of penetration depth. In
this study, the spatial resolutions of LA-PAT system are 43 µm in axial direction, 94 µm in lateral
direction and 633 µm in elevational direction. The resolution voxel size is ~2 × 10-3 µL. The
typical RBC density is ~5 × 106 cells/µL, so the [𝑅𝐵𝐶]𝑤𝑜 is ~1 × 104 cells. Plugging in the values
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of 𝑃𝐴𝐶𝑇𝐶 ⁄𝑃𝐴𝑅𝐵𝐶 and [𝑅𝐵𝐶]𝑤𝑜 , the typical CNR of a single melanoma CTC is ~15, which is much
higher than the threshold of 2 and ensures the high detection sensitivity of melanoma CTCs by
LA-PAT.

It is worth noting that in the model above, noises from resources other than the fluctuation of RBCs
are not considered because they are usually much smaller than the photoacoustic amplitude
variation due to the fluctuation of RBCs. However, as the imaging depth increases, the
photoacoustic signals from RBCs attenuate and the noise 𝜎𝑃𝐴 can be expressed as:
𝜎𝑃𝐴 = 𝑃𝐴𝑅𝐵𝐶 ∗ √[𝑅𝐵𝐶]𝑤𝑜 + 𝜎𝑜 .

(4.10)

Here 𝜎𝑜 stands for noises coming from resources other than the fluctuation of RBCs, and it mainly
comes from three resources: thermal acoustic noise from the medium, thermal noise from the
ultrasonic transducer, and electronic noise from the amplifier. The CNR is then expressed as:

CNR =

𝑃𝐴𝐶𝑇𝐶
𝑃𝐴𝑅𝐵𝐶 ∗ √[𝑅𝐵𝐶]𝑤𝑜 + 𝜎𝑜

.

(4.11)

The CNR decreases as the imaging depth increases.

Estimation of total number of melanoma CTCs in patients
The total number of melanoma CTCs 𝑁𝑡 in a patient can be estimated by the following equation
assuming a random distribution of melanoma CTCs in blood.

𝑁𝑡 = 𝑁𝑑

𝑉𝑡
.
𝑉𝑓 (𝑡)
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(4.12)

Here 𝑁𝑑 stands for the number of melanoma CTCs detected by LA-PAT, 𝑉𝑡 stands for the total
blood volume in the patient, and 𝑉𝑓 (𝑡) stands for the fresh (i.e. unrepeated) blood volume examined
by LA-PAT in a given imaging time 𝑡.
To determine the fresh blood volume 𝑉𝑓 (𝑡) we can sample during a given observation time 𝑡, we
tackle the problem by assuming the followings: (1) After each complete cycle of the blood stream
we randomly sample a γ fraction of the entire blood volume; and (2) The blood is completely
mixed at the end of each cycle. Each cycle is defined as the time it takes to pump the entire blood
volume through the body

𝑇=

𝑉𝑡
.
𝑄CO

(4.13)

Here 𝑄CO stands for the average cardiac output (as a volumetric flow rate, or volume of blood per
unit time) defined as
𝑄CO = 𝑟HR × 𝑉SV .

(4.14)

Here 𝑟HR stands for the heart rate of the patient and 𝑉SV represents for the stroke volume. So the
cycle duration becomes

𝑇=

𝑉𝑡
.
𝑟HR × 𝑉SV

(4.15)

The sampling ratio γ of the entire blood stream by the observed vein is defined as

𝛾=

𝑄O
𝑄O 𝑇
=
.
𝑄CO
𝑉𝑡
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(4.16)

Here 𝑄O stands for the volumetric flow rate of blood observed by LA-PAT (the subscript “O”
stands for “observed”). Because we want to capture the flowing melanoma CTC multiple times,
𝑄O is always limited by the volumetric flow rate of the vein monitored and can be expressed as

𝑄O = 𝜋 ×

𝐷2
× 𝑣.
4

(4.17)

Here 𝐷 stands for the diameter of the vein and 𝑣 stands for the average blood flow speed in the
traverse direction.
During a given observation time 𝑡, if 𝑡 ≤ 𝑇, in which case there is no repeated blood sampled by
LA-PAT, the fresh blood volume can be calculated by the following equation
𝑉𝑓 (𝑡) = 𝑄O × 𝑡 .

(4.18)

If 𝑡 > 𝑇, in which case multiple cycles occur during the observation time, at cycle 𝑖, the fresh
blood volume we can observe is
𝑉𝑖 = 𝑄O 𝑇(1 − 𝛾)𝑖−1 .

(4.19)

Therefore, the total fresh blood volume we can observe during the observation time 𝑡 is
𝑡
⌊ ⌋
𝑇

𝑡
𝑡
𝑉𝑓 (𝑡) = ∑ 𝑄O 𝑇(1 − 𝛾)𝑖−1 + 𝑄O (𝑡 − ⌊ ⌋ 𝑇) (1 − 𝛾)⌊𝑇⌋
𝑇
𝑖=1

(4.20)
𝑡

𝑡
1 − (1 − 𝛾)⌊𝑇⌋
𝑡
= 𝑄O 𝑇
+ 𝑄O (𝑡 − ⌊ ⌋ 𝑇) (1 − 𝛾)⌊𝑇⌋
𝛾
𝑇
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= 𝑉𝑡 [1 − (1 −

𝑄O 𝑇 ⌊ 𝑡 ⌋
𝑡
𝑄O 𝑇 ⌊ 𝑡 ⌋
) 𝑇 ] + 𝑄O (𝑡 − ⌊ ⌋ 𝑇) (1 −
)𝑇.
𝑉𝑡
𝑇
𝑉𝑡

Here ⌊𝑎⌋ is the largest integer that is less than or equal to the real number 𝑎. Briefly, the expression
consists of two parts: the sum of a geometric series representing a decreasingly efficient sampling
of the blood stream at each full cycle and a residual term at the last incomplete cycle. If we had
infinite time, mathematically, we can ignore the residual term and take the infinite limit of the sum

lim 𝑉𝑓 (𝑡) = lim 𝑉𝑡 [1 − (1 −

𝑡→+∞

𝑁→+∞

𝑄O 𝑇 𝑁
) ] = 𝑉𝑡 .
𝑉𝑡

(4.21)

Therefore, the entire blood volume can be sampled. In summary, the total number of melanoma
CTCs 𝑁𝑡 can be estimated by

𝑁𝑡 = 𝑁𝑑

𝑉𝑡
𝑉𝑓 (𝑡)

𝑁𝑑
=

𝑁𝑑
{

𝑉𝑡
𝑄O 𝑡

𝑉𝑡 (1 − (1 −

(4.22)

𝑖𝑓 𝑡 < 𝑇
𝑉𝑡
𝑄O 𝑇 ⌊𝑇𝑡 ⌋
𝑉𝑡 ) )

𝑡
+ 𝑄O (𝑡 − ⌊𝑇⌋ 𝑇) (1 −

𝑄O 𝑇 ⌊𝑇𝑡 ⌋
𝑉𝑡 )

𝑖𝑓 𝑡 > 𝑇

.

If 𝑡 < 𝑇, in which case there is no repeated blood sampled by LA-PAT, the fresh blood volume
can be calculated by the following equation:
𝑉𝑓 (𝑡) = 𝑄O × 𝑡 .

(4.23)

If 𝑡 > 𝑇, in which case multiple cycles occur during the observation time, the fresh blood volume
can be calculated by the following equation:
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𝑉𝑓 (𝑡) = 𝑉𝑡 (1 − (1 −

𝑄O 𝑇 ⌊ 𝑡 ⌋
𝑡
𝑄O 𝑇 ⌊ 𝑡 ⌋
) 𝑇 ) + 𝑄O (𝑡 − ⌊ ⌋ 𝑇) (1 −
)𝑇.
𝑉𝑡
𝑇
𝑉𝑡

(4.24)

Here ⌊𝑎⌋ is the largest integer that is less than or equal to the real number 𝑎, 𝑄O stands for the
volumetric flow rate of blood observed by LA-PAT (the subscript “O” stands for “observed”), and
𝑄O 𝑇
𝑉𝑡

stands for the sampling ratio of the entire blood stream by the observed vein. Because we want

to capture the flowing melanoma CTC multiple times, 𝑄O is always limited by the volumetric flow
rate of the vein monitored and can be expressed as

𝑄O = 𝜋 ×

𝐷2
× 𝑣.
4

(4.25)

4.2.3 Results
LA-PAT of melanoma tumor cells in phantoms

To initially demonstrate the capability of LA-PAT, we first applied LA-PAT to image melanoma
tumor cells in phantoms. To mimic melanoma CTCs in blood, cultured B16 melanoma tumor cells
were suspended into bovine blood and pumped through microtubes. They were then imaged by
LA-PAT with an excitation wavelength of 680 nm, which maximizes the contrast between
melanoma tumor cells and blood (Fig. 4.5). Due to the strong optical absorption of melanin at 680
nm, the flowing melanoma tumor cells showed much stronger photoacoustic signals than the blood
in the background and were detected by LA-PAT (Fig. 4.9a).

The ability to detect and visualize the melanoma tumor cells in the bloodstream depends on the
CNR. To determine the maximum depth that melanoma tumor cells can be detected by LA-PAT,
we studied how the imaging depth affected the CNR. The microtubes mimicking blood vessels
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were embedded into scattering gelatin phantoms at different depths and melanoma tumor cells
suspended in blood were pumped through the microtubes. We used LA-PAT to image the flowing
melanoma tumor cells at different depths (Fig. 4.9a–d) and calculated the CNR at each depth (Fig.
4.9e). The CNR decreases with the increasing imaging depth because the acoustic signal
attenuation. With a CNR threshold of 2, the maximum depth that a melanoma tumor cell can be
detected by LA-PAT was ~3.5 mm. The depth is adequate for imaging most of the superficial veins
in humans.

We also studied the melanoma tumor cell detection efficiency of LA-PAT. With the high detection
sensitivity, there are two situations when a melanoma tumor cell can be missed by LA-PAT. In
one situation, when the diameter of the blood vessel is larger than the slice thickness of the
ultrasonic detection, i.e. elevational resolution, chances are that the melanoma tumor cells may
flow outside of the FoV and will not be detected by LA-PAT. In the other situation, when the
blood flow speed is so fast that melanoma tumor cells may flow through the imaging FoV before
they are detected by LA-PAT. To quantify the melanoma tumor cell detection efficiency, we
imaged melanoma tumor cells with different flow speeds in microtubes with different diameters
by LA-PAT and calculated the detection efficiencies at different parameter combinations (Fig.
4.9f). The results show that the detecting efficiency decreases with increasing blood flow speed
and vessel diameter. The detection efficiency curves may serve as a reference to estimate the total
number of melanoma CTCs based on the number detected by LA-PAT.
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Figure 4.9. LA-PAT of single melanoma tumor cells in phantoms. a, Photoacoustic snapshots of a single melanoma
tumor cell 0 mm deep in phantom with a CNR of 16.4. The yellow arrows show the microtube boundaries. The red
arrows highlight the flowing single melanoma tumor cell. b, Photoacoustic snapshots of a single melanoma tumor cell
1.5 mm deep in phantom with a CNR of 14.2. The yellow arrows show the microtube boundaries. The red arrows
highlight the flowing single melanoma tumor cell. c, Photoacoustic snapshots of a single melanoma tumor cell 3 mm
deep in phantom with a CNR of 4.3. The yellow arrows show the microtube boundaries. The red arrows highlight the
flowing single melanoma tumor cell. d, Photoacoustic snapshots of the phantom at depth 4 mm. No melanoma tumor
cells could be detected. e, CNRs of the melanoma tumor cells in photoacoustic images degrade with increasing
imaging depth. With a CNR threshold of 2, the maximum depth that a melanoma tumor cell can be detected was ~3.5
mm. f, The melanoma tumor cell detection efficiency of LA-PAT decreases with increasing blood flow speed and
vessel diameter.
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LA-PAT of a single melanoma CTC and a melanoma CTC cluster in Patient 1

In the first case, we imaged a patient who had recurrent metastatic melanoma in her right lower
extremity and went through multiple resections for in-transit metastases (Table 4.1). We imaged
the small saphenous vein in the right leg of the patient. The vein had a diameter of ~1.7 mm and
was ~3.1 mm deep from skin surface to lower vessel boundary. In the photoacoustic images,
structures including skin, vessel boundaries, and subcutaneous fat layer were clearly resolved (Fig.
4.10a).

Figure 4.10. LA-PAT of a single melanoma CTC in patient 1. a, Photoacoustic snapshots of the single melanoma
CTC in the patient. The yellow arrows show the structures including skin, vessel boundaries, and subcutaneous fat
layer. The red arrows highlight the flowing single melanoma CTC. b, Differential photoacoustic images showing only
the flowing single melanoma CTC. c, Differential photoacoustic images (b) superimposed on structural photoacoustic
images (a), highlighting the flowing single melanoma CTC.
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In one imaging session, a single melanoma CTC was detected in this patient by LA-PAT. The
CNR of the melanoma CTC was ~12.6. The single melanoma CTC was captured 5 times while it
flew through the entire imaging FoV (Fig. 4.10a). To highlight the flowing melanoma CTC,
differential photoacoustic images were obtained (Fig. 4.10b). The differential photoacoustic
images were then superimposed on the structural images to better illustrate how the single
melanoma CTC flew through the entire imaging FoV (Fig. 4.10c). By tracking the melanoma CTC
and analyzing the movement in the space-time domain, the flow speed of the melanoma CTC was
computed (Fig. 4.8). The flow speed of this single melanoma CTC was 10.3 mm/s. Although the
flow speed of the melanoma CTC does not necessarily match the flow speed of blood, it is a close
approximation given the low concentration of melanoma CTC and the large vessel diameter.

In another imaging session, a melanoma CTC cluster was detected in this patient by LA-PAT. The
CNR of the melanoma CTC cluster was ~11.6. The melanoma CTC cluster was captured 9 times
when it flew through the entire imaging FoV (Fig. 4.11a). It was captured more times than the
single melanoma CTC because of its smaller flow speed. Similarly, to highlight the flowing
melanoma CTC cluster, differential photoacoustic images were obtained (Fig. 4.11b). The
differential photoacoustic images were then superimposed on the structural images to better
illustrate how the melanoma CTC cluster flew through the entire imaging FoV (Fig. 4.11c).
Applying the same method as in the single melanoma CTC, the flow speed of the melanoma CTC
cluster was computed to be 5.4 mm/s. There are two possible factors contributing to the smaller
flow speed of the CTC cluster compared to the single melanoma CTC. First is the location in the
blood vessel. The melanoma CTC cluster was closer to the vessel boundary while the single
melanoma CTC was closer to the vessel central line. Assuming a parabolic flow model, the flow
speed near the vessel central line may be larger compared to that near the vessel boundary. Second
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is the CTC size. Because the melanoma CTCs were driven by the blood flow, a smaller single
melanoma CTC could be driven to a higher flow speed than a CTC cluster.

Figure 4.11. LA-PAT of a melanoma CTC cluster in patient 1. a, Photoacoustic snapshots of the melanoma CTC
cluster in the patient. The yellow arrows show the structures including skin, vessel boundaries, and subcutaneous fat
layer. The red arrows highlight the flowing melanoma CTC cluster. b, Differential photoacoustic images showing only
the flowing melanoma CTC cluster. c, Differential photoacoustic images (b) superimposed on structural photoacoustic
images (a), highlighting the flowing melanoma CTC cluster.

LA-PAT of a single melanoma CTC in Patient 2

In the second case, we imaged a patient who had metastatic melanoma in his brain and heart while
there was no known primary melanoma (Table 4.1). We imaged the cephalic vein in the right arm
of the patient. The vein had a diameter of ~1.0 mm and was ~3.2 mm deep from skin surface to
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lower vessel boundary. In the photoacoustic images, structures including skin, vessel boundaries,
and subcutaneous fat layer were clearly resolved (Fig. 4.12a).

Figure 4.12. LA-PAT of a single melanoma CTC in patient 2. a, Photoacoustic snapshots of the single melanoma
CTC in the patient. The yellow arrows show the structures including skin, vessel boundaries, and subcutaneous fat
layer. The red arrows highlight the flowing single melanoma CTC. b, Differential photoacoustic images showing only
the flowing single melanoma CTC. c, Differential photoacoustic images (b) superimposed on structural photoacoustic
images (a), highlighting the flowing single melanoma CTC.

In one imaging session, a single melanoma CTC was detected in this patient by LA-PAT. The
CNR of the melanoma CTC was ~9.4. The single melanoma CTC was captured 5 times while it
flew through the entire imaging FoV (Fig. 4.12a). Differential photoacoustic images were obtained
to highlight the flowing melanoma CTC (Fig. 4.12b). To better illustrate how the melanoma CTC
flew through the entire imaging FoV, the differential photoacoustic images were then
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superimposed on the structural images (Fig. 4.12c). Using the same method of converting the
movement of the single melanoma CTC to the space-time domain, the flow speed of the melanoma
CTC was estimated to be 9.6 mm/s.

LA-PAT of a melanoma CTC cluster in Patient 3

Figure 4.13. LA-PAT of a melanoma CTC cluster in patient 3. a, Photoacoustic snapshots of the flowing melanoma
CTC cluster in the patient. The yellow arrows show the structures including skin and vessel boundaries. The red arrows
highlight the flowing melanoma CTC cluster. b, Differential photoacoustic images showing only the flowing
melanoma CTC cluster. c, Differential photoacoustic images (b) superimposed on structural photoacoustic images (a),
highlighting the flowing melanoma CTC cluster.

In a third case, we imaged a patient who had recurrent metastatic melanoma in her scalp (Table
4.1). We imaged the cephalic vein in the right arm of the patient. The vein had a diameter of ~1.0
mm and was ~2.2 mm deep from skin surface to lower vessel boundary. In the photoacoustic
images, structures including skin and vessel boundaries were clearly resolved (Fig. 4.13a).In one
imaging session, a melanoma CTC cluster was detected in this patient by LA-PAT. The CNR of
the melanoma CTC cluster was ~12.5. The melanoma CTC cluster was captured 3 times while it
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flew through the entire imaging FoV (Fig. 4.13a). Again, to highlight the flowing melanoma CTC,
differential photoacoustic images were obtained (Fig. 4.13b). The differential photoacoustic
images were then superimposed on the structural images to better illustrate how the melanoma
CTC cluster flew through the entire imaging FoV (Fig. 4.13c). Using the same method as above
the flow speed of the melanoma CTC cluster was estimated to be 8.6 mm/s.

CNR analysis of melanoma CTCs

Figure 4.14. CNRs comparison between melanoma CTCs and phantoms. a, A representative photoacoustic image of
the phantom without melanoma tumor cells. b, A representative photoacoustic image of the phantom with a melanoma
tumor cell. The flowing object with the highest CNR was identified as a melanoma tumor cell. c, CNRs of melanoma
tumor cells were significantly higher than peak CNRs in the microtube in phantom (n = 105 melanoma tumor cell
events, ***p < 0.001).

To fully validate that the flowing objects detected by LA-PAT were melanoma tumor cells, we did
a thorough CNR analysis of the flowing objects in phantoms and in patients. In phantoms, blood
without melanoma tumor cells were first pumped through the microtube and imaged by LA-PAT.
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No flowing objects were detected in the photoacoustic images (Fig. 4.14a). We searched the entire
area within the microtube to find the pixel with the highest CNR, referred as the peak CNR in the
microtube. Then, melanoma tumor cells suspended in blood were pumped through the microtube
and imaged by LA-PAT. Flowing objects were detected in the photoacoustic images (Fig. 4.14b).
For each flowing object, we calculated the average CNR of all its appearances. The CNRs of the
flowing objects were significantly higher than the peak CNRs in the microtube (Fig. 4.14c).
Because only melanoma tumor cells were added to the blood compared to the control experiment,
the flowing objects with the high CNRs must be the melanoma tumor cells. At an excitation
wavelength of 680 nm, only melanin, with much stronger optical absorption than blood, can
generate such high photoacoustic signals. In addition, the average CNR of the flowing objects was
~14.7, close the theoretically estimated value of 15.

In patients, to further validate the flowing objects in blood vessels detected by LA-PAT were
melanoma CTCs, we did a similar CNR analysis as in phantom, with more types of control groups.
First, we calculated the average CNR of each flowing object in the photoacoustic images (Fig.
4.15a). For the first type of control group, we compared the CNRs of the flowing objects with the
peak CNRs in the blood vessels in patients in whom flowing objects were detected, referred as
CTC-positive patients. In the frames without flowing objects, we searched the entire area within
the blood vessel and found the pixel with the highest CNR (Fig. 4.15b). The CNRs of the flowing
objects were significantly higher than the peak CNRs in the blood vessels in CTC-positive patients
(Fig. 4.15e). For the second type of control group, we compared the CNRs of the flowing objects
with the peak CNRs in the blood vessels in patients in whom no flowing objects were detected,
referred as CTC-negative patients. Similarly, we searched the entire area within the blood vessel
and found the pixel with the highest CNR (Fig. 4.15c). The CNRs of the flowing objects were also
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significantly higher than the peak CNRs in the blood vessels in CTC-negative patients (Fig. 4.15f).
For the third type of control group, we compared the CNRs of the flowing objects with the peak
CNRs in the blood vessels in healthy volunteers (Fig. 4.15d). A similar result that the CNRs of
the flowing objects were significantly higher than the peak CNRs in the blood vessels in healthy
volunteers further showed that only melanoma CTCs can generate such high photoacoustic signals
in the blood vessels.

Figure 4.15. CNR comparison between melanoma CTCs and blood vessels in vivo. a, A representative photoacoustic
image of a melanoma CTC in a blood vessel in a patient, referred as a positive patient. The flowing object with the
highest CNR was identified as a melanoma CTC. b, A representative photoacoustic image without melanoma CTCs
in the positive patient. c, A representative photoacoustic image in a patient in whom no melanoma CTCs were detected,
referred as a negative patient. d, A representative photoacoustic image in a healthy volunteer. e, CNRs of melanoma
CTCs were significantly higher than peak CNRs in blood vessels in positive patients (n = 23 melanoma CTC events,
***p < 0.001). f, CNRs of melanoma CTCs in positive patients were significantly higher than peak CNRs in blood
vessels in negative patients (n = 23 melanoma CTC events, ***p < 0.001). g, CNRs of melanoma CTCs were
significantly higher than peak CNRs in blood vessels in health volunteers (n = 23 melanoma CTC events, **p < 0.01).
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Estimation of the total number of CTCs and the clinical relevance of CTC imaging in patients

To demonstrate the clinical translational potential of melanoma CTC imaging by LA-PAT, we
estimated the total number of CTC in patients based on the imaging results and tracked the statuses
of the patients after photoacoustic imaging (Table 4.1). Based on the number of melanoma CTC
detected and the effective blood volume screened by LA-PAT, the total number of melanoma
CTCs in the three patients were estimated to be 214, 333, and 370, in the same range as reported
previously using ex vivo CTC detection methods170,171. We then monitored the statuses of patients
imaged by LA-PAT for up to one year to see whether the detection of CTCs is predictive of patient
response to treatment and disease progression172. Because the clinical meaning of the melanoma
CTC imaging results is presently unclear, the data was strictly protected from patients and their
treating physicians and did not affect any clinical decisions. The follow-up results showed that 2
out of 3 CTC-positive patients had disease progression despite on systemic therapy. In contrast,
only 3 out of 13 CTC-negative patients had disease progression (Table 4.2). The higher disease
progression percentage of the CTC-positive patients over the CTC-negative may indicate that the
number of CTCs detected by LA-PAT is possibly predictive of treatment response and prognostic
outcome.
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12 months

Time of Scan

Time of Follow Up
Post LA-PAT

214

Estimated Total
CTC Count

Disease Progression on Therapy

46.8 mL

Effective Blood
Volume Examined

Follow-up Clinical
Status

2

CTC Events
Imaged by LA-PAT

 Had recurrent metastatic
melanoma in right lower
extremity
 Went through multiple
surgical resections of intransit cutaneous metastases
 Received systemic
immunotherapy
 Showed no evidence of
systemic disease at time of
imaging

IIIb

Clinical Stage at
Time of Scan

Clinical Status at

M3

Patient ID

133

8 months

Disease Progression on
Therapy

 Had no known
primary melanoma
 Received targeted
and systemic
immunotherapy
 Had metastatic
melanoma in brain
and heart at time of
imaging

333

15.0 mL

1

IV

M11

7 months

No disease Progression on
Therapy

 Had no known primary
melanoma
 Received course of local
immunotherapy and
started systemic
immunotherapy
 Showed interval
progression disease at
time of imaging

370

13.5 mL

1

IIIc

M14

Table 4.1: Status of CTC-positive patients

Table 4.2: List of melanoma patients imaged by LA-PAT
Patient

Gender Photoacoustic Clinical

ID

Imaging

Stage at

Result

Time of

Follow-up Clinical

Time of

Status

Follow Up
Post LA-PAT

Scan
M1

Male

Negative

IV

Disease Progression on 11 months
Therapy

M2

Male

Negative

IIIc

No Disease Progression 4 months
off Therapy

M3

Female

Positive

IIIb

Disease Progression on 12 months
Therapy

M4

Female

Negative

IIIa

No Disease Progression 11 months
off Therapy

M5

Female

Negative

IV

No Disease Progression 9 months
on Therapy

M6

Female

Negative

III

Disease Progression on 10 months
Therapy

M7

Female

Negative

IV

No Disease Progression 5 months
off Therapy
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M8

Male

Negative

IV

Disease Progression on 8 months
Therapy/Death

M9

Female

Negative

III

No Disease Progression 8 months
on Therapy

M10

Female

Negative

IV

No Disease Progression 7 months
off Therapy

M11

Male

Positive

IV

Disease Progression on 8 months
Therapy

M12

Female

Negative

IV

No Disease Progression 7 months
off Therapy

M13

Female

Negative

III

No Disease Progression 8 months
on Therapy

M14

Female

Positive

IIIC

No Disease Progression 7 months
on Therapy

M15

Female

Negative

IV

No Disease Progression 6 months
off Therapy

M16

Male

Negative

IV

Disease Progression off 7 months
Therapy
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4.2.4 Discussion
Ultrasonically imaging optical absorption, PAT is inherently suitable for melanoma imaging and
offers four unique advantages. (1) PAT has a 100% relative sensitivity to optical absorption (i.e.,
a given percentage change in the optical absorption coefficient yields the same percentage change
in the photoacoustic amplitude) thus allowing high-sensitivity detection of strongly absorbing
targets40; (2) Melanoma tumor cells express high-concentration melanin, which has much stronger
optical absorption than hemoglobin in the red to NIR spectrum and serves as a perfect contrast for
high-sensitivity photoacoustic detection of melanoma CTCs in the bloodstream169; (3) Taking
advantage of the ultrasonic transparency of biological tissue, PAT achieves high resolution at
depths, thus providing access to screen large blood vessels for high-throughput melanoma CTC
detection; (4) LA-PAT, the linear-array-based implementation of PAT, well aligns the imaging
FoV with the blood vessel, which maximizes the blood imaging efficiency (i.e. the ratio between
the volume of blood examined and the entire volume imaged by LA-PAT) and the chance to detect
melanoma CTCs in patients in vivo. Owing to these advantages of LA-PAT, we successfully
achieved label-free high-throughput imaging of melanoma CTCs in patients in vivo for the first
time. After initially demonstrating the capability of LA-PAT to detect and characterize melanoma
CTCs in phantoms, we successfully imaged 16 Stage III and IV melanoma patients and detected
CTCs in 3 of them. By optimizing the excitation wavelength, we maximized the CNR of melanoma
CTC in LA-PAT, thus achieving the highest melanoma CTC detection sensitivity. By carefully
selecting the imaging sites and target blood vessels, we tried to maximize our chances to detect
melanoma CTCs in patients.

To successfully detect the rare melanoma CTCs in patients in vivo, the key is to differentiate the
single melanoma CTCs from the blood background, which mainly consists of red blood cells
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(RBCs). The melanoma CTC detection sensitivity of LA-PAT ultimately depends on the CNR,
which characterizes the ability to visualize a melanoma CTC from the huge number of RBCs in
the background. The CNR can be expressed as following when ignoring noises other than the
fluctuation of RBC number in each resolution voxel

CNR =

𝑃𝐴𝐶𝑇𝐶 /𝑃𝐴𝑅𝐵𝐶
√[𝑅𝐵𝐶]𝑤𝑜

.

(4.26)

The photoacoustic signal ratio of a melanoma CTC and a RBC is determined by the optical fluence,
the absorption coefficient ratio, and the absorption volume ratio, among which the absorption
coefficient ratio can be maximized by optimizing the illumination wavelength. The number of
RBCs in each resolution voxel is determined by the RBC density and the resolution voxel size,
which is affected by the ultrasonic transducer frequency. A higher ultrasonic frequency gains the
melanoma CTC detection sensitivity by reducing the resolution voxel size, at the expense of
shallower penetration depth. In our study, we not only optimized the illumination wavelength by
analyzing the optical absorption spectra of melanin and venous blood, but also considered the
tradeoff between imaging depth and resolution voxel size. An excitation wavelength of 680 nm
not only maximizes the photoacoustic signal ratio of a melanoma CTC and a RBC, but also allows
sufficient light penetration in biological tissue to access large blood vessels at depths. However,
there is a minor drawback that locating the blood vessels in patients may be difficult given the
weak optical absorption of hemoglobin at 680 nm. This was overcome by applying an excitation
wavelength of 850 nm to locate the blood vessels in patients before switching to 680 nm for
melanoma CTC imaging. A 40-MHz center frequency of the ultrasonic transducer array was
chosen to have sufficient sensitivity to detect single melanoma CTCs while the imaging depth is
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adequate to screen large blood vessels for high-throughput melanoma CTC imaging. On one hand,
a lower ultrasonic frequency, such as 30 MHz, can achieve deeper penetration in biological tissue
and the required sensitivity to detect single melanoma CTCs at tissue surface. However, as the
depth of the target blood vessel increases, the melanoma CTC detection sensitivity drops quickly,
and it fails to detect single melanoma CTCs in deeper blood vessels140. On the other hand, a higher
ultrasonic frequency, such as 50 MHz, can achieve an even higher melanoma CTC detection
sensitivity, but suffers from stronger acoustic attenuation and cannot reach the deep target vessels
for high-throughput melanoma CTC imaging. So, an illumination wavelength of 680 nm and a
detection center frequency of 40 MHz is the perfect combination to enable label-free highthroughput melanoma CTC imaging in patients in vivo.

It is worth noting that there is a type of skin cancer in which the cells do not highly express melanin.
This type of skin cancer, namely amelanotic melanoma, only makes up ~5% of the total melanoma
cases173. Since some amelanotic melanoma cells also produce a small amount of melanin, the high
detection sensitivity of LA-PAT may still help to detect these cells. As an alternative, other tumor
biomarkers can be used detect CTCs originating from amelanotic melanoma.

The functionality of LA-PAT can be further boosted. The melanoma CTC detection sensitivity can
be improved by spectrally unmixing melanoma CTCs and RBCs. To achieve spectral unmixing,
two or more illumination wavelengths should be employed174. The blood screening throughout can
be enhanced by optimizing the blood imaging efficiency. To optimize the blood imaging
efficiency, a larger blood vessel should be targeted, and the imaging frame rate can be adjusted to
better match the blood flow speed, thus minimizing the blood examined repeatedly. Moreover, by
applying a second laser pulse with higher energy immediately after identifying a melanoma CTC,
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we can achieve selective laser fragmentation of melanoma CTCs and induce immunoresponse with
the released antigens to further treat the primary tumor, CTCs and metastases155,175. In addition to
CTC detection, LA-PAT can also measure other parameters, including depth, pH, oxygen
saturation, stiffness, glucose metabolism, angiogenesis, and therapy response, to provide
comprehensive information on tumor41,58,62,176–179.

Label-free high-throughput imaging of melanoma CTCs by LA-PAT in patients holds great
promise for clinical translation. First, the label-free noninvasive nature of LA-PAT provides an
inherent advantage for clinical translation. Second, the high blood screening throughout and
melanoma CTC detection sensitivity give it the potential as a reliable routine clinical tool for
melanoma progression monitoring and therapy evaluation. Third, although we have focused on
melanoma in this work, LA-PAT can image CTCs of other types of cancer by studying their
absorption spectra and selecting proper illumination wavelengths. Fourth, it is not limited to CTCs
in the bloodstream. LA-PAT can be applied to image CTCs in the lymphatic system180, in which
the detection sensitivity can be even higher given the low optical absorption of lymph. Last, our
results showed that the CTC-positive patients imaged by LA-PAT had greater tendency for disease
progression than the CTC-negative patients, further indicating its clinical translational potential.

In summary, we have developed and optimized LA-PAT and achieved melanoma CTCs imaging
in patients in vivo for the first time. We demonstrated its abilities in phantoms and clinical
feasibility in melanoma patients. Follow-up monitoring of the melanoma patients further revealed
the clinical translational potential of LA-PAT. Our initial success in melanoma patients not only
showed its feasibility detect and characterize melanoma CTCs in vivo, but also established the full
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potential of LA-PAT as an important clinical tool to incorporate CTC detection for cancer
diagnosis and therapy.
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Chapter 5 Summary
In this dissertation, I have further advanced PAT by developing photoacoustic elastography to
enable elasticity imaging with PAT, improving the performance of PAM for various applications,
and accomplishing label-free high-throughput photoacoustic imaging of melanoma CTCs in
patients in vivo.

In Chapter 2, I have developed three novel photoacoustic elasticity imaging techniques. First, I
have developed VE-PAT capable of detecting blood vessel elasticity changes due to abnormal
hemodynamic states by incorporating a linear-array-based photoacoustic imaging probe with a
customized compression stage. We demonstrated the capability of VE-PAT by detecting vascular
compliance changes caused by simulated thrombosis in phantoms and in a human subject in vivo.
VE-PAT has potential for use in many clinical applications, including detection of deep venous
thrombosis, characterization of vulnerable plaque, and evaluation of atherosclerotic tissues.
Second, I have developed and demonstrated photoacoustic elastography on gelatin phantoms and
in vivo. Lacking speckles, photoacoustic elastography can still measure tissue displacements using
optical absorption contrast provided by abundant endogenous biomolecules, especially
hemoglobin in red blood cells181. Photoacoustic elastography has a 100% relative sensitivity to
optical absorption contrast, which means a given percentage change in the optical absorption
coefficient yields the same percentage change in the photoacoustic signal amplitude. Photoacoustic
elastography is well suited for mapping the elastic properties of diseased tissues with highly
vascularized structures, such as carcinoma and glioblastoma182. At longer wavelengths where
water and lipids have relatively strong absorption, photoacoustic elastography can potentially map
the elastic properties of tissues by using water and lipids as the contrast78,84. Third, I have further
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enhanced the capability of photoacoustic elastography by developing QPAE. Surpassing
conventional photoacoustic elastography, QPAE achieves quantification of absolute Young’s
modulus instead of relative values by utilizing a piece of silicone rubber with known stress–strain
behavior as a reference stress sensor. An important underlying assumption in QPAE is that the
compression stress is uniform along each A-line (the depth). During the phantom and in vivo
experiments, to maintain the validity of the assumption by eliminating boundary effects, the
compression plate was made much larger than the object to be imaged. Although internal structures
of the object can also affect the assumption, the method should remain sufficient for tissues with
laminar structures, such as the skin and muscles183. To obtain more accurate results without the
assumption of uniform stress along depth, an inverse problem for the three-dimensional
distribution of stress within the object needs to be solved184.

In Chapter 3, I have further boosted the performance of PAM systems. First, we have developed
and demonstrated NIR-OR-PAM that offers new imaging contrast and better resolution at greater
imaging depths than VIS-OR-PAM. By employing NIR light with our fast-scanning OR-PAM107
and incorporating multiple wavelengths21, we should be able to measure hemodynamic parameters,
including blood flow speed, the oxygen saturation of hemoglobin, and the metabolic rate of
oxygen111. Then, we have upgraded an HF-OR-PAM to image cerebral microvascular responses
during epileptic seizure propagation, including changes in total hemoglobin concentration and
vessel diameters, in mouse brains in vivo. Hemodynamic responses to epileptic seizure propagation
were imaged with high spatial (~3 μm lateral resolution) and temporal (~0.5 Hz volumetric frame
rate) resolutions simultaneously for the first time. With HF-OR-PAM, we were able to capture the
waves of photoacoustic signal changes in response to epileptic seizure propagation. Different
propagation patterns of the waves were observed. Since the waves of photoacoustic signal changes
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observed were induced by the epileptic waves of neuron cluster hyper-excitation, the observed
hemodynamic changes reflected the elevated neural activities. Possible reasons for the various
behaviors of the waves are the different strengths of neural activities and randomness in neuron
cluster triggering185. Blood vessels dilated in response to epileptic seizures. The magnitude of
vessel diameter changes decreased with the increasing distance from the 4-AP injection site. All
the changes detected by HF-OR-PAM correlated well with EEG signals recorded simultaneously.
Last, we have developed and optimized SCM-PAM, which combines a wide-field fast-scanning
functional OR-PAM with a high-density microwell array, for label-free high-throughput singlecell imaging of intratumoral metabolic heterogeneity. We have demonstrated its capability by
measuring the single-cell OCR distributions of cultured cells and showed its potential for clinical
translation by imaging intratumoral metabolic heterogeneity in breast cancer patient specimens. In
addition, with rich optical absorption contrast, the wide-field fast-scanning functional OR-PAM
subsystem of SCM-PAM can provide multiple dimensions of information about tumors, including
angiogenesis, metastasis, and drug responses, along with intratumoral heterogeneity141–143. With
its unique capability for label-free high-throughput single-cell OCR measurement and the potential
of providing multidimensional information about tumors, SCM-PAM is a promising tool for both
fundamental cancer research and clinical personalized cancer therapy.

In Chapter 4, we have accomplished label-free high-throughput imaging of melanoma CTCs in
patients in vivo with LA-PAT systems. First, we applied an LA-PAT system with a 21 MHz center
frequency to detect and quantify melanoma CTC clusters in rats in vivo. Since the spatial
resolutions of the 21MHz LA-PAT were not enough to resolve single melanoma tumor cells, the
numbers of cells in the CTC clusters were quantified based on the CNRs. A linear relationship
between the CNRs and the numbers of cells in the CTC clusters was found and verified. In ex vivo
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experiments, LA-PAT quantified the numbers of cells in the CTC clusters, and the results were
validated by an optical microscope. In experiments in vivo, LA-PAT detected and quantified
melanoma CTC clusters immediately after injection, as well as when they were circulating in the
rat bloodstreams. The results by LA-PAT also showed that larger CTC clusters have faster
clearance rates. Then, we have developed a LA-PAT system with a 40 MHz center frequency. We
initially demonstrated its capability by imaging CTC-mimicking melanoma tumor cells in
phantoms, and then successfully achieved melanoma CTC imaging in patients in vivo. Out of the
16 melanoma patients imaged, we detected melanoma CTCs in 3 of them. Follow-up monitoring
of their statuses further showed the clinical translational potential of label-free high-throughput
imaging of melanoma CTCs in patients in vivo.
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